<SEC-DOCUMENT>0001731122-20-000103.txt : 20200206
<SEC-HEADER>0001731122-20-000103.hdr.sgml : 20200206
<ACCEPTANCE-DATETIME>20200206172435
ACCESSION NUMBER:		0001731122-20-000103
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		40
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200206
DATE AS OF CHANGE:		20200206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		20583700

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e1699_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">(Mark One)<BR>
<BR>
<B>[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&nbsp;ACT&nbsp;OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended: <B><U>December
31, 2019</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[ ] TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE&nbsp;ACT&nbsp;OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from _____to _____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <U>001-37606</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>ANAVEX LIFE SCIENCES CORP.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B><U>Nevada</U></B></TD>
    <TD STYLE="width: 50%; text-align: center"><B><U>98-0608404</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of</TD>
    <TD STYLE="text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">incorporation or organization)</TD>
    <TD STYLE="text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>51 West 52<SUP>nd</SUP> Street, 7<SUP>th</SUP>
Floor, New York, NY USA 10019</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices) (Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>1-844-689-3939</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>N/A</U><BR>
</B>(Former name, former address and former fiscal year, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities Registered Pursuant to Section&nbsp;12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify">Title of Each Class</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify">Trading Symbol</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify">Name of Each Exchange on Which Registered</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 32%; text-align: justify">Common Stock Par Value $0.001</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: justify">AVXL</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: justify">NASDAQ Stock Market LLC</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>[X] Yes [&nbsp;&nbsp;] No</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>[X] Yes [&nbsp;&nbsp;] No</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; text-align: justify">Large accelerated filer </TD>
    <TD STYLE="width: 3%; text-align: justify">[&nbsp;&nbsp;]</TD>
    <TD STYLE="width: 41%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: justify">Accelerated filer </TD>
    <TD STYLE="width: 3%; text-align: justify">[<B>X</B>]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Non-accelerated filer </TD>
    <TD STYLE="text-align: justify">[&nbsp;&nbsp;]</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">Smaller reporting company </TD>
    <TD STYLE="text-align: justify">[<B>X</B>]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Emerging growth company </TD>
    <TD STYLE="text-align: justify">[&nbsp;&nbsp;]</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>[ ]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>[ ] Yes [X] No</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding of
each of the issuer&rsquo;s classes of common stock, as of the latest practicable date: 58,664,946 shares of common stock outstanding
as of February 6, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_001">PART I - FINANCIAL INFORMATION</A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_001">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_002">Item 1. FINANCIAL STATEMENTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_002">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_003">Item 2. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_003">17</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_004">Item 3. Quantitative and Qualitative Disclosures about Market Risks.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_004">31</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_005">Item 4. Controls and Procedures.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_005">31</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_006">PART II &ndash; OTHER INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_006">31</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_007">Item 1. Legal Proceedings.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_007">31</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_008">Item 1A. Risk Factors.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_008">32</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_009">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_009">32</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_010">Item 3. Defaults Upon Senior Securities.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_010">32</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_011">Item 4. Mine Safety Disclosures</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_011">32</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_012">Item 5. Other Information.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_012">32</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_013">Item 6. Exhibits.</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_013">33</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_014">SIGNATURES</A></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><A HREF="#a_014">34</A></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_001" TITLE="part 1"></A>&nbsp;PART
I - FINANCIAL INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><A NAME="a_002" TITLE="item 1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
1. FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED BALANCE SHEETS</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 31, 2019 and September 30, 2019</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 4%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,458,423</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,185,630</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
    and tax receivables</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,730,672</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,642,745</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and deposits</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">234,972</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,998</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Assets</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,424,067</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,329,373</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities and Stockholders'
    Equity</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Liabilities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,127,498</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,523,332</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,336,419</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,516,342</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,463,917</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,039,674</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments - Note
    5</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital stock</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized:</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000
    preferred stock, par value $0.001 per share</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000,000
    common stock, par value $0.001 per share</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    and outstanding:</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,080,356
    common shares<BR> &nbsp;(September 30, 2019 - 52,650,251)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,082</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,652</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in
    capital</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,891,753</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,633,807</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(139,988,685</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,396,760</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders' Equity</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,960,150</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,289,699</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Total
    Liabilities and Stockholders' Equity</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,424,067</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,329,373</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended December 31, 2019 and 2018</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    months ended December 31,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="width: 4%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,352,035</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,761,307</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,348,668</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,712,210</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,700,703</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,473,517</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expenses)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant income</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,944</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,528</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    incentive income</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">943,215</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">413,682</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income, net</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,720</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,800</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange gain (loss), net</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,113</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,507</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income, net</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,117,992</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">562,503</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss before provision
    for income taxes</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,582,711</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,911,014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax expense, current</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,214</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,717</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss and comprehensive loss</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,591,925</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,919,731</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss per share</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.12</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.15</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of shares outstanding</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,773,685</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,327,482</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><B>ANAVEX
LIFE SCIENCES CORP.</B></B></FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended December 31, 2019 and 2018</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Flows used in
    Operating Activities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD><TD STYLE="width: 4%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,591,925</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,919,731</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments to reconcile
    net loss to net cash used in operations:</FONT></TD><TD STYLE="color: red; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="color: red; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="color: red; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,264,424</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,066,987</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in non-cash
    working capital balances related to operations:</FONT></TD><TD STYLE="color: red; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="color: red; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="color: red; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="color: red; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
    and tax receivables</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,087,927</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(403,883</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and deposits</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">266,026</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,189</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(395,834</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,083,531</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">820,077</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92,262</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating
    activities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,725,159</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,160,169</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Flows provided
    by Financing Activities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common shares</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,997,952</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,994,700</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    financing charges</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by
    financing activities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,997,952</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,944,700</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease)
    in cash and cash equivalents during the period</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,272,793</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,215,469</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents, beginning of period</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,185,630</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,930,638</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents, end of period</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,458,423</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,715,169</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended December 31, 2019 and 2018</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="9" STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
                                         Stock</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="vertical-align: middle; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par
                                         Value</FONT></TD><TD STYLE="vertical-align: middle; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</FONT></TD><TD STYLE="vertical-align: middle; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="vertical-align: middle; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: middle; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, October 1, 2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,650,521</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,652</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,633,807</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,396,760</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,289,699</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under
    2019 purchase agreement</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Purchase shares</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,394,160</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,394</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,993,558</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,997,952</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Commitment shares</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,675</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,264,424</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,264,424</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,591,925</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,591,925</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December
    31, 2019</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,080,356</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,082</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,891,753</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(139,988,685</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,960,150</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, October 1, 2017</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,933,472</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,935</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129,377,542</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(108,931,967</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,491,510</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under
    2015 Purchase Agreement</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Purchase shares</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">950,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,993,750</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,994,700</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Commitment shares</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,584</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,066,987</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,066,987</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,919,731</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,919,731</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December
    31, 2018</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,887,056</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,888</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,438,276</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(115,851,698</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,633,466</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Business Description and Basis of Presentation</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. (the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&ldquo;CNS&rdquo;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&rsquo;s lead compound ANAVEX&reg;2-73
is being developed to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&ldquo;MECP2&rdquo;).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of Presentation</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&ldquo;SEC&rdquo;) and accounting principles generally accepted in the United States of America
(&ldquo;U.S. GAAP&rdquo;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&rsquo;s annual report on Form 10-K
for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies
in the preparation of interim reports.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
results for the three months ended December 31, 2019 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&rsquo;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Business Description and Basis of Presentation</U> &ndash; (continued)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated
financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&nbsp;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to
change.&nbsp;The actual amount of the Company&rsquo;s expenditures will vary depending upon a number of factors including but
not limited to the design, timing and duration of future clinical trials, the progress of the Company&rsquo;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels
based on the timing of future clinical trials.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Use
of Estimates</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&rsquo;s estimates. To the extent
there are material differences between the estimate s and the actual results, future results of operations will be affected.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment
of Prior Period Financial Statements</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed in Note 1 to the Company&rsquo;s consolidated financial statements included in the Company&rsquo;s annual
report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial
statements which were immaterial<FONT STYLE="color: gray">. </FONT>These adjustments were identified in connection with the preparation
of the consolidated financial statements for the year ended September 30, 2019 and related to the timing of recognition of research
and development incentive income. Previously the Company accounted for research and development incentive income when received
in cash. During the year ended September 30, 2019, based on a continuing assessment regarding the Company&rsquo;s eligibility
for the incentive programs under which it was receiving such income, the Company determined that the income should have been accrued
and recorded in the period in which the qualifying research and development expenditures were incurred.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interim condensed consolidated financial statements for the three months ended December 31, 2018 have been similarly adjusted
to reflect the adjusted research and development incentive income for the quarter accordingly in the amount of $413,682 and should
be read in conjunction with Note 1 to the Company&rsquo;s consolidated financial statements for the year ended September 30, 2019.</FONT></P>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Business Description and Basis of Presentation</U> &ndash; (continued)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Principles
of Consolidation</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value Measurements</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - &#9;quoted prices (unadjusted) in active markets for identical assets or liabilities;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - &#9;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2019 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Basic
and Diluted Loss per Share</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2019, loss per share excludes 9,226,266 (September 30, 2019 &ndash; 8,812,933) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Recent Accounting Pronouncements</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recently
Adopted Accounting Pronouncements</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases.
The main difference between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees
for those leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability
to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is largely
unchanged from that applied under previous U.S. GAAP. The adoption of this standard on October 1, 2019 did not have any impact
on the Company's results of operations, financial condition, cash flows, and financial statement disclosures. The Company elected
to the package of practical expedients permitted under the transition guidance that allowed, among other things, the historical
lease classifications to be carried forward without reassessment. Further, the Company elected to not recognize lease assets and
lease liabilities for leases with a term of 12 months or less.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recent
Accounting Pronouncements Not Yet Adopted</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Other Income </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
Income</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received
in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for
a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant income is deferred when received and amortized to other income as the related research and development expenditures are
incurred. During the three months ended December 31, 2019, the Company recognized $74,944 (2018: $74,528) of this grant on its
statement of operations within grant income.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development incentive income</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development incentive income represents the receipt by the Company&rsquo;s Australian subsidiary, of the Australian research
and development incentive credit, (the &ldquo;ATO R&amp;D Credit&rdquo;).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2019, the Company recorded research and development incentive income of $943,215 (AUD 1,345,000)
(2018: $413,682 (AUD 587,000)) in respect of the ATO R&amp;D Credit for eligible research and development expenses incurred during
the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Equity Offering Agreements</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled
Equity Offering Sales Agreement</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2018, the Company entered into a Controlled Equity Offering&nbsp;Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with
Cantor Fitzgerald&nbsp;&amp; Co., as agent (&ldquo;Cantor Fitzgerald&rdquo;), pursuant to which the Company may offer and sell
shares of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the
&ldquo;Offering&rdquo;).&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of a placement notice based on the Company&rsquo;s instructions and subject to the terms and conditions of the Sales
Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an &ldquo;at the market offering&rdquo; offering, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.
The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend
or terminate the offering of Shares upon notice to the other party, subject to certain conditions.&nbsp; Cantor Fitzgerald will
act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable
state and federal law, rules&nbsp;and regulations and the rules&nbsp;of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds
from the sale of the Shares pursuant to the Sales Agreement.&nbsp; The Company also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. As of December 31, 2019, no shares had been sold pursuant to the Offering.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Equity Offering Agreements</U> &ndash; Continued</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015
Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &ldquo;2015 Purchase Agreement&rdquo;) with Lincoln
Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2019, the Company did not issue any shares to Lincoln Park under the 2015 Purchase Agreement.
During the three months ended December 31, 2018, the company issued to Lincoln Park an aggregate of 953,584 shares of common stock
under the 2015 Purchase Agreement, including 950,000 shares of common stock for an aggregate purchase price of $1,994,700 and
3,584 commitment shares. At December 31, 2019 and September 30, 2019, all remaining purchase amounts available for issuance under
the 2015 Purchase Agreement had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further
shares will be sold under the 2015 Purchase Agreement.</FONT></P>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Lincoln
Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000
in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares
of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day
of the next month following the 36-month anniversary of June 12, 2019.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &ldquo;Regular Purchase&rdquo;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&rsquo;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2019 Purchase Agreement limits the Company&rsquo;s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common
Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i)
shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock
to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on
the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock
on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company&rsquo;s
sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company&rsquo;s
outstanding shares of Common Stock at any given time.</FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Equity Offering Agreements</U> &ndash; Continued</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock
as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company&rsquo;s
discretion the $50,000,000 aggregate commitment.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2019, the Company issued to Lincoln Park an aggregate of 4,429,835 shares of common stock
under the 2019 Purchase Agreement, including 4,394,160 shares of common stock for an aggregate purchase price of $10,997,952 and
35,675 commitment shares. At December 31, 2019, an amount of $34,367,543 remained available under the 2019 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9;<U>Commitments </U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Leases
                                         </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">During
the three months ended December 31, 2019, the Company incurred office lease expense of $50,054 (2018: $37,754).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Litigation</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share
                                         Purchase Warrants</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of the Company&rsquo;s outstanding share purchase warrants is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price ($)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2018</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">678,379</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.87</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,750</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(319,629</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2019</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2019</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.88</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2019, the Company had share purchase warrants outstanding as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry
    Date</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 29%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,000</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 29%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30,
    2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6, 2024</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Commitments</U> &ndash; Continued</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock&ndash;based
                                         Compensation Plan</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015
Stock Option Plan</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 66pt; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2015, the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) approved a 2015 Omnibus Incentive Plan (the
&ldquo;2015 Plan&rdquo;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees
and consultants of the Company.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event
of a change of the Company&rsquo;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were
granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&rsquo;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Stock Option Plan</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &ldquo;2019 Plan&rdquo;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&rsquo;s 2007 Stock Option
Plan (the &ldquo;2007 Plan&rdquo;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&rsquo;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.</FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2019</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Commitments </U>&ndash; (Continued)</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock-based
                                         Compensation Plan &ndash; (Continued)</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of Company&rsquo;s outstanding stock purchase options is presented below:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price ($)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Grant Date Fair Value ($)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    intrinsic value ($)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: middle; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2018</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,506,917</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.83</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353,088</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,265,399</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.79</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(309,383</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.25</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2019</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,462,933</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.58</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,115,032</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">265,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.36</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.98</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,667</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.64</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    December 31, 2019</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,726,266</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.54</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,195,111</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
    December 31, 2019</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,883,586</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.85</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,047,275</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&rsquo;s stock for the options that were in-the-money at December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2019, the Company recognized stock-based compensation expense of $1,264,424 (2018: $2,066,987)
in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have been
included in general and &#9;administrative expenses and research and development expenses on the Company&rsquo;s statement of
&#9;operations as follows:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 90%; font: 10.5pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">481,101</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,011,399</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">783,323</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055,588</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    share based compensation</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,264,424</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,066,987</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
amount of approximately $4,602,000 in stock-based compensation is expected to be recorded over the remaining term &#9;of such
options through fiscal 2022.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 90%; font: 10.5pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.88</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options
    (years)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.45</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized volatility</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106.15</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend rate</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE><BR STYLE="clear: both">



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_003" TITLE="item 2"></A>Item
2. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Forward-Looking
Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">This Quarterly
Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained in
this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone events,
future financial position, business strategy and plans and objectives of management for future operations, are forward-looking
statements. The words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;expect&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;suggest,&rdquo;
&ldquo;plan&rdquo; and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to generate any revenue or to continue as a going
    concern;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to successfully conduct clinical and preclinical
    trials for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to raise additional capital on favorable terms and
    the impact of such activities on our stockholders and stock price;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to execute our research and development plan on
    time and on budget;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our products ability to demonstrate efficacy or an acceptable
    safety profile of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain the support of qualified scientific collaborators;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability, whether alone or with commercial partners, to successfully
    commercialize any of our product candidates that may be approved for sale;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to identify and obtain additional product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our reliance on third parties in non-clinical and clinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to defend against product liability claims;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to safeguard against security breaches;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain and maintain sufficient intellectual property
    protection for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to comply with our intellectual property licensing
    agreements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to defend against claims of intellectual property
    infringement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to comply with the maintenance requirements of the
    government patent agencies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to protect our intellectual property rights throughout
    the world;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competition;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the anticipated start dates, durations and completion dates
    of our ongoing and future clinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the anticipated designs of our future clinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our anticipated future
    regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our anticipated future
    cash position.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have based
these forward-looking statements largely on our current expectations and projections about future events, including the responses
we expect from the U.S. Food and Drug Administration, (&ldquo;FDA&rdquo;), and other regulatory authorities and financial trends
that we believe may affect our financial condition, results of operations, business strategy, preclinical and clinical trials,
and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including
without limitation the risks described in &ldquo;Risk Factors&rdquo; in Part I, Item 1A of our Annual Report on Form 10-K filed
with the Securities and Exchange Commission on December 16, 2019. These risks are not exhaustive. Other sections of this Quarterly
Report on Form 10-Q include additional factors which could adversely impact our business and financial performance. Moreover,
we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible
for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the
events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as required by applicable laws including the securities
laws of the United States, we assume no obligation to update or supplement forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">As used in this
Quarterly Report on Form 10-Q, the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and &ldquo;Anavex&rdquo; mean
Anavex Life Sciences Corp., unless the context clearly requires otherwise.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our
Current Business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Anavex Life
Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying
precision medicine to central nervous system (&ldquo;CNS&rdquo;) diseases with high unmet need. We analyze genomic data from clinical
studies to identify biomarkers, which we use to select patients that will receive the therapeutic benefit for the treatment of
neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our lead compound,
ANAVEX<SUP>&reg;</SUP>2-73, is being developed to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and potentially other
central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder
caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&ldquo;MECP2&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our total portfolio
currently consists of five programs. To prioritize the allocation of our resources, we designate certain programs as core programs
and others as seed programs. We currently have two core programs and three seed programs. Our core programs are at various stages
of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">The following table summarizes key
information about our programs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 317.25pt; width: 468pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Anavex has a
portfolio of compounds varying in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which is
an intracellular chaperone protein with important roles in cellular communication. S1R is also involved in transcriptional regulation
at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order to validate
the ability of our compounds to activate quantitatively the S1R, we performed, in collaboration with Stanford University, a quantitative
Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<SUP>&reg;</SUP>2-73 target
engagement or receptor occupancy (RO) with S1R in the brain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 329.25pt; width: 468pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Cellular
Homeostasis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Many diseases
are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases like Rett
syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In
neurodegenerative diseases, such as Alzheimer&rsquo;s and Parkinson&rsquo;s diseases, chronic cellular stress is possibly caused
by age-correlated buildup of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein
or ribonucleic acid (&ldquo;RNA&rdquo;) lead to the death of neurons and dysfunction of the nervous system. The spreading of protein
aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer&rsquo;s and Parkinson&rsquo;s diseases that results
from disorders of protein synthesis, trafficking, folding, processing or degradation in cells. The clearance of macromolecules
in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in nerve cells. For example,
Alzheimer&rsquo;s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates
of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation of microglia.
With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<SUP>&reg;</SUP>2-73, our approach is to restore cellular balance,
i.e. homeostasis. Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental
and neurodegenerative disease progression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;<B><I>ANAVEX</I></B><SUP>&reg;</SUP><B><I>2-73-specific
Biomarkers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">A full genomic
analysis of Alzheimer&rsquo;s disease (AD) patients treated with ANAVEX<SUP>&reg;</SUP>2-73 resulted in the identification of
actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<SUP>&reg;</SUP>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<SUP>&reg;</SUP>2-73-specific
biomarker hypothesis. It is expected that <I>excluding</I> patients with these two identified biomarker variants (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically
significant improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<SUP>&reg;</SUP>2-73,
which are considered independent of AD pathology, as well as multiple endpoints and time-points, provides support for precision
medicine clinical development of ANAVEX<SUP>&reg;</SUP>2-73 by using genetic biomarkers identified within the study population
itself to target patients who are most likely to respond to ANAVEX<SUP>&reg;</SUP>2-73 treatment in AD as well as indications
like Parkinson&rsquo;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<SUP>&reg;</SUP>2-73 is currently studied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>Clinical Studies Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Alzheimer&rsquo;s
Disease</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In November
2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX<SUP>&reg;</SUP>2-73
in mild-to-moderate Alzheimer&rsquo;s patients. This open-label randomized trial met both primary and secondary endpoints and
was designed to assess the safety and exploratory efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in 32 patients. ANAVEX<SUP>&reg;</SUP>2-73
targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed
to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer&rsquo;s disease. In October 2017,
we presented positive pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 2a study, which established a concentration-effect
relationship between ANAVEX<SUP>&reg;</SUP>2-73 and study measurements. These measures obtained from all patients who participated
in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the study appears to show that ANAVEX<SUP>&reg;</SUP>2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which
also targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In March 2016,
we received approval from the Ethics Committee in Australia to extend the Phase 2a clinical trial by an additional 108 weeks,
which had been requested by patients and their caregivers. Subsequently, in May 2018, we received approval from the Ethics Committee
in Australia to further extend the Phase 2a extension trial for an additional two years. The two consecutive trial extensions
have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX<SUP>&reg;</SUP>2-73, providing
an opportunity to gather extended safety data for a cumulative time period of five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In October 2018,
we presented new long-term clinical data for ANAVEX<SUP>&reg;</SUP>2-73 in a presentation at the 2018 Clinical Trials on Alzheimer&rsquo;s
Disease (CTAD) Meeting. At 148 weeks into the five-year extended Phase 2a clinical study, data confirmed a significant association
between ANAVEX<SUP>&reg;</SUP>2-73 concentration and both exploratory functional and cognitive endpoints as measured by the Alzheimer&rsquo;s
Disease Cooperative Study-Activities of Daily Living&nbsp;(ADCS-ADL)&nbsp;evaluation and the Mini Mental State Examination (MMSE),
respectively. The cohort of patients treated with higher ANAVEX<SUP>&reg;</SUP>2-73 concentration maintained ADCS-ADL performance
compared to the lower concentration cohort (p&lt;0.0001). As well, the patient cohort with the higher ANAVEX<SUP>&reg;</SUP>2-73
concentration performed better at MMSE compared to the lower concentration cohort (p&lt;0.0008). A significant impact on the drug
response levels of both the SIGMAR1 (p&lt;0.0080) and COMT (p&lt;0.0014) genomic biomarkers, identified and specified at week
57, was also confirmed over the 148-week period. Further, ANAVEX<SUP>&reg;</SUP>2-73 demonstrated continued favorable safety and
tolerability through 148 weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">A larger Phase
2b/3 double-blind, placebo-controlled study of ANAVEX<SUP>&reg;</SUP>2-73 in Alzheimer&rsquo;s disease commenced in August 2018,
which is independent of the ongoing Phase 2a extension study. The Phase 2b/3 study will enroll approximately 450 patients for
48 weeks, randomized 1:1:1 to two different ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo. The trial is currently taking place in
Australia; however, additional regions are being added. The ANAVEX<SUP>&reg;</SUP>2-73 Phase 2b/3 study design incorporates genomic
precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a study. Primary and secondary endpoints will
assess safety and both cognitive and functional efficacy, measured through Alzheimer&rsquo;s Disease Assessment Scale &ndash;
Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &ndash; Sum of Boxes for cognition and function (CDR-SB).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In October 2019,
we initiated a long-term open label extension study of ANAVEX&reg;2-73, entitled the ATTENTION-AD study, for patients who have
completed the 48-week Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last two years and will
give patients the opportunity to continue their treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Rett Syndrome
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In February
2016, we presented positive preclinical data for ANAVEX<SUP>&reg;</SUP>2-73 in Rett syndrome, a rare neurodevelopmental disease.
The study was funded by the International Rett Syndrome Foundation (&ldquo;Rettsyndrome.org&rdquo;). In January 2017, we were
awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter Phase
2 clinical trial of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome. This award is being received in quarterly instalments
which commenced during fiscal 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In March 2019,
we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment
of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The first Phase
2 study, which commenced in March 2019, is taking place in the United States and is a randomized double-blind, placebo-controlled
safety, tolerability, pharmacokinetic and efficacy study of oral liquid ANAVEX<SUP>&reg;</SUP>2-73 formulation to treat Rett syndrome.
Pharmacokinetic and dose findings will be investigated in a total of 21 patients over a 7-week treatment period including ANAVEX<SUP>&reg;</SUP>2-73-specific
genomic precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<SUP>&reg;</SUP>2-73
under a voluntary open label extension protocol. Primary and secondary endpoints include safety as well as Rett syndrome conditions
such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity. The ANAVEX<SUP>&reg;</SUP>2-73 Phase
2 Rett syndrome study designs incorporate genomic precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase
2a Alzheimer&rsquo;s disease study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In June 2019,
we commenced the second Phase 2 study of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome, called the AVATAR study.
This study is taking place in Australia using a convenient once-daily oral liquid ANAVEX<SUP>&reg;</SUP>2-73 formulation. Similar
to the United States-based Phase 2 study for Rett syndrome, the study will evaluate the safety and efficacy of ANAVEX<SUP>&reg;</SUP>2-73
in approximately 33 patients over a 7-week treatment period including ANAVEX<SUP>&reg;</SUP>2-73 specific precision medicine biomarkers.
All patients who participate in the study will be eligible to receive ANAVEX<SUP>&reg;</SUP>2-73 under a voluntary open label
extension protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In September
2019, we announced approval from the Australian Human Research Ethics Committee to commence the third study of ANAVEX<SUP>&reg;</SUP>2-73
for the treatment of Rett syndrome, called the EXCELLENCE study. Similar to the AVATAR study, this study is taking place in Australia
and is using a convenient once-daily oral liquid ANAVEX<SUP>&reg;</SUP>2-73 formulation. The study will evaluate the safety and
efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in approximately 69 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating
ANAVEX<SUP>&reg;</SUP>2-73 specific precision medicine biomarkers. All patients who participate in the study will be eligible
to receive ANAVEX<SUP>&reg;</SUP>2-73 under a voluntary open label extension protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Parkinson&rsquo;s
Disease</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In September
2016, we presented positive preclinical data for ANAVEX<SUP>&reg;</SUP>2-73 in Parkinson&rsquo;s disease, which demonstrated significant
improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael
J. Fox Foundation. Additional data was announced in October 2017 from the model for experimental parkinsonism. The data presented
indicates that ANAVEX<SUP>&reg;</SUP>2-73 induces robust neurorestoration in experimental parkinsonism. The encouraging results
we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer&rsquo;s disease trial, support
the notion that ANAVEX<SUP>&reg;</SUP>2-73 is a promising clinical candidate drug for Parkinson&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In October 2018,
we initiated a double-blind, randomized, placebo-controlled Phase 2 trial with ANAVEX<SUP>&reg;</SUP>2-73 in Parkinson&rsquo;s
Disease Dementia (PDD), which will study the effect of the compound on both the cognitive and motor impairment of Parkinson&rsquo;s
disease. The Phase 2 study will enroll approximately 120 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<SUP>&reg;</SUP>2-73
doses or placebo. The ANAVEX<SUP>&reg;</SUP>2-73 Phase 2 PDD study design incorporates genomic precision medicine biomarkers identified
in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a study. The study is currently taking place in Spain and Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Our Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our research
and development pipeline includes ANAVEX<SUP>&reg;</SUP>2-73 currently in three different clinical studies, and several other
compounds in different stages of pre-clinical study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our proprietary
SIGMACEPTOR&trade; Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding
of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature,
including Alzheimer&rsquo;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin
or development) of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Compounds that
have been subjects of our research include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">ANAVEX<SUP>&reg;</SUP>2-73</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">ANAVEX<SUP>&reg;</SUP>2-73
may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In Rett syndrome,
administration of ANAVEX<SUP>&reg;</SUP>2-73 resulted in both significant and dose related improvements in an array of behavioral
paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<SUP>&reg;</SUP>2-73
was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident.
Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<SUP>&reg;</SUP>2-73
for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse. Additionally, chronic
oral dosing daily for 6.5 weeks of ANAVEX<SUP>&reg;</SUP>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett
syndrome disease mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths,
some of the core deficits observed in Rett syndrome. Administration of ANAVEX<SUP>&reg;</SUP>2-73 resulted in both significant
and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In March 2019,
we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment
of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions, as more fully described
above under <I>Clinical Studies Overview &ndash; Rett Syndrome</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In May 2016
and June 2016, the FDA granted Orphan Drug Designation to ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome and infantile
spasms, respectively. In November 2019, the FDA granted to ANAVEX<SUP>&reg;</SUP>2-73 the Rare Pediatric Disease (RPD) designation
for the treatment of Rett syndrome. The RPD designation provides priority review by the FDA to encourage the development of treatments
for rare pediatric diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Further, subsequent
to December 31, 2019, the FDA granted Fast Track designation for the ANAVEX<SUP>&reg;</SUP>2-73 clinical development program for
the treatment of Rett syndrome. The FDA Fast Track program is designed to facilitate and expedite the development and review of
new drugs to address unmet medical needs in the treatment of serious and life-threatening conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">For Parkinson&rsquo;s
disease, data demonstrates significant improvements and restoration of function in a disease modifying animal model of Parkinson&rsquo;s
disease. Significant improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints.
In July 2018 the Company received approval from the Spanish Agency for Medicinal Products and Medical Devices (AEMPS), to initiate
its Phase 2, double-blind, placebo-controlled 14-week trial of the safety and efficacy of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment
of Parkinson&rsquo;s disease dementia. The Phase 2 study commenced in October 2018 and will enroll 120 patients, randomized 1:1:1
to two different ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo, in approximately 24 clinical study sites across Spain and Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In Alzheimer&rsquo;s
disease (AD) animal models, ANAVEX<SUP>&reg;</SUP>2-73 has shown pharmacological, histological and behavioral evidence as a potential
neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors
and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<SUP>&reg;</SUP>2-73 has shown a potential dual
mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576, ANAVEX<SUP>&reg;</SUP>2-73
induced a statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as
well as significantly increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent.
It also statistically alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both
in terms of spatial working memory and long-term spatial reference memory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Based on the
results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<SUP>&reg;</SUP>2-73.
In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent
dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram
(ECG) parameters. ANAVEX<SUP>&reg;</SUP>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some
subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were
moderate in severity and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The ANAVEX<SUP>&reg;</SUP>2-73
Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers between the ages of 18 and
55 received single, ascending oral doses over the course of the trial. Study endpoints included safety and tolerability together
with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug, the rate at which a drug
enters the blood and the duration of its effect, as well as chemical changes of the substance in the body. This study was conducted
in Germany in collaboration with ABX-CRO, a clinical research organization that has conducted several Alzheimer&rsquo;s disease
studies, and the Technical University of Dresden.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In December
2014, a Phase 2a clinical trial was initiated for ANAVEX<SUP>&reg;</SUP>2-73, for the treatment of Alzheimer&rsquo;s disease.
The open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in 32
patients with mild-to-moderate Alzheimer&rsquo;s disease. ANAVEX<SUP>&reg;</SUP>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and
to reverse the pathological hallmarks observed in Alzheimer&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Phase 2a
study met both primary and secondary objectives of the study.&nbsp;The 31-week&nbsp;preliminary exploratory&nbsp;safety and&nbsp;efficacy
data from the&nbsp;Phase 2a study of ANAVEX<SUP>&reg;</SUP>2-73 in Alzheimer&rsquo;s&nbsp;patients, with most receiving also donepezil,
the current standard of care, demonstrated&nbsp;favorable&nbsp;safety, maximum tolerated&nbsp;dose, positive dose response, sustained
efficacy response through 31 weeks for both cognitive and functional measures, as well as&nbsp;positive unexpected therapeutic
response events. ANAVEX<SUP>&reg;</SUP>2-73 continued to demonstrate a favorable adverse event (AE) profile&nbsp;through 31 weeks
in a patient population of elderly Alzheimer&rsquo;s patients with varying degrees of physical fragility. The most common&nbsp;side
effects across all AE categories tended to be of mild severity grade 1 and were resolved with dose reductions that were&nbsp;anticipated
within the adaptive design of the study protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">Through
57 weeks, Alzheimer&rsquo;s patients taking a daily oral dose between 10mg and 50mg of ANAVEX<SUP>&reg;</SUP>2-73 was well tolerated.
There were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing
of ANAVEX<SUP>&reg;</SUP>2-73 throughout the 57-week study, continued significant improvements from baseline of cognitive, functional
and behavioral scores in a group of patients were observed, respectively. This data was analyzed using refined mathematical modeling
methods in conjunction with the detailed pharmacokinetic (PK) information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">In
October 2017, we presented positive PK and PD data from the Phase 2a study, which established a concentration-effect relationship
between ANAVEX<SUP>&reg;</SUP>2-73 and study measurements. These measures, obtained from all patients who participated in the
entire 57 weeks, include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the study appears to show that ANAVEX<SUP>&reg;</SUP>2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which
also targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">Pre-specified
exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization
of both cognitive and functional measures in patients treated with ANAVEX<SUP>&reg;</SUP>2-73 was observed. This correlation was
positive within all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">In
July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000
genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp;
RNA data in patients exposed to ANAVEX<SUP>&reg;</SUP>2-73. The analysis identified genetic variants that impacted response to
ANAVEX<SUP>&reg;</SUP>2-73, among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<SUP>&reg;</SUP>2-73.
Results showed that study participants without the SIGMAR1 (rs1800866) variants, which is about 80 percent of the population worldwide,
demonstrated improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation may enable a precision
medicine approach, since these signatures can now be applied to neurological indications tested in clinical studies with ANAVEX<SUP>&reg;</SUP>2-73
including Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease dementia and Rett syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">ANAVEX<SUP>&reg;</SUP>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018,
the Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of early Alzheimer&rsquo;s disease. This Phase
2b/3 study design incorporates inclusion of genomic precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73
Phase 2a study. The Phase 2b/3 study, which is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different
ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo, commenced in October 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Preclinical
data also validates ANAVEX<SUP>&reg;</SUP>2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&rsquo;s
disease, Parkinson&rsquo;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman
syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX<SUP>&reg;</SUP>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In a study sponsored
by the Foundation for Angelman Syndrome, ANAVEX<SUP>&reg;</SUP>2-73 was assessed in a mouse model for the development of audiogenic
seizures. &nbsp;The results indicated that ANAVEX<SUP>&reg;</SUP>2-73 administration significantly reduced audiogenic-induced
seizures. In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<SUP>&reg;</SUP>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX<SUP>&reg;</SUP>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed
in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Preclinical
data presented also indicates that ANAVEX<SUP>&reg;</SUP>2-73 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Preclinical
data on ANAVEX<SUP>&reg;</SUP>2-73 related to multiple sclerosis indicates that ANAVEX<SUP>&reg;</SUP>2-73 may promote remyelination
in multiple sclerosis disease. Further, data also demonstrates that ANAVEX<SUP>&reg;</SUP>2-73 provides protection for oligodendrocytes
(&ldquo;OL&rsquo;s&rdquo;) and oligodendrocyte precursor cells (&ldquo;OPC&rsquo;s&rdquo;), as well as central nervous system
neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In March 2018,
we presented preclinical data of ANAVEX<SUP>&reg;</SUP>2-73 in a genetic mouse model of tuberous sclerosis complex (&ldquo;TSC&rdquo;).
TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence
of seizures. The new preclinical data demonstrates that treatment with ANAVEX<SUP>&reg;</SUP>2-73 significantly increases survival
and reduces seizures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>3-71</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">ANAVEX<SUP>&reg;</SUP>3-71
is a preclinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric
modulation, which has been shown to enhance neuroprotection and cognition in Alzheimer&rsquo;s disease models. ANAVEX<SUP>&reg;</SUP>3-71
is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. It is highly
effective in very small doses against the major Alzheimer&rsquo;s hallmarks in transgenic (3xTg-AD) mice, including cognitive
deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial dysfunctions.&nbsp;ANAVEX<SUP>&reg;</SUP>3-71
indicates extensive therapeutic advantages in Alzheimer&rsquo;s and other protein-aggregation-related diseases given its ability
to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">A preclinical
study examined the response of ANAVEX<SUP>&reg;</SUP>3-71 in aged transgenic animal models and showed a significant reduction
in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016,
the FDA granted Orphan Drug Designation to ANAVEX<SUP>&reg;</SUP>3-71 for the treatment of Frontotemporal dementia (FTD).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">During pathological
conditions ANAVEX<SUP>&reg;</SUP>3-71 demonstrated the formation of new synapses between neurons (synaptogenesis) without causing
an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer&rsquo;s and Parkinson&rsquo;s
disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that in addition to reducing
oxidative stress, ANAVEX<SUP>&reg;</SUP>3-71 demonstrates protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>1-41</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">ANAVEX<SUP>&reg;</SUP>1-41
is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration
or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell
viability. In addition, in animal models, ANAVEX<SUP>&reg;</SUP>1-41 prevented the expression of caspase-3, an enzyme that plays
a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning,
emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Preclinical
data presented also indicates that ANAVEX<SUP>&reg;</SUP>1-41 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>1066</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">ANAVEX<SUP>&reg;</SUP>1066,
a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<SUP>&reg;</SUP>1066
was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic
constriction injury model of neuropathic pain, a single oral administration of ANAVEX<SUP>&reg;</SUP>1066 dose-dependently restored
the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy
was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by
injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX<SUP>&reg;</SUP>1066 returned
the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any
effects on normal gastrointestinal transit with ANAVEX<SUP>&reg;</SUP>1066 and a favorable safety profile in a battery of behavioral
measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>1037
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">ANAVEX<SUP>&reg;</SUP>1037
is designed for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high
affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar
levels. In advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill
human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient
mice models. Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell
death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate
sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions
with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our compounds
are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated in
pre-clinical models will be shown in human testing.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We continue
to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our programs
and realize maximum shareholder value. Further, we may acquire or develop new intellectual property and assign, license, or otherwise
transfer our intellectual property to further our goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Our Target
Indications</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have developed
compounds with potential application to two broad categories and several specific indications. including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Central Nervous
System Diseases</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Alzheimer&rsquo;s
    disease &ndash; In 2019, an estimated 5.8 million Americans were suffering from Alzheimer&rsquo;s disease. The Alzheimer&rsquo;s
    Association<SUP>&reg;</SUP> reports that by 2025, 7.2 million Americans will be afflicted by the disease, about a 24 percent
    increase from currently affected patients. Medications on the market today treat only the symptoms of Alzheimer&rsquo;s disease
    and do not have the ability to stop its onset or its progression. There is an urgent and unmet need for both a disease modifying
    cure for Alzheimer&rsquo;s disease as well as for better symptomatic treatments.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Parkinson&rsquo;s
    disease &ndash; Parkinson&rsquo;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,
    and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the
    neurotransmitter dopamine. Parkinson&rsquo;s disease afflicts more than 10 million people worldwide, typically middle-aged
    and elderly people. The Parkinson&rsquo;s disease market is set to expand to $3.2 billion by 2021, according to business intelligence
    provider GBI Research.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Rett syndrome - Rett
    syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain develops, including
    protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered
    a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because males have a
    different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating ways.
    Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments,
    affecting nearly every aspect of the child&rsquo;s life; severe mental retardation, their ability to speak, walk and eat,
    sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000
    females.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Depression - Depression
    is a major cause of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment for depression
    is dominated by blockbuster brands, with the leading nine brands accounting for approximately 75% of total sales. However,
    the dominance of the leading brands is waning, largely due to the effects of patent expiration and generic competition.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Epilepsy - Epilepsy
    is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs
    and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease
    Control and Prevention, epilepsy affects 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medication
    that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy
    afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs
    and second generation anti-epileptic drugs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Neuropathic Pain &ndash;
    We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of
    the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain
    medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane
    stabilizing drugs or antidepressants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cancer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Malignant Melanoma
    - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant
    melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor,
    adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide malignant melanoma
    market is expected to grow to $4.4 billion by 2022.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Prostate Cancer &ndash;
    Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system.
    The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug
    therapeutics for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Pancreatic Cancer
    - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 55,000 new cases of pancreatic
    cancer will be diagnosed this year and approximately 44,000 patients will die as a result of their cancer, according to the
    American Cancer Society. Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment of pancreatic
    cancer in the United States and five largest European countries will increase to $2.9 billion by 2021.</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Patents,
Trademarks and Intellectual Property </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We hold ownership
or exclusive rights to nine U.S. patents, ten U.S. patent applications, and various PCT or ex-U.S. patent applications relating
to our drug candidates, methods associated therewith, and to our research programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We own one issued
U.S. patent entitled &ldquo;ANAVEX<SUP>&reg;</SUP>2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection&rdquo;
claims a composition of matter of ANAVEX&reg;2-73 directed to a novel and synergistic neuroprotective compound combined with donepezil
and other cholinesterase inhibitors.&nbsp; This patent is expected to expire in June 2034, absent any patent term extension for
regulatory delays. We own two issued U.S. patents each with claims directed to crystalline forms of ANAVEX&reg;2-73. The first
of these two patents claims crystalline forms of ANAVEX&reg;2-73, dosage forms and compositions containing crystalline ANAVEX&reg;2-73,
and methods of treatment for Alzheimer&rsquo;s disease using them. This patent is expected to expire in July 2036, absent any
patent term extension for regulatory delays. The second of these two patents claims pharmaceutical compositions containing a crystalline
form of ANAVEX&reg;2-73, and methods of treatment for Alzheimer&rsquo;s disease using the compositions. This patent is expected
to expire in June 2037, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims
methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either:
(i) ANAVEX&reg;2-73 and its active metabolite ANAVEX&reg;19-144; or (ii) ANAVEX&reg;19-144. This patent is expected to expire
in October 2035, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims methods
for treating a neurodevelopmental disorder or multiple sclerosis by administering ANAVEX&reg;2-73, ANAVEX&reg;19-144, and/or ANAVEX&reg;
1-41, another sigma receptor ligand similar to ANAVEX&reg;2-73. This patent is expected to expire in January 2037, absent any
patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with claims directed to methods of treating
melanoma with a compound related to ANAVEX<SUP>&reg;</SUP>2-73. This patent is expected to expire in February 2030, absent any
patent term extension for regulatory delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We also own
one issued patent with claims directed to methods for treating or preventing pain with ANAVEX<SUP>&reg;</SUP>1066. This patent
is expected to expire in November 2036, absent any patent term extension for regulatory delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">With regard
to ANAVEX<SUP>&reg;</SUP>3-71, we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<SUP>&reg;</SUP>3-71
compound and methods of treating various diseases including Alzheimer&rsquo;s with the same. These patents are expected to expire
in April 2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights
to related patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand,
Russia, and South Africa, and are expected to expire in January 2030.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We also own
other patent applications directed to enantiomers, formulations and uses that may provide additional protection for one or more
of our product candidates.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We regard patents
and other intellectual property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property
in developing our business strategy including the selective development, protection, and exploitation of our intellectual property
rights. In addition to filings made with intellectual property authorities, we protect our intellectual property and confidential
information by means of carefully considered processes of communication and the sharing of information, and by the use of confidentiality
and non-disclosure agreements and provisions for the same in contractor&rsquo;s agreements. While no agreement offers absolute
protection, such agreements provide some form of recourse in the event of disclosure, or anticipated disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our intellectual
property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions for
which important legal principles are unresolved. For more information regarding challenges to our existing or future patents,
see &ldquo;Risk Factors&rdquo; &rdquo; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange
Commission on December 16, 2019.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Financial
Highlights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Operating
expenses for the first quarter of fiscal 2020 were $7.7 million, compared to $7.5 million for the comparable quarter in fiscal
2019. The operating expenses include an aggregate of $1.3 million, as compared to $2.1 million in the first quarter of fiscal
2019, in non-cash charges related to the issuance and vesting of stock options. During the quarter, a $0.6 million increase in
research and development expenses was largely offset by a $0.4 million decrease in general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Net loss
for the first quarter of fiscal 2020 was $6.6 million, or $0.12 per share, as compared to $6.9 million, or $0.15 per share in
the comparative quarter of fiscal 2019.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Results
of Operations</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Revenue</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-style: normal">We
are in the development stage and have not earned any revenues since our inception and we do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-style: normal"><B>Three
months ended December 31, 2019 compared to three months ended December 31, 2018</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Operating
Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">Total
operating expenses for the first quarter of fiscal 2020 were $7.7 million, which represents an increase of $0.2 million from the
comparable quarter of fiscal 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Research and
development expenses for the first quarter of fiscal 2020 were $6.3 million, as compared to $5.7 million fiscal 2019, an increase
of $0.6 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">During the quarter
our general and administrative expenses were $1.4 million as compared to $1.8 million in the comparable quarter of fiscal 2019,
a decrease of $0.4 million, primarily related to a decrease in stock-option compensation charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt"><I>Other
income </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">The
net amount of other income for the first quarter of fiscal 2020 was $1.1 million as compared to $0.6 million for the comparable
quarter of fiscal 2019. The increase in other income is attributable to an increase in Australian research and development incentive
income in connection with the increase in eligible clinical activities in Australia over the comparable period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Liquidity
and Capital Resources</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Working
Capital</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 19%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December
    31, 2019</B></FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 19%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>September
    30, 2019</B></FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Current Assets</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 12.8pt; text-align: right"><FONT STYLE="font-size: 10pt">31,424,067</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding-right: 8.95pt; vertical-align: middle"><FONT STYLE="font-size: 10pt">$&#9;25,329,373</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Current Liabilities</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 12.8pt; text-align: right"><FONT STYLE="font-size: 10pt">5,463,917</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 8.95pt; text-align: right"><FONT STYLE="font-size: 10pt">5,039,674</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Working Capital</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 12.8pt; text-align: right"><FONT STYLE="font-size: 10pt">25,960,150</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: black 1pt solid; padding-right: 8.95pt; vertical-align: middle"><FONT STYLE="font-size: 10pt">$&#9;20,289,699</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: white"><BR>
At </FONT><FONT STYLE="font-size: 10pt">December 31, 2019, we had $27.5 million in cash and cash equivalents, an increase of $5.2
million from September 30, 2019. The principal reason for this increase is due to cash received from financing activities of $11.0
million from the issuance of shares of common stock under the 2019 Purchase Agreement (as defined below).</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cash
Flows</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three
    months ended December 31, </B></FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; padding-right: 13.7pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2019</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 13.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; padding-right: 0.9pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 17%; padding-right: 13.7pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Net
    cash flows used in operating activities</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 10pt">(5,725,159)</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.9pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 10pt">(4,160,169)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Net
    cash flows from financing activities</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 10pt">10,997,952</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.9pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 10pt">1,944,700</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Increase
    (decrease) in cash and cash equivalents</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 10pt">5,272,793</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.9pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 13.7pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-size: 10pt">(2,215,469)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cash
flow used in operating activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Net cash
used in operating activities for the three months ended December 31, 2019 was $5.7 million, compared to $4.2 million during the
comparable quarter of fiscal 2019. The principal reason for this increase in net cash used from operating activities in the current
period is due to an increase in research and development incentive income receivables, and a reduction in trade payables during
the period, as compared to the comparable period.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cash
flow provided by financing activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cash provided
by financing activities for the three months ended December 31, 2019 was $11.0 million, attributable to cash received from the
issuance of common shares at various market prices under the 2019 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cash provided
by financing activities for the three months ended December 31, 2018 was $1.9 million, attributable to cash received from the
issuance of common shares at various market prices under the 2015 Purchase Agreement with Lincoln Park.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Other
Financing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"><B>Purchase Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">On June 7, 2019,
we entered into the 2019 Purchase Agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln
Park&rdquo;), pursuant to which Lincoln Park committed to purchase up to $50,000,000 of our common stock. Concurrently with the
execution of the 2019 Purchase Agreement, we issued 324,383 shares of our common stock to Lincoln Park as a fee for its commitment
to purchase shares of our common stock under the 2019 Purchase Agreement and shall issue up to 162,191 shares pro rata, when and
if Lincoln Park purchases, at our discretion, the $50,000,000 aggregate commitment. The purchase shares that may be sold pursuant
to the 2019 Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time until July 1, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We may direct
Lincoln Park, at our sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any
business day (a &ldquo;Regular Purchase&rdquo;). The amount of a Regular Purchase may be increased under certain circumstances
up to 250,000 shares provided that Lincoln Park&rsquo;s committed obligation for Regular Purchases on any business day shall not
exceed $2,000,000. In the even we purchase the full amount allowed for a Regular Purchase on any given business day, we may also
direct Lincoln Park to purchase additional amounts as accelerated and additional purchases. The purchase price of shares of common
stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as
described in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">At December
31, 2019, approximately $34.4 million in shares of our common stock remained available for purchase by Lincoln Park under the
2019 Purchase Agreement, including $4.4 million of our shares of common stock currently registered under an effective registration
statement.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-style: normal">Controlled
Equity Offering Sales Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">On July 6, 2018,
we entered into a Controlled Equity Offering&nbsp;Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald&nbsp;&amp;
Co., as agent (&ldquo;Cantor Fitzgerald&rdquo;), pursuant to which we may offer and sell shares of common stock, for aggregate
gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the &ldquo;At-the-Market Offering&rdquo;).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Upon delivery
of a placement notice based on our instructions and subject to the terms and conditions of the Sales Agreement, Cantor Fitzgerald
may sell shares of common stock by methods deemed to be an &ldquo;at the market offering&rdquo; offering, in negotiated transactions
at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method
permitted by law, including negotiated transactions, subject to our prior written consent. We are not obligated to make any sales
of shares under the Sales Agreement. We or Cantor Fitzgerald may suspend or terminate the At-the-Market Offering upon notice to
the other party, subject to certain conditions.&nbsp; Cantor Fitzgerald will act as sales agent on a commercially reasonable efforts
basis consistent with its normal trading and sales practices and applicable state and federal law, rules&nbsp;and regulations
and the rules&nbsp;of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have agreed
to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&nbsp; We have also agreed to provide Cantor Fitzgerald with customary indemnification
and contribution rights. To date, no shares of common stock have been sold pursuant to the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Liquidity&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We expect that
we will be able to continue to fund our operations through existing cash on hand and through equity and debt financing in the
future. If we raise additional financing by issuing equity securities, our existing stockholders&rsquo; ownership will be diluted.
Obtaining commercial loans, assuming these loans would be available, would increase our liabilities and future cash commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Other than our
rights related to the Lincoln Park financing and the At-the-Market Offering, there can be no assurance that additional financing
will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not
able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale down
some or all of our research and development activities or perhaps even cease the operation of our business.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-style: normal">Off-Balance
Sheet Arrangements</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>CRITICAL ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">We
prepare our interim condensed consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America, and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue
and expenses, and the related disclosures of contingent liabilities. We base our estimates on historical experience and other
assumptions that we believe are reasonable in the circumstances. Actual results may differ from these estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Other
than as described in Note 2 &ldquo;Recent Accounting Pronouncements&rdquo; to our Consolidated Financial Statements included herein,
there have been no significant changes in the critical accounting policies and estimates described in our Annual Report on Form
10-K for the year ended September 30, 2019 as filed with the SEC on December 16, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.3in; margin-right: 0; margin-left: 0.3in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.3in; margin-right: 0; margin-left: 0.3in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.3in; margin-right: 0; margin-left: 0.3in"><FONT STYLE="font-size: 10pt"><B>RECENT
ACCOUNTING PRONOUNCEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Please
refer to Note 2 &ldquo;Recent Accounting Pronouncements&rdquo; in notes to our Interim Condensed Consolidated Financial Statements
included in this Form 10-Q.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_004" TITLE="item 3"></A>Item
3. Quantitative and Qualitative Disclosures about Market Risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Not applicable</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_005" TITLE="item 4"></A>Item
4. Controls and Procedures.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Disclosure
Controls and Procedures </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We maintain
disclosure controls and procedures that are designed to provide reasonable assurance that material information required to be
disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time
periods specified in the SEC&rsquo;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions
regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We carried out
an evaluation, under the supervision and with the participation of our management, including our principal executive officer and
principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined
in Rule 13a 15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on
this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures
were effective as of December 31, 2019.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Changes
in Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Related to accounting
for the Australian research and development incentive program, in response to a material weakness identified during the preparation
of our consolidated financial statements for the year ended September 30, 2019 and with the oversight of the Audit Committee of
our Board of Directors, during the quarter ended December 31, 2019, we evaluated our policies and procedures in respect of the
accounting for the Australian research and development incentive program and established additional quarterly procedures which
ensure the accounting, estimates and disclosures of this program are assessed and reconciled on a quarterly basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Other than as
described above, during the quarter ended December 31, 2019, there were no changes in our internal control over financial reporting
identified in management&rsquo;s evaluation pursuant to Rules 13a 15(d) or 15d 15(d) of the Exchange Act during the period covered
by this Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_006" TITLE="part ii"></A>PART
II &ndash; OTHER INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_007" TITLE="part ii item 1"></A>Item
1. Legal Proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"><FONT STYLE="font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"><FONT STYLE="font-size: 10pt; background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&rsquo;s interest.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_008" TITLE="part ii item 1a"></A>Item
1A. Risk Factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In addition
to the information set forth in this Form 10-Q, you should carefully review and consider the risk factors discussed in &ldquo;Risk
Factors&rdquo; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019 filed with the
SEC on December 16, 2019. These risks could materially and adversely affect our business, financial condition and results of operations.
The risks described in herein and in our Form 10-K are not the only risks we face. Our operations could also be affected by additional
factors that are not presently known to us or by factors that we currently consider immaterial to our business. There have been
no material changes in the significant factors that may affect our business and operations as described in &ldquo;Risk Factors&rdquo;
in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_009" TITLE="part ii item 2"></A>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">During
the period covered by this Quarterly Report on Form 10-Q, we have not sold any equity securities that were not registered under
the Securities Act of 1933 that were not previously reported in a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_010" TITLE="part ii item 3"></A>Item
3. Defaults Upon Senior Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_011" TITLE="part ii item 4"></A>Item
4. Mine Safety Disclosures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Not applicable.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_012" TITLE="part ii item 5"></A>Item
5. Other Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; text-transform: none">On
February 4, 2020, the Company entered into Amendment No. 1 to the Amended and Restated Employment Agreement (the &ldquo;Amendment&rdquo;)
with the Company&rsquo;s Principal Financial Officer (the &ldquo;PFO&rdquo;) in her continuing capacity as PFO of the Company,
to be effective March 1, 2020. The Amendment amends the Amended and Restated Employment Agreement by and between the Company and
the PFO dated October 4, 2017 (the &ldquo;Employment Agreement&rdquo;). Pursuant to the terms of the Amendment, the PFO shall
receive an annual base salary of $200,000 Canadian dollars and she is entitled to certain compensation from the Company in the
event of termination without Cause (as defined in the Amendment).</FONT><FONT STYLE="font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_013" TITLE="part ii item 6"></A>Item
6. Exhibits.</FONT></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>Exhibit
    <BR>
    Number </B></FONT></TD>
    <TD STYLE="width: 88%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B><BR>
    Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>(3)
    </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>Articles
    of Incorporation and Bylaws </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm" STYLE="-sec-extract: exhibit">Articles
    of Incorporation (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended March
    31, 2019 filed on May 9, 2019)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" STYLE="-sec-extract: exhibit">3.2</A></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" STYLE="-sec-extract: exhibit">Bylaws
    (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm" STYLE="-sec-extract: exhibit">3.3</A></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm" STYLE="-sec-extract: exhibit">Articles
    of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated
    by reference to our Current Report on Form 8-K filed on January 25, 2007)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>(10)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>Material
    Contracts</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_10-1.htm">10.1*</A></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_10-1.htm">Amendment
    No. 1 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 4, 2020</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>(31)
    </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>Rule
    13a-14(a)/15(d)-14(a)Certifications</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_31-1.htm">31.1*</A></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_31-1.htm">Certification
    of Christopher Missling, PhD.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_31-2.htm">31.2*</A></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_31-2.htm">Certification
    of Sandra Boenisch</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>(32)
    </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>Section
    1350 Certifications</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_32-1.htm">32.1*</A></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><A HREF="e1699_32-1.htm">Certification
    of Christopher Missling, PhD and Sandra Boenisch.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>(101)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt"><B>XBRL</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">101.INS*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">XBRL
    INSTANCE DOCUMENT</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">101.SCH*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">XBRL
    TAXONOMY EXTENSION SCHEMA</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">101.CAL*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">101.DEF*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">101.LAB*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">101.PRE*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt">* Filed herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="a_014" TITLE="Signature"></A>SIGNATURES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>ANAVEX LIFE
SCIENCES CORP. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/Christopher
Missling, PhD&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Christopher
Missling, PhD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"><FONT STYLE="font-size: 10pt">Chief
Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Date: February
6, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/Sandra
Boenisch&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Sandra Boenisch,
CPA, CGA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"><FONT STYLE="font-size: 10pt">Principal
Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting
Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Date: February
6, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>e1699_10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT
AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>THIS AMENDMENT NO. 1
(the &ldquo;Amendment&rdquo;) </B>to the Amended and Restated Employment Agreement, dated October 4, 2017 (the &ldquo;<B><U>Employment
Agreement</U></B>&rdquo;) is dated February 4, 2020 with an effective date of March 1, 2020, is by and between Anavex Life Sciences
Corp. (the &ldquo;<B><U>Company</U></B>&rdquo; or &ldquo;<B><U>Anavex</U></B>&rdquo;), and Sandra Boenisch (the &ldquo;<B><U>Employee</U></B>&rdquo;).
Except as otherwise provided herein in this Amendment, capitalized terms used in this Amendment shall have the same meanings given
to them in the Employment Agreement. Company and the Employee are referred to each individually as a &ldquo;<B><U>Party</U></B>&rdquo;
and collectively as the &ldquo;<B><U>Parties</U></B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 203.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Employee
is currently employed by the Company as Principal Financial Officer pursuant to the terms of the Employment Agreement; and<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parties
desire to amend the Employment Agreement as described below, but to otherwise maintain in effect in full all other terms of the
Employment Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, for the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 194.65pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>AMENDMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B><U>Adoption of Recitals</U></B>. The Company and Employee adopt the above recitals as being true and correct</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B><U>Section 1(a) Employment</U></B>. The Parties agree that Section 1(a) of the Employment Agreement shall be amended and restated as follows: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;(a)&#9;<B><U>Employment</U></B>. This Agreement
will commence on March 1, 2020 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;) and shall terminate on February 28, 2022 (the &ldquo;<B><U>Term</U></B>&rdquo;),
unless sooner terminated in accordance with the provisions of this Agreement. The Term and any extensions shall be referred to
as the &ldquo;<B><U>Employment Period</U></B>.&rdquo; This Agreement must be renewed in writing, signed by both parties. If the
Agreement is not renewed in writing, the non-renewal is not considered a Termination.&rdquo;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B><U>Section 3(a) Base Salary</U></B>. The Parties agree that Section 3(a) of the Employment Agreement shall be amended and restated as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&ldquo;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Base
Salary</U></B>. During the Employment Period, the Company shall pay to the Employee an annual base salary (&ldquo;<B><U>Base Salary</U></B>&rdquo;)
of Two Hundred Thousand Canadian Dollars ($200,000 CAD) payable by the Company and payable in accordance with the Company&rsquo;s
payroll schedules throughout the term of such employment, subject to the provisions of Section 4 hereof (governing Terminations),
and subject to any applicable tax and payroll deductions; <I>provided, however</I>, that in the Company&rsquo;s sole discretion,
based on factors such as the market and the Employee&rsquo;s job performance, salary increases may be made. There, however, is
never a guarantee of an increase in Base Salary. Salary decreases may be made through a written modification of this Agreement
executed and signed by the Parties.&rdquo;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. <B><U>Section 3(b) Annual Bonus</U></B>. The Parties agree that
Section 3(b) is deleted in its entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. <B><U>Section 4(d)(ii) Obligations Upon
Termination by the Company without Cause</U></B>. The Parties agree that Section 4(d)(ii) of the Employment Agreement shall be
amended and restated as follows:</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&ldquo;(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination
by the Company without Cause</U></B>. In the event that the employment of the Employee is terminated pursuant to Subsection 4(b),
the Employee shall be entitled to Compensation (as set forth in Section 3 above) equal to six (6) months&rsquo; Base Salary, which
shall be paid by the Company over the six-month period in accordance with the Company&rsquo;s normal payroll practices (excluding
any Base Salary or other payments as may have been accrued but not yet paid prior to the Date of Termination) (the &ldquo;<B><U>Severance
Compensation</U></B>&rdquo;). The Company may opt to have the Employee cease providing services to the Company during the thirty
(30) day notice-period. In such event, Company shall continue the Compensation and Benefits (as set forth in Section 3 above) during
the thirty (30) day notice-period, in addition to the Severance Compensation. Further, any outstanding stock option or other stock
awards vesting in the contract year of Termination held by Employee as of the Date of Termination shall immediately vest and become
exercisable.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Full
Force and Effect</U></B>. Except as expressly amended herein, all other terms and provisions of the Employment Agreement shall
remain in full force and effect and are hereby ratified and confirmed in all respects. The Parties mutually acknowledge and agree
that any and all other prior agreements, offer letters or contracts between Employee and the Company, are declared null and void
with no legal effect as of the date this Amendment is executed by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Further
Amendments</U></B>. The Employment Agreement shall be further amended wherever appropriate to reflect the changes indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Right
to Review and Seek Counsel</U></B>. The Employee acknowledges that she has had the opportunity to seek independent counsel and
tax advice in connection with the execution of this Agreement, and the Employee represents and warrants to the Company (a) that
she has sought such independent counsel and advice as she has deemed appropriate in connection with the execution hereof and the
transactions contemplated hereby, and (b) that she has not relied on any representation of the Company as to tax matters, or as
to the consequences of the execution hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Governing
Law</U></B>. This Amendment shall be governed and construed in accordance with the laws of the State of New York without regard
to conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Headings
and Captions</U></B>. The titles and captions of paragraphs, sections, subparagraphs and subsections contained in this Amendment
are provided for convenience of reference only, and shall not be considered terms or conditions of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Validity</U></B>.
The invalidity or unenforceability of any provision of this Amendment shall not affect the validity or enforceability of any other
provision of this Amendment, which shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Counterparts</U></B>.
This Amendment may be executed in one or more separate counterparts, each of which, when so executed, shall be deemed to be an
original. Such counterparts shall, together, constitute and shall be one and the same instrument. This Amendment, and the counterparts
thereto, may be executed by the Parties using their respective signatures transmitted via facsimile machines or via electronic
mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have executed this Agreement on February 4, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ANAVEX LIFE SCIENCES CORP. </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>SANDRA BOENISCH</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 51%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ Christopher Missling</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Sandra Boenisch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Christopher U. Missling</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/04/2020</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: 02/04/2020</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: white">&nbsp;</P>

<P STYLE="font: 11pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>e1699_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">1. I have reviewed this Quarterly Report
on Form 10-Q for the three months ended December 31, 2019 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">4. The registrant's other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">5. The registrant's other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(b) any fraud, whether or not
material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: February 6, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><U>/s/Christopher Missling, PhD </U><BR>
Christopher Missling, PhD<BR>
Chief Executive Officer, President and Secretary<BR>
(Principal Executive Officer)</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>e1699_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">I, Sandra Boenisch, certify
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">1. I have reviewed this Quarterly Report
on Form 10-Q for the three months ended December 31, 2019 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">4. The registrant's other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">5. The registrant's other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify">(b) any fraud, whether or not
material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: February 6, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>/s/Sandra Boenisch</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sandra Boenisch, CPA, CGA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white">Principal
Financial Officer, Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial and Accounting Officer)</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>e1699_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Quarterly Report
of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended December 31, 2019 as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on
the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 30.6pt; text-align: justify">(1) the Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 30.6pt; text-align: justify">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dated: February 6, 2020</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">/<U>s/Christopher Missling, PhD </U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Chief Executive Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Principal Executive Officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/Sandra Boenisch</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><BR>
&nbsp;<BR>
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging,
or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required
by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!K0)V P$1  (1 0,1 ?_$ 2   0 !! ,! 0
M       &!0<("0$"! ,* 0$  00# 0$             !@0%!P@! @,)"A
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M>]W_ .1Q[G'"+4M1>57F8H]+H!*[=DJW9IFF[ >7^*:,%9>MUZSR.L8ZOQB
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MRJ91$$75KLD&E%Q+9RX.V:+F7E(_PQ%\HE(Q"QH]2/!4'"9'3=15$3$*<IC
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M>/1[T3!A_P"C@[^2RTZQ_&-U.DRUN=[LV<!I\1O[OW%8;C@YP\B][:3?'?\
M*4O8[ZVRN'%2W+#\/^YL.'=_U/<8=[)9:<?>*LE!+E;8N/8LF=I6*YX6:#BV
M-MI1[;W_ "E,V&Y]F+=$%+,H?\/[WQ@"/$/AX,PX<,EF/XV\2Y:,DNK>0U]]
MT#&?<I3[_.K!<\-M&L%60O'_ $G=M3-CM*^*%#K9]4XC_P#0X\/_ (+4 R7V
M7%G7DQ#)9[?>[/1L[2L-SH;2T1(;"_E^$[MJ7L]@6Y4I>G,*&$>CW?!F@#WN
M_P!Q#AQ')79<1M6W!W7RP_$;VE8+C2.!9M9&X#VSVU,V-KL"P!UDB<W>_P"X
MM@_D=Q(._DIL=8Y^X-7O93_%':4?N<%B8Z[L;A]T]M31C-20B0RBXK!Q*8R9
MDT_C!WC%XD(!P[G=#A\.33'YN^N*.EINUVBBC=UC[5M>C!!I[*F8/$Q;&<@!
MAZ!0$R?\^4X\  @A^$1'O_@R5^,,,'3\P')_@5CZ%W2]%[/*K3\Q/^0;<?\
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M1I:="@-<>=,:$]22T_9@H>#)HM3VAY,-Y"[M$;,=R#)\8*C*-FX-B !@6BA
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M-U_P7>XG13_-R?%=VE4X:$E['+QL# 1CR8FYAVC'Q<6P0.X>/G;D>@DW11(
MB;IB/=$>!2EXB80 !$+Q@<!F=39FSP&G[=]WFK^3<@AC[I\CJT(IS4H:EU
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MY#8[F!YEW=UP>),A)DM\>YQ:14MFJ >4"DHY5V)]F/I G>M>QP#CQ "R4$4
M'CQX]R [HB/X<Z1_V=G!6'=='?9SI&LW:F:!W<\M*&WIS\M*KCUP.(S8FPPV
M>*8&BE1'*7$=@DRDT0/LQ](!QX6K8X=+N&X2<$'2#_4B'B#NE_0[V/[NK@EN
MB,7F<$8K0=-#L)VEP_$<OL]C8NHZWO$1H.Y98@5Y:0O]W\HGW8^D./2"U;&
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M\->VV*M*5_L]G28*<'U>M,]*2T),L%1*#IBZ;NG"Q6YU2!^QN" "J"G Q>/
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M<:TM)9N='O2.8:U:XC9W*Z/KMK$C2QD2EG4U .I=Q/4JH2%/,A*4*:D)]G,
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M&395H<]MD&W!>2T/IOA[V=Q790 G8I7C=)9BUO\ #RF.!IM-*2V4@$XV71#
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MF^;(,@Z>(-?*X;13:-O/3L=E:Z^ ?A'_ $/U\^=6])\T_P!T+<O?/8;\=J<
M_"/^A^OC>D^:?[H3?/8;\=J^S9JX>N6[)BW</7KQPBT9LVJ)W#IVZ<*E20:M
M6Z(&47<+JG I"%#I&$> 956-O>W]_!C[*VFGO)Y6QQQ-&\97N-&QT:"[NCR4
M!-:<U5Y3WD-C"_(74D4%M TR/D>YI8QK0:N=V!3GYC19\WKE6D](\K,U?+LZ
M=(7ZVV&E-%JZ@]4",KL-X>JX29R"")_!9*>,8 ,H<X'(U_J:0\14.;?36O5F
MO>#'59O]0:Q=,_6>9R..$UM$^D5K$V5[V1D#N9)FU/2.VAM=UO.3JMHKC#9\
M1>.EOI[2\1;I>VMKYS)7@.EEE?$ ]X<[:R([H#&BE1M/,%A+'_SO=X]T>'P=
MSO</T<TIM)8R&NC%;9P#F4<TD;U:AVWE!&Q;,2VAC&Z87LN0QF_0[P)IL(KR
M;.936/$O<#B''@ \.(?!PR4V5'T<&OY>RWMJQ74$H! CD(^YVU,6? #!W0^#
MX>_\'<_5R6V0?048:?XS>VK!<P7#F[(GT^XIFPX?$#\'Z.2NTFA #730M>!R
M$FH]@T'*H]=,F:"TQ2>X%,F)N E$. ]_CW>]Q#X?P9*[26#9^,9S=E1NZ>_D
MZ*7W IA'B'Q>Z'>$/Y(B&3&SEAWA61E*^SVE'KEKZU,<H^X-GWU-6'=$/Y C
M^ADOLIK=Q $L=:^SV%8KEA+M@-?N*8QPAU@=T![H?RP[OZ7')A8.C+@!+%6G
M9/:5BNHY*DAIK]Q3)CP 2A^B/^C^IDPL"UI)+XS4<Q*CTXD%0YCE-&(@ EXC
M\'ZGZ>2VQ?&>5P%%';MLAJ0QWWE,&? W1, ]SH@''X.^/<X_A[N2_'F.FQ[:
M5[2C5T7LJ"Q]5,V'P<>/\[\ _!QR7V3CNC=<RGMJQ3->Z.H%*\QY5,V0 ;AQ
M'@'?_E?AR56<L= '5WJ;:"H^XK%<[S1S54QCNL$Z9$B=/I"(&$!X 0H=\PC_
M "<FV-8^<?BQL]G8HK>2-;LY5*VS<&Z8$ 1,8> G,(CW1X? 'P!DJ8P,;0*S
M+T9W1,(F$3")A$PB81,(F$3")A%9[F$3.KHG<2:9#J*'UK<P(FF4QSF'Q _X
M 4I0$QA_2S$O'J.27@EJV.)KGRNT[?@-:"7$^+24  VDD\RGG"Z9EMQ(P,\C
MFLC9E[4ESN0 3,J3[ 6 7+7SN:%UAHW7M$M4K8T;!78MVTDT659?/FR:RTO(
MO" B[0$4ER=0Y+\8.YQS2/J_=</@CPUX-X#0VJ+R_9J#'V4C)FLLY7-:[II7
MEH<-A(#@VO.0>1;.\6NKMQ,UEQ*RFH,+%8/QEW(V2)QNHF[S!&Q@)!VAQW:[
MO-57P^\;Y9?RQ;_4Z2_7S+O]X%U</+<GYC*L=^J=Q>^9QWGD2?>-\LOY8M_J
M=)?KX_O NKAY;D_,94]4[B]\SCO/(D^\;Y9?RQ;_ %.DOU\?W@75P\MR?F,J
M>J=Q>^9QWGD2?>-\LOY8M_J=)?KX_O NKAY;D_,94]4[B]\SCO/(D^\;Y9?R
MQ;_4Z2_7Q_>!=7#RW)^8RIZIW%[YG'>>1)]XWRR_EBW^ITE^OC^\"ZN'EN3\
MQE3U3N+WS..\\B3[QOEE_+%O]3I+]?']X%U</+<GYC*GJG<7OF<=YY$GWC?+
M+^6+?ZG27Z^/[P+JX>6Y/S&5/5.XO?,X[SR)/O&^67\L6_U.DOU\?W@75P\M
MR?F,J>J=Q>^9QWGD2?>-\LOY8M_J=)?KX_O NKAY;D_,94]4[B]\SCO/(D^\
M;Y9?RQ;_ %.DOU\[-_M .KD]P:V\RA<>3^0RKI)U4>+L;"\PX\@=B[BJL7N8
MCF;U7O\ MO+M#:X>3CZ1@=R5^1?HR,$[C0%JZ=L&J/@YEA'PA4R_ !*4!$ X
MB.:_\;>L-PRX]:CT)@^'\F0GRMCK"SN'QR6DL58]]K7$.-15M=XBG("LO<->
M#VL^%F%U3D=8-LX<?=:?FB9(RYC?W="]HW1M.\1N\U"5N/SZKK0],(F$3"*R
MNY]:Z3V"Q@5=U,8!U'0CUWXB7L,^O7VK=])(I Z3173E(Q-===!B4>@83B!2
M"( '=S$O%OA_PCUWB[8<7H+&7$VDKC"ZZN#;QLDD:&NH\2Q N<&C82>2H"G^
M@-7<0=*W=R.'TMU'>W,(;*((1,]T;37:#'(0 3R@#EVE8_\ N[<AG=_>_6'X
M/\I3CZ69@QG OJ4Q,;&R'30:P@C_ 'IR$$D';><O=':LICBQUF)?Q@FS3@X<
MHL 01V/YM0CV.1<>[KR%_D_5_P!93C\'#TLP>!?4J/+#IK:*?^J\WGGW/:V)
M]JG68Y.DS5.QXAL]]O<GBU.7M<BY]W;D,_)^L/T?^$I?N_I_VV9Y1\!.I'$]
MLC+?3.\PU'^]20#[1O:)]JG69^=S?F'_ -,GN[<AG=_>_5_=X_\ ]R5_A_\
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M-/EWZ9D_/E5?:?UD=T,IE-T<WT9'^:+GW;^07\E:K^L97Z5X' ?J5#D9I_\
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M'IJD15%#W5:[NQ030\>LYL\V'07C7UA=&\-\7.[(6$=V :C812NU8L(C]G8
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M!H(^X5TERN4GC,,]S.^(\K72/(/M@FBK67A4"81,(F$6MS[3I,BFE::!R@8
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M;5 RB0@0!!7BF'=[@9>V\4[V2\L+Z>WR,UW8:*&*C._O.9<0R]+%)5K6D-8
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M/=X@/]J4KW>(\1X_VO\ =XCG/K.]5^H_WMCJC:/Y'+L]D?R=/L2X[M%#87P
MV_SF/9S5_+;.PN?>XY/.'#SWJ7#\'FG+</T/][^<#K/=5T.V9?&[P_U26NWE
M_P#+\ZZ_8?QT]]]'7OM^,Q^&7'O<<G?'^[>H\>Y_O3EN/<'B'^]_X!QZS?5=
M+:_2V-W3_J<M#_\ E]JY^Q#CL1_Z??$"O_F8^<;?\]SCE]A/>WY.@'^[:H /
M<_WI2OP=[_>_G8]:#JO[O=9C';O]$E_-UV/!'CQNU./OMW^DQT_CES[W/)W\
M%XJ7JI+?1_!ZSO5@!H<OCJT\DFY/-^1=?L.XZFG^[KWDV?RB/D]C\<GO=<GG
MIQ4O526^C^=?6?ZKWIC&^:2_FZ?89QV]&WWG$?AD][GD\].*EZJ2WT?SGUH.
MJ]Z8QOFDOYN@X&\=AR8V^\XC\,N/>YY._3>H^J<M]'\>M!U7O3&-\TE_-US]
MAW'?T=?><1^&7/O<\G@?[^*EZJ2WT?QZT'5>],8WS27\W7!X&\=CRXV^\XC\
M,GO<\G@]P;Q4A 0X#_:I+=X>^']S_>SCUG^J[6OTQC:_T27\W3[#>.PVC&WU
M?Z1'X9<#S<<G0]^[U$?TZG*_1_'K/]5WTQC?-)?S==AP/X\ 4&.OP/Z0SPRX
M][?DZ]-JAZI2OT?QZS_5>],8WS27\W7/V(<>?1]_YRSPR>]OR=>FU0]4I7Z/
MX]9_JO>F,;YI+^;I]B''GT??^<L\,GO;\G7IM4/5*5^C^/6?ZKWIC&^:2_FZ
M?8AQY]'W_G+/#)[V_)UZ;5#U2E?H_CUG^J]Z8QOFDOYNGV(<>?1]_P"<L\,J
MO \S?*799J,K\1<J4M*S#Q%A'(N*\ZCTEWC@W0;H"\?PS9FB==3@4G6*% QQ
M H#Q$ R[8+K"]6[4>7M\%B<MBGY.ZD$<370.C#GN]ZW?DA:P%QV-JX5) &TA
M4&4X1\;L/CYLI?V&1;90,+WN$P>6M'*=UDKG$ ;30&@VK);S9K?H_"?-3#Y/
MF??H3"^1VO>H_DK$GTQE_*KGOK_E)YLUOT?A/FEA\GQ]!X7R.U[U'\E/IC+^
M57/?7_*3S9K?H_"?-+#Y/CZ#POD=KWJ/Y*?3&7\JN>^O^4GFS6_1^$^:6'R?
M'T'A?([7O4?R4^F,OY5<]]?\I/-FM^C\)\TL/D^/H/"^1VO>H_DI],9?RJY[
MZ_Y2>;-;]'X3YI8?)\?0>%\CM>]1_)3Z8R_E5SWU_P I/-FM^C\)\TL/D^/H
M/"^1VO>H_DI],9?RJY[Z_P"4GFS6_1^$^:6'R?'T'A?([7O4?R4^F,OY5<]]
M?\I/-FM^C\)\TL/D^/H/"^1VO>H_DI],9?RJY[Z_Y2]+2&B&"HKL(J-9+&(*
M8K-&+5LJ*8B!A(*B*1#B01* B''AQ#/>WQV/LWF2T@ABD(I5C&M-.Q4 &FP;
M%XSY"_NF='<SS21UK1SW.%>S0DBJJ65JI$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81:O_ +43_)SJ[^_Q_P#XMO\ /FO_ &EG]7NG/TS-_L<JW-ZE_P#Q
M;F_T2W_:(UJWU/K^I7LUK"UWR.HY(. <2D<=[X,;QDZ3(J<42%7<(',5'JP$
MQ0#HCTN!E$^YTOFQP@X>Z1U_+E':MSC<1XG:!T%7M:9' >]:'$;Q'8'WEMYQ
M)USF]$ML7:=QC\F^\EZ.8;CW",;!3N6D#>J=VO+38#S5V"T@-A@G<DQL1"2?
M9W%W6&BUV( 6;DI2SS4 WK35R1P8$WCM&#54;J"4057,5( [H&&48G@'/G,+
M-E,=?/;<LQ(NF1N%#+.^]DM8[5HK4LECCWXR*[[C055GR?%R;#Y5EA=X]@LO
MIE]D^45I%'';QSND.SDCZ0.?\!@WCL79/2R*<'-S:KBX2Q(=O15U&=5JS>5<
MHEN=.6MAW$F"\DU!BQBQ2\'%3X_2$>D(%'N976W 2V^A[J_N)<M<-MA8_BK2
M%TO1&\Q\MXXRAM=QC)H^C>3[T@@T(5)-Q5R-Y>6F+L8,:VXO9<@TS7<XB;)'
M8W,<#3$XCNW.:_> '*30<E48Z.*M)ZDCG5F(T)L!VG%VA0D:*QZ#*N8YO8VC
M!VB#@HOU7%5?(/ #]B'I"=, $2<1I[;@7'<932-KEKQ]O!J5S8KNHH<=,\-E
M9"]II2MK)%=-C=M>"V@HX%54G&&*6RU)D;*PCFEQQ$MMV+Z)I,!N6D#NG-F!
MBJVHHC32\>UDX**M$_)LU;#L-U08QQ!Q#.1:K=-"NO8.Q)J/I)AUD1,QM@*N
M02 8X$*' !$1 .N,X*8?'YBUP^K;Z[9+>9YN.MI86,D ;(R&6*X#GO8QS)F2
M[SVAU8.Y#AW2\[CBCEKK'WU]IZPLY;:PQD5Y<-ED?'N@%_C$)W&EPFCEC#"P
MTH:@THO,RU'!S"2[R%L,UX&A-WJ#6&4A&+=R+JCTEW;G"Y",Y5VD=!\HTZ@O
M$P'(4P'$!'N90V'"/3.99TV)R=Z^W\8R,3FS1QQ[TMA8S7@>S<D>7!W0D5H!
M0$@[%ZGB/G\"X,S6/L&7C;*SGBZ*61XZ&ZNX[9K29&C:ULI- *UV5HJ'':W3
M=ZN0V,<+:[3</K(R,2#K[1]"Q/B)&*.BYGI9>3;*L47YY4O#HHG$"D$>Z/ ,
MLN'X;6-[PL/$*8YF:\?<7D&];0"6"-MLVW(\8D]]%4SG=IRM#CS*_937>3L]
M?NT790XQEFQL3G":81S'II)6_B8R"9#2+D%-M!7:O@QUZP=Z_1NJTE,+KNI2
M0B>IA89O)Q->=LW4>W8HVY]XS0>Q'CX'QCM5?!S(]%+@)C&$0+TP_#K%7/#N
MWUIX[?27DMT^W;XI$)H(I08>C;?R22-=;F5LCS$"W<=N.W22'4XOM>W]EK8:
M7AM[86S8HWN;<R]%-<A[)G.9:QNB?TPBZ(%X#JMK6E-JN>^Y=HYE9FL6XMDM
M#U]"Q6N L4Y8ZP,6M&-ZLW8G/98QLG(N4I:NR#Z3;M2*@HF)%U. @/<S*TG5
MWLH\_!C(\K<6>#9/,V[GN[7HY86P-;O21EI<Q]L^69K&2!VZ7"-M0X@* 6_'
M"^?B)\G-8VEQDH[.&6WAAE$T<K[IY,<,I#6EEQ#"V8F,BH;M5OE-6C'U.R3\
MNYFCR=<L<Y69!A!P[>6:P+R%!N5HZM3@9!N\BHN?=N3)-'!&ZB0"B<3&X\"Y
MCIW"N"STCE,_EIKXYO%Y&:Q-K:VY?! Z"-FY=7M91+;03/)W) P,/,5,).(<
MMUJNPP>&M[9N#O;2.</FDZ-UQTHW'= "TB9\;6C>:""!3VU.5>7%<FVXK7@6
MH#5N2B6DVM=QBQ!%FR.*<>^1.R\+%-1^SLRI8XJ?6AUBBB9NX!N 2VZZM1;Q
M;M>'S<ETF N+!ER[(-%8P2&M>P0UJYHN7MM@=I+WM%:E6-W&POT#<ZJ=CVC4
M<5Z^W%EMW'<KVNY/PH&NG)^"UQYBK>6K7K2LU&"LA7TQ)JSR93IO6<.V4J:#
ML'D@U?U]U-IR"KAG9(I)D155!5NGTRJ@!.( !C0G5/#/%Z:TA8ZA;=WMUEKV
MM9.B_P!W0EIGZ6T9<B9SA<LZ-@,,@!&\VHVJ38+7N1S.LI]-.MK:%EE$0QID
M(G,>[ 1((2T$Q.$K]V0.(.Z>PK49AN@644Q0(F*!$Q0(F*!$Q0(F*!$Q0(F*
M!$Q0(@?Z8?R/P"'#N\0'/2)KC(-P5<#6G)O4VTWOP">9^S=.U><E=WWK'BHJ
MUW(X<[1V7$>]'.5N6Y$N;6=MSN.T?L,LE-S2#%P>H6U-%P^77C8U#K58NT*)
ME4.F9FW+P0?*?%.'!)4>GT#'^P/4GZT&9UL^/A+K475]E8+9S[*_W'/<^"*C
M717CF@T?%4-CN3W$H :\[]"[YY=9;@EA]-%_$#23XX,1/,!/:O(88Y7DG\2#
M2M=I=$-H%7-&Z"!M2SZ2K39,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PBUR?:/TRWW.@ZX:4^K6"TNF5U>NGC:O1#Z77:MC5]ZB
M5PX28HK'11,J<"@8P  F'AW\^?7]H3H_5>L-":?M=)XV^R=U%EY'/9:P23N8
MUUK(T.<V-KBUI<0-XT%=E5MGU2-1X#3FJLM+G[VVLHIL:UC'32-C:Y_3,=NA
MSB!6@)Y5J(["=V=S_@@V6/\ ZE6'O_ (?M#O_HY\H&\%>-#?R.EM1L=V?HZZ
M\$M\F\2.&[SNS9O#[H_UNWYO^\5S@KG,.C7F\"TTSL)F+.OU:!:RC6GVI*0;
M!4;9)7"-D$3 SZL'AI"1,0W .B!"%$/C<<RR,-QWCP$.$L-%YBWNX;.UM&W
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MHBTG;<161FM>EMWM=OPQ6USTG2"&(NW9*G?<UM!RE50TCS*BJ90-%W8@>?\
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M-%!%(@%*4H   ' ,^C-G9VF/M8[&QCCALH6-9'&QH:QC&BC6M:  UK0
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MFB^T1IR+FI*01:+;'!DRIJEK(U7UF9O9WPIST9"E0BXI2;\#E6"A),JXN4G
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MG1-9=I2DE+.Y^-C90'9(%)&IND'\<F]<%KUC2DG02B\0X5\%=)*(H*$7*?N
M4 XQK7?"_!Z)Q>,R#+ZYO'WT%O+(3;&WLVBXL_&&B&^,DK)71S;]O)&Z..0/
MC>-T;"K]H_7.2U/GKW&3V[+>SM)I(B3,?& Z-Q;62W/=,$@&^RA>"PCNJE43
M6[)H_P!BT%@]:H.V3V[59F\:KHD50<M'$XQ1<(+HG 2*I+(G$IBCQ P#PR*\
M-[#%WFO\%!D(F3V4F2LF2,(.Z\33!KVN!Y0WD:>0\O(KQK.:;ZEYJXL)Y!/'
M8RO9)W;'-<QA]Z":C:.7GY0MA.L=IT"P\U&^-+WO0NEXFIZRBC3,#:X:EHNX
MNQLH:!EY2=AHA\LF"#ZU)/H]R=0#D2*+5BH0A0,F)E/TM7O5JX,->(H--8=U
MW,VW='TEE#_GJ &4TKL]O;4&M%\/;#C[Q1D8RYO,U?LL8Y+YDVY<S;W\D!(Z
M(;]*.YZ@]@;5/V',GR(R::R+34%;4F4:]6K0I#&I%-2.WA;,JWZ+]_**/RPL
M8TK[*18N995PX22CT)%N94X=(P%OS^I?H&.Z9;G3>F=LCV;PLV$%S 3L:(R^
MDA!;'1IJYKJ5"C<76]U#)9OG.8U!T@8QP9XTWD?2H)-P&UB!#I 7-(#AL!JK
M?<SXZHM_+/$;)UWJ6.UT5;;!ZNB\"'J;*3DTH/SFAYDR3FL/9-(T6,Q%*IEZ
M2P"J*/3 O0$HC\]_[1'@WP]X7\);?ZO8W!6V2ES%JQTMI:B-^[+%-)NASXHG
M@D,;6@Y#V5NKU*.*6I.(FN)[K*SY2.U9CYRV&ZD:X;S988Q01R2CD>:'>K7V
M%K#X!_J2_P!(7];/B_XO!\'[Y7T^Z5W9=\9W;3@'^I+_ $A?UL>+P?!^^4Z5
MW9=\9W;3@'^I+_2%_6QXO!\'[Y3I7=EWQG=M. ?ZDO\ 2%_6QXO!\'[Y3I7=
MEWQG=M. ?ZDO](7];'B\'P?OE.E=V7?&=VTX!_J2_P!(7];'B\'P?OE.E=V7
M?&=VTX!_J2_TA?UL>+P?!^^4Z5W9=\9W;3@'^I+_ $A?UL>+P?!^^4Z5W9=\
M9W;3@'^I+_2%_6QXO!\'[Y3I7=EWQG=M. ?ZDO\ 2%_6QXO!\'[Y3I7=EWQG
M=M<@ <2B =$Q#%.0Q/B'*<@](IBG)P,4Q1[H"'PYZP,Z&5LEJU_C0/<%KB',
M?RM>T@U#FD5!'(5TD=TL3XY"[H2PAX)W@YE.Z;1U1M&SL]A;F^2;G,6M2D3I
MK:[]1:T& C*DVQR85#V$B9!!&"FE.Z?QVDDG^P.#?^%%#HG'K0 5/L=U.NMT
MS7#+3A+Q(FD^O<;#';7+P?Y6V-M1'*X?^8#02'&@E V]W[[YW=8W@"S3KI-?
M:&M]S2CP'30@UZ!Q]](P':(B>5NW<)V=SL;M-SZ.+31,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBU-?:?M'+@^DCHQCF411>7
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M/,%Y8K2=IB=6.U?D,O;WMV83%$QA@B>V(O+VB1[-KRPDAI=[UNQ4O739[%;
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M$[Y[%\_.O92-=.&,A&Z HCZ/?M%#(NF+YG>[XZ:.VRY/C(N6SA$ITS!W2F*
MAWLWJZN%M#><.KBVN&ET#\C<---O+;Q@ ^WS#GYE\_\ K.W$MIQ+M+J ALS,
M=;D5]BXE)/W.?L+7'1^;^UR*F^+5O.P-MN6^TZ(A=;T6.VA GO-:?NHW96MY
MOQ3(Q!SH,FR",'773SK3B0JCY/K3&,LIQ-.\GP_ABBL<7I]KL?C8<HZXEDBI
MODFV=5[10\KME*;*TYECG&:]O''(WN;<+J_FQPMX1<T?$&MN!1K6MV@!NT \
MVWD5T:AS:ZYC-/U/7;V*JD-*CIS9S64L4%0A93E8NRO,%(;EK.J8Z80277+J
M#9$*S1BI)BW S=GX6F8YP!)0IK/D>'>7NL\_*LFE<'7=I'M<.Z8ZQBB=,X4%
M7,))<:@;P<*55ZL=>8JSP5OCRQF]%:7+Z#DWQ>RR-C'8#P!NCEW2"-B]A-W\
MO5+VING=-=V9-W-SS(7VGR3BBNJ%.PTEK&N.-ZTS<]T?7B:?J*P]CF*R6KFC
MHE.',\*[ZT5S&0#]B'J,#K7)XG'XEUI#:,QMJ&LNFN&_.[H);4-+.4!XHYV\
M!N@[1M"'/Z2Q.4OLVVXDNGY.Y<9+:AW(&]-%=;S75H2TU#:<I!'95'WKS3ZR
MW%I2UQ;M:65W,\YGZU-+S*T6MXNV!I*B&V>77]IE7:@@=G=*["71"&707#K7
M#)HT,/QTU.%7IS1.<P^;ADBMXH].R8F5@BWA^(N961,DA ^;/0F4.Y-YU.<+
MRU!K?!Y?#31SSS29YN7C>Z3=-)[=CI9&3'_M 9NB+>7='L+&/F<L.OM@[>V?
MMBCVX\P386Y-B3:-=6K4G#N8RI+R+)_6K"XDGIR-G*UB!ZX(+,I"KM!:\5./
M6%R7:0L\I88&UP%S#T$=MBK9@>#7>>8Y0YA'L;-[VP%$M79#$WN>NM06LAFF
MGREP_=/,P2QEKQ[>W=IRBJSE2YCN76B[WV'L^!V1+7EIO7?.B;Q-,&FOI^#C
M-9T76^P8._S\E/&F^I=6VX@M$ R9MXYL=$K91R85A,H0@XWBTCJ[):<M<=/8
MQPPV6-R!#]]O22OD8YC6 <K2>5N]M)I0;%D'ZT:5LM0SY2.]DEEN\C8 M+28
MXV1O#G//9:.0TV#;51FI<RFJ=2W3;,^VM>N[S&;&B=<UY_ ZKTS,:FK%BI7:
MA)GV=5YJ$>Q,:FM.O-;S+DYI Y1*X6ZD@&$Y.Y7W6B\QE,;8V\EO?6UY:R7,
MD1N)V3TG$!Z%T983T;'/ C<'4KO5Y%26>K<'BKN^E,UG<V-RRV$S8(G1;T#)
MVF>-P<!OO+#OM+2?>44[K?-=R]04_1J17[2ZCM0:=NNW*CK!U<Z%(V-FIK2P
M\L\QK>$O=SJ;5NY"2=WS:DV\DIB.*15<J3LP'*)"!EGN]!:JELWWUU";C.7%
MDU]R62!KW3B^B<YC'&@_%Q-#8S6E&[P%-JNMMK/2T64AL[2=L6,MIYX8#(S?
MC$+;&2-LKVC;O3R[TKN?>DW:UHK7U+F2U7J^OVNCNIZM;#IVQMW5-[M&OZQU
MM)ZNI<[IN0U0]JMI-6ZM)1\:A#V6F6<64C'<4B"I*LR.2?$$V7S):-U!G71/
M;;36^3CQ,K;9UQ,V65EX+AI8Z20$M+'1"@!.QAW>4*Q8[5^%P=I]&OGBNK"Z
MR-M+<PP,,<$]HRW+7]RX MECDYJ N<-ZAJK7[NW1J^X^^ZA69>0D4MR\R&N-
M@ZU<2$&\8KSE/JTGLI:0DI,JI#%A'Q&EC9G!!<P*',J8"@/1'+YI[3>9L_J]
MX^ VYL\=(R:FT-DI;U%>3:0ZG9IL4?U%J+#7SL^^P<Z2TO,@Q\1>*/='6>AH
M=NP%H/WUE*^YQ^6B$OEIZN&M%^K.^MLWB<V_8&K^5J!*_KFQ45/3T+%.:PY@
M'I[RI#U^8F)]-J"S4$GRJ( ?K2AT80[0.KKK$-EWFVDF/QT3X0.Z=)(Z=]T0
M.=KZM:UU 2*T(VK(,FN]+8_+!K6F\;=WTC+W>(#3#T#;>/=/(X#>)!]BO,L8
M.7BSU*K:]M!5[$@=CJOFZY9-RS,AU"B$A8=5U66MU2DI^/AU.C(NU89].,G*
MC,A#+IE>\>C\4<F^KK2]OLQ;UC>9KG!7<#: T;+)%%N@N H#L=RTV-)[*@VE
M+JRQN-FDG</%;;-6LSVD@%\4<DKGEHK5PI0; >4*/PN_J9(;WVG?YNNT>EUZ
M?U;S+TJNCKRAEKJ,R_V-5;C%4][.1;(SA=:6E7TT@1T[5Z/5$-Q.!0*(9Y'1
M^3LL#86#III;KQRT>2X[W1B.:)S@* 4: TG;[))7A'J?%RZBR&1DC9XI+;W+
M86\FU\,C17;R]U3W KDT;=.DJ76N6O:#J_/WNPM#Z%V;K9?3D?1YL[FR6JVS
M>VSQ825T<G;55M1C1NP4%Y "F<NE2(G0*B)C@8*;)X#4]_DLEBX[2)MCDLG#
M(ZY+A5L<(@<:-Y>ZW"!S5Y]A5WQF>T_:8_'90W,LE_C<;*QEON[#),9V5KV6
M])O'GHK <T+EHG-Z9J9'+-[,ZYY:M,4JV.F+A%VCYS$AGEF=1YG*"BJ2R\%'
M65JP5 ##U2K8R8_S' )'HFWG%O?WVXZ."[RER\-((/XMS8VNH=NZ\ N!Y#RA
M1G6,L;;VULW/9));8ZWBWFD%M&M)I4;*@NH1R[%C+DTW7=@J);[.R/=3&Z[L
M%-]G9'NIC==V"F^SLCW4QNN[!3?9V1[J8W7=@IOL[(]U,;KNP4WV=D>ZF-UW
M8*;[!RD>Z@\"@)C< *4!,8QN %* =T1$1[@  8&^-HY!R^P.<GV .?F71TT0
M&PASCR &IKS4^ZMUW+7]GKNNH\A_-=SL;!G[;K"ES>@YV%H&N6:ZL4]VU!3$
MC$E"QWV.<)& *(W/T7$4W.0KEXX*1T4Z2)$Q<:_:IXF8C(<0<5H_#6L%]<Q9
M%KG/)#FM=N.;NL<#[_;M-:#:VA)V;&:.X7YG&\/<QK?-W4]C;W&,>UL="USF
M[['!TC3^!L&[L!)V@@#;JYJW>3_D_P"GF9\@QPG>*$=UM;38T[-@*P99/:8F
MNJ""T4=SN&W;19(5;_N7Z0?_  @R+7;'[W(?<4IM'L%*D>ZLBJM\'\G^6&1R
MX8^G(>7L*56KFEHH0LCZO_.?ID_^#D9NP0XU!4FLW- &T+(VJ_S*/Z9?Y1<B
M]V0":]DJ66C'N:"T$B@YED?5^\E^AP'^3W0X9&+@;37V5)[,C[X61E3[I$O@
M !*/'\/<+W,C]VI/; UY"LC:Q_5$_P!(G^ED8N^0^V%*+3WH_P"7,LCJWQ J
M8]W^;)PX (\1#O%  XB(B/P9%;LAH)=L"E>.:XOV G9_A61L,U6;M2BMTB&4
M H@D8 XD#H@'QO\ W0_@^#(Y*X.=LY%*XFEK!7E58SR7HF$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6(W/Y_ ?YN/\ FZ;?_P 1
MIK)?P_\ ^.</^DK;^-:H+Q/_ *N<Y^BKG^*<K ?8U?\ Z9G*;_>1/?X_V[))
MQK_K1S'](;_%,5CX'_U4X;^CO_CI5LXS%BRLM4OVF^BMT<W1--\K>OZ%5K!J
M^P.;YM'>%AV:^M<#K0S.D5P*[J^DJSU/C9>7-<E]E7EG:XYN5N*8#3Q44.4
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M>J>N?^43'K"ZA_9AONO_ #=/5BTW^TP[S#X=/XO+RX_](8W]4]<_\HF/6'U
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MX_&IL87CW.'#XLV(Y;I>*UY)R6<31V-\[/8VM5RBX.XR,=U>W+G4VF@%3V:
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M\U<.570G3*@0Q2BY(<I%%('[1^\/M?Z[O<URGV=O'7KF_/RKNI^J[4I]LUQ
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M[Y&,$C0XD;SB!N@,<=[D]T*KT[E$O.QY^+@=;W;46P$IC8VM=5,;'6[C(#6
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M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7' /P!^IA$X!^ /U,+FI3@'X
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M N6,C,59Q6.D?Y0M=0]T.;;R55#C^']QDL#)G8;DM=&)2ZW=(\2 0?E"7UW
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MJ2F$5HOLU?X#O+W_ 'JRG^-E@PBSFPB^:JR*"8JKJIHI%$H&45.5-,!.<J9
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M=)3:E4*K/LY:1K=8:R%T>3=@CHBT2%45>Q[I&OFKZ:#I[%KK(BX>HF.W(!A
MIC%*)%:#P]_^4)#]W._]FPBVZ_9U?:-/M&OHS2^[I=W(Z;D796U;M3Y5=X^U
M@^=J_P!2=*G%5PZI#I<XF4)\8\><PJ)\4A.0"+]/#)ZSDF;61CG;9^P?-T7;
M)\R72=,WC1PF59NZ:N4#'1<-UTC@8AR&$IBB @(AA%Z<(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7Y>
M/MJ%"%YHJ,!CE*(Z8B! #& .YYV6GN]T<(L :+OF3H&K7] K<C*0,C-[(:6F
M8L426%._)5_-1>M2,7"NW[9=_#3JX.5#$<MCH&ZLPE,H #PPBOG'\YE;4M9)
M27US'QL%5=ETN_ZT+446;&S1:-+C%:8RC;+(OI!9K(KJZ_\ !VXJ()I%!VS3
M/P,7N@14J(YR%63:2G9J)?6C85EU7#:FO+R7<QYZU=ZU"7E"5%M+M4#HNT G
M-?G5B'AT"$4!T1)R3XXG$2*+-^8:G56LJUK7L=<(A.+I^Q*W3)21D8D\O"/;
M9MBI;)K;YTZ:*%!<:XWKAFZBI (=982' H )@ BN ?FPUO(;!@=C.*[?JHXB
MJ+5*U.4JFR=36H=_59/)V8O%:M$).M5T@I%NG9?KD@Z*ZC%$RA2("<$SE(H&
MEO\ UMXW@-I*52SMMOU*A#1X&*82\,75_7L*\_I]8LKD5DALZ9X*M/$R#'$*
M9)PY:D4%<A3')A%['?-'#O:CM*E.Z\]?1=PU;4*C273A^R3>TFVQ%5HU4MLG
MP**A%Z[;V5/(95N004!9!LKPZ13X10:C;>I5.U/=*:NG=YV5N4'-0[NIR+ZN
M.=3I3;]5$L'L)FT<(&GX:UU=HD )>"@4ZZI0Z;@J'%$2*KT/=>M:I6-3.I6O
M6Z8V#I:8N,W5&S:2@V%&E).?EFLW"O; X.1Q813A)%L0ZC9N0@.@*!>M(43"
M!%*J?S)42$FH2S2S78ZS^(UU3*+-52,D*F?7^SF5=A';*4@+]#S#=V88&2EW
M(+IKIE7<((]($TTUNBJ4BJP<S]$,KJ6<='V?(/\ 4M9JJ,)KB0=5E?4A;I2J
MF]AX"P$1%[X]\#+.&;.U4S$!0Z1#DX\1 1(J=!<SM0=O=?VFS,;E1[S0HV3K
M@26E#UN+KUDIRM@+8F=9L5=MJ\FE(M7JK^0;NP5.JAU2J9A15 !(4BH.Q-_T
M^]:R2IT<KL.CBR4M*K+7U>=UPVHU@G=D3-XC2O4554)LAH5C+%;$!)#H]8V(
M)0*3N 18F=<E_74_Z<OZ^$6R3D$Y!K%S6V)*YW!.0KVAZ[(=7,S"8&;/[R_:
MF*9:K558Q?ZB AT7[XH"1L0>@F(KB'0(OUBUJM0-.KT+5*O%,X.N5V,9PT'#
MQZ0(LHV,CT"-F;-LGQ'HI(()@4.(B(\.(B(\1PBK>$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+3-]HK
MS::_T'N&I5:T\KVK]V2$OKYM.I6>[$C1E(]J,],L20K<7=9FE19)J-C+%_92
ME ZIOB_")%@ /VD^F0 1'[/[E]  #B(BG!!_+H6$3[RC3 B(!]G]R^CP#B/Q
M((. <>'$>-"#HAQ_#P[N$7 ?:4Z6'O<@'+V/'\!($?@$0#^X+OB!1PBX'[2K
M2P=_D Y>P[O1XB2! .(=T0_N"[H@'=PB[?>3Z8_Z/[E][_#^IP7'B'=X</,+
MO\.[P_!W<(AOM*-,% 1-]G]R^EZ( )N)('XO2'@''^T+N<1PBZ_>5:7'AP^S
M_P"7P>(<0X$@1X]WHB ?VA=T0'X._A%V'[2C3!1 #?9_<OI.(@!>DG!!TA'N
M  <:%W^.$0WVE&F"" '^S^Y?"B/<#I$@0$1[G> :%Q'^:#"(/VE&F Z7'[/[
ME]^* "(]7! '='@' 1H0 /$<(N!^TJTN' /N_P#E\XCPX!T(+CW>Z'<\POA#
MO?A^#"+G[R?3' QON_N7W@01 P]""X%$ XCQ_M"[@!\/Z>$7'WE.E^ #[@'+
MWP'O")8$ 'O!P 1H7='B.$78?M)M-=X?L_.7[^Q0?T!PBW4\BG-[J'F6UXE"
MTF A]8VVD-"MIW4+#P-NV@HX5C%:RU73:-(YO(UAVHH =:D@F9NX,*:Q"F$A
ME"+.[")A$PB81,(F$3B'X?AX?R?P?IX1./\ [/\ 1_E81,(F$3B'<[O?[WZ/
MZ6$3C\'PCA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(OS$_;6_PD]<?YFV?^-]EPBP3Y6H.$3MMAV=:RTXU8U- EF1;[#,8E+F+?87
M1:_3X";X,),%T7:SAR[ZKJ#@8K(1'@ <0(KK;(T7.P-2<,-5TY_=_ N9*3FJ
MA/UFKJ6921U[9-=U&T:^5=.R1CDB\$JE(E I'8 U.J57I% >F $5T+1%'*:]
M4/;M47BF.OM"79S9MG0^G*U#2$SL=];: M-EI*:<53HF8B:0D*<6S5*X(*G2
M=N0/T%B%PB]<+7JO%5:<DJ#$6F1!#3_+"YA9B"T73-A7IT68=;(\:/WM-E'$
MG%1IIA9D@5\[3<KJ""*0"8_2X 1?"C56ARE#/&76L0#56]\OVIZPI8W<!'Q\
MA5+O>=U[*@XVY$41:I&C9)K/-&"#TY!(;P(IT1'H%  (I%2-;U2GL]5:Z=5.
M)D+QKFT;W@-B3,?58:Z3,GL=+E]5N,A$LXY^0[*SC09AP@R8,E3B@9XR.8G
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MW= %>;: 7 #::[>PM:W:_P"+.I]2YC%:+L<8^TQ-QT0-Q(02XEP;[()#23L
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M22=$1F4%4$3K2+0C<K<XB!.BND?N=W@$NTMJZZSIPD$SV$W3KEET!39- T5
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M1-ZCY:-O>\+E*5:YO]>'N_*N6X'6KA7"BB\@=_:O!3)&=Q_2(LA:S]G1RO\
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M05\=8[ IJ$7J2KVB<9L&->9V6S,)-0QC#5;>A/3YR,'Q2!TT6-O@G)4C<>(
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MS%\1O:4&VA4:HAK38:Z-8KR*R-&MJJ*J4+&D4253@) Z:B9RM@,0Y#E 0$!
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M71Y=.8J?T;/]2KX1+T27<$&P5T#B)VYS=$@S4(!S FC*($#BH3N$=$#HFX&
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M9% ^Z(GCMY83#O20-C@+7'>W   *DC>:*<H)79]QEFVY$S:6CF;@;3N:$U
MY*5J?;53;.+VO LH.-K=AZZ$+9H):08P\BZ5&&LY6RTE6GR L5B(@1?I+ /Q
M50\($. !P'*B*75<F+CL8;6\\<8'L=-$S?+HGT)BV^]83M(Y">9>D4N7\29;
MV<8WXR[>--H:X<GL*C0[R]1R\;%0:4XDZBI3SKCH]I%++NT)$K<K,98K<&:K
M@Q#MDBD-TP%$Q0$! >(AEOMIM3F88_'-OV92%W3QUMVU?*UNX6DTVM,1=4<A
M VJEMGY>$%D0/+6G8)%#0>R-A[(7O=W+83"$:PCZ0?LHQ_&+MV0+,&;9ZO!
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M'0-C0CG7.OU*75D5FY2 1RW0<K@BFFNU*)S$5@M9;NN^V=%<G]*V;SC[3U]
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MG*Z_DIF2BDZG!0%/DII8E[1EG;\U9J+=1:"1HPR)"M'RLHQ!J E3(8YA'I"
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M^LU-VT=N?:/[W%#\>]K7#S_[8NR:W]G7;=YL?VG]C?F)UO@7@']J_A?5=/\
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M>;G[9ZGK?"/VKT\(L6[K[M/F+&\/?9\ \[N?CQ1Y@>#^?/F3YV#[T7BWQ?\
MVQ=G_GWT/$G5?VX>%_\ @G[!UN$5?C_=%[5(?S;]Y/S5[3M;>;/FWU_N_=N7
MND079[X)X+^^7G1V(>(/ ?#OWB\XO%_@W[Y]/"*MZ9]V'M-9]@O;[X'V0Z>\
M<>;WF7YC?Y F?9'X?YV_\(?:9V5>*>'B3][O#_ O#?VUT\(LGN3KLL\6;=\R
M>T?M#[2FW;SVO^:_:9VB>8--\5>=WF)_:/XP[/\ Q/P\7=WH_P#A7[<Z_"+,
MG")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
#1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!P0)S P$1  (1 0,1 ?_$ /T  0 !! ,! 0$
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M-\FJF(@9!TS7NW-YZE\S#A&G0+#M7S"[G.<$>2.XMSO.4NI]_P!>VM4('?\
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MM9UISVY=;(\NJH;_ .'C#B51.!FSZ_O3:NS'FZ=;[(C]J["UUI^Y:GJ-)T'
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MKAR@W(JH ',8  RYP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , I&NZ_H5/E;3/5*D5&KSEYDRS=VF:[
M6X:$E;A,D*J4DO:9&,9-GE@DR%6. .'9UE0 YO==HX!5V , H2N:MUE3K-:[
MI4==42K7&^.4WEXME<J-?A+-<WB0F,D[M<]&1[64L3E,QA$JCQ58P"(]!P"N
M\ 8 P!@# & , 8 P!@# & , 8!0^Q]9:XW#3I?7NV:%3=FT.P))HSE,OU:A[
M=5Y9-%0JR 2$%/,W\:Z,W7(51,QTQ,FH4#%$#  @!2FEN/&AN.%;=4_C_IG6
M&E:N^>>^,A!:OH];H\;)2($%(LA)MJ['1Y))\5(>X59?Q%"D "@(%  P"\>
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M+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W
M'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\
M+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#
M]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[
MM7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X
M]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C
M^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W
M 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z
M\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I
M#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W +U?KDND/@-\-/R']K=/[$_[8/>W
M^UZH_/\ Y1/]@7P<]<^"'SG7_P#%?7?"Z_\ JO@?^L8!_/\ _,!_V[>9O^]/
MOW_6G:< Q$P!@# & , 8 P!@# & , 8 P!@# & , 8 P!G*5?%(#.7&GBF#]
MZ9U Z#_Y\/@<I5550_!#I@-4&#@8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MM:U.3KR #-3_ $&?\%?_ (BN 0WF _[=O,W_ 'I]^_ZT[3@&(F , 8 P!@#
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M(M2<N-%)<$^7B69UGUC8]V?7AWHNVI4X-1Y>YI_>6MW)Y8=_:"D>D03QT_4
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MM^UG#X(RQXN:&LN]=AQ%;@XU9\0'C15V5),ZA?#%8O0IRIE,;NG[.OR,SF[
M]N8Y-ZUNS6U:M:'C782FYT4>E-NM7\.)9GO'W-TCMQM#)UK5;JL1C;FHS;Y2
MIX+QXG]&3R^.-]6HM*H= 6@$(=4D6BI.'8I%0<*+=P.]XBY4P5 !$/0(]<T(
M?UO/6/O>UOR_MGM7N3R-L8=Z,%"Q=Z5SC7Z7QI0T]^G/9FC>JGU'7,;?\<K.
MT2]=?E?,U;4'5OJ=:)MI4]U3,W=^M:7!0[&28,#QYWCEPV5A98R2[E1!LH9,
MSSN'#O>$L3M*(YJ\]%GJR]1.?WGQ='CKVH9VF7;\%T^9.2XJ*HN? R _J)^D
M'L_V!VIC:WV^N6<35Y=,5;C=ZI-.3XTK7W,U26Z?J$98'32,CP5(FZ.EU!(@
M$*)5!+T*!0[I>Z(=/E9]IW;;:G<;<FT_YIK5W(A?_)1N5E)UHXU7!M>\U@:5
MIVKYNGK-SN"5M)/E6BYT]YFII>EPUO/746S1BV4E$RBHX,@D9?J82@)$SF+U
M+T'/GS_J8^JCNSV0N3TC;>I9F-"_)Q<XSE54BO!<"O?3MVEM]ZNZ$=FZS?E#
M!5R*44Z=751TJVBG_,!TR>O:FN5<C(L\^K(5PRK!/P =JG<E-W3%0$"B;W!3
M"/9[64E_1.]7._M\>H>6G[_W%.YI=RPU_O%YN/4Z_NR=%X<#)WU+>G30_3#W
M>VW;TQ7L;2+JBY7G)]"?#AU5^9>]T?/V'\Z_E5Q_V'KZS2E@L55DX2-DW[@Z
M:CE@N@W(8QQ$@=\Y"D*4^?2_WOV1+<.-E;CTZ=G*P;*<W*W1J5>->#=*FT7L
MGW+VUNO3;6CZ=FV;V=;MQC]:;=$D8/*IB41Z]?2/L>T/[89KZS]/OVWU25*N
MID.I4?3XH\AR]#B'7Y/[(=<IBY:4+KMUJD1#AD$# & , 8 P#F00#YO3.\8]
M0/40@FZB'4>@@'0/DCDUP(T5(\9.5$ON.5;G.+<%5(R X_Z&NG('8$)0*7'J
MO)24<I(G.5/OD;(G.4IEC^QT* YE'V>[5W=TYOYG5_\ =M(L1E=O7II>7"W%
M5X-M)OG5>!;#N=W+V]VPVSD[FW#=\O'M6_E2_?E_"O>?9!P>\A^ITA*OW2Z-
MW5QM,?ZJ[6;@BW)%,W)3E5%!99P'A 85  !*'41S"[U)_P!7KT_>FG^:; [?
MQCJ6[\=SL*=I\%)KZXRA&56J\5P2?"IK0UCNAZF?5+&]I'9K1KZVC\T7=2FN
MJ'%2?7TI<Z\*LW@V6M_V9-4HV0C@B4H:-\<K-)$J*31HV2_@R(%( $$O<* =
M?9S4_P!@.^VZ?67WRM7<G)N9.?DYRE",V^KIDTJN+I2G*GC2IKW[U]E-P]G,
MVQH6[K%Q;BRI4FYU34Y.O!_O<T:^8[DD:7VBM P2IC^L/A;B"9NHBF9?NDZ%
M >@AW?EY]1N9Z1,+2.TMW(W!Y$[N#A0NN4XQ3<NA-Q?%TX\*_@2O([:?E-K0
MS\R+\Q6HNK7-TY\S(W=/'.F<@*8\A;A'+K@[8F1/( BFH1NNJB)1.)3D,(B0
M##Z!S4%H?]3#9OIN[D7>W<KD;V@_GE9G%R<4JNDFDE)-1=4O:E4A=J5W2VM=
MCN_:-F;P,:<FXT:BTF^<DG3E[#XE?,H\O>P\4[F[E(Y,KVERBIW#%RD7IX:2
MBA@3-T(4"=!#TYMFU);'[^=L\;NAVTDK^#?3\Q12?ENG@^;X^U(W<>E;U-Z9
MW=TI:/G-V=QV5\UNK?+WM)^'L-1"R0)@<G< /9 1#J/9U'L$?1US"34]&RL"
M_D1R$U*W)QY<S.1SM]$90=:D7E-N+CPEP9V&< 8 P!@# & , 8![FZ8G$@%[
M1$ Z_P#I&$,GNWL>_F:K:PK47*5UT1!NUA%S?TF]KRL?*O6Y>R)+G?5G#'7C
M)9LB5!L"B;J876.)4T$3^&("(F#M !]&7T[Q=QNU'HO[)7>['<N/FZQD<,2U
MS\RZU51E]3@J\VDZ&"7J3]3^I['UW%[9]NK?YC?>HW.F,75J*?#J27-_'@?4
M78O)7TEJBG-W-9IPQ#I,J?A2!GJ4@**P)@=-)^F1(#ME%O2(&[<P ]-_]?C;
M^]NY=C8V[]O?E=(OW'"U>A:C*5$Z)*+C%2227%M-\^%3%+O?M'UD=L-$P>X_
M<IQN;1RI)W.B3?E0DDTZ4YT?)T2=>)B<SHE<U[)N(&?;,^]'+BB0#D2[@>&H
M8.I._P!WO=2E[0SZ=]%W#I_<#:V/N;9<D\?)A6%/A6M?<8OSU_/W#!ZAIDYR
M33\7P+F+<?*)O%-HP;';(H+$$[@R!$R>KI)!T/T!,I_8]C,7.['J R^P>Q]2
MW1W'@EI6*YSA*K;N>7%RHXTI\U.5>)(,7N/NO9F5*]<GYEZ7*M8T?MX5;:9E
MQKGRDN-2U=81T_7JJ[D+*W<*Q25A>>%/SA4R*>*>.:I)@H5 % 'H<W8(]F?-
M5WZ__P!!/<F]W-N9_:_0\5;$PFK-^/DUZXIT;JX44G[*T]YL'[,>EGUC]Z.W
M][NUI^KV])VQ;MRNV_EE)RC%=2IU=*550^4_SC/+NK/&6UM[AJR/5:529,L#
MV-*J*Y6*J)SD.!.Z4ON2F3_8S<MV4[B;?]8'IHT_O?H\9X^Z[RC^9Q(IQA!M
MJK22I+GXTIS1<OTD=_\ <&Y=1U+MSOR[&>O:9D2L>96OF=$FJR;^E\."5?B:
M '*/A")>WKV@(=.G: _X,LQKNGY.!G3L7H],DVJ&P:U)3<E[*4]Z/ /I'*2O
MVW-M/AQ(YU'*(=O9T$?8'YO;DM:HZ S1_P!!G_!7_P"(KG (;S ?]NWF;_O3
M[]_UIVG ,1, 8 P!@# & , 8 P!@# & , 8 P!@#.5Q= >@H>Y^5_AR>8MB*
MAU5=3I)\#W-@ZJ%[>G0 ^1Z.F5AH%B-W4+*<G&DT_ @W*>6ZJJH?35Y#E+@7
M]U<S;MV!'[?Q5&R G* F4( F( >R "8H9F7W7NZIM_THZW>VY;\_4[F-*BX]
M7&+K3IH_@:D?ZB6N9T-)6G68TL3735IT?RNOX'VZ:LW=&:_K"\,ZCCK'<$54
M4<F('=*8X"!A./9V=1SX5.\'I5[U]S>YF9K&B:3J65YMV4JNW6DI2XKZ:T5.
M'B/2AZX.W?9+M-;[?:C%3SKMJCI&O&C7&G^486;DNU9EC29"R+<'<P\!PV:-
MSD,< [QQ 3%*8  @CV>WGT#?TN?3/W8[5X&'K6\M)O8]BU"DG.+CPZ75^'%&
MNCNCKZWWW8U#=V#;E'2[EUNK5**3JJ?84%1JK.N%6CQ1$J,<4Q52+F,4AC>Z
MZ@'='H)@^3FP'O+W9V9IMK,P\B\OYA"4E"$FJ<J>''G4MCN'5].BI8\$YY#Y
M>RGV&1**YVBRJP"0$NX!1.J)2E >[T.81'IV!FBSO+V&W1WNW6[FWK%R</.A
M/Y%6/S-^+3=#V;!WXMHPO/HZHWDU&-&Z-_B:VN?<'![:UM(U).21.*;=R=8Z
M?=$@J  CU*!@,7W'H^5GT)_TP>P>N]HML96W=7M2LSN8]9MI*KE622X4Y,O)
MV/W-J^D[^M:_D1Z?,NJ7RI\57A^%#X6>1.MD-:WJ3@TW(."BJLJ40$G4O54W
M4/<AV%'KV?*R[_J)VGI^E2NY$6G-S;\#Z#.U6[I[LV_#490<:I)<&JKE5^\Q
MG<=[O!T#L#IV@ ^P'3, M3LN-ZD:],N/WEWHKH=%X'G[IO:']C)7T27 [-UX
MG'.H& , 8 P#N0'HH'9U[0_=SVZ=/R\R$TJM,X_>7Q-[GDE;KUOJK>KU/83A
MFQ;RC1(C%\[*GX;=<QRIE.)S@8P=P>WLS/+0\+7.XGI[U+9FSKL;>Z+EF:M*
MK3DVFDE1KDU^)KI_J#[%W)O#MET;=\R;LWW*=N-:SC\O#\&?8G9.;^E-.0YK
M"WV'$"H* '3+&."KNG ]WO!X?0H>'UZ]@".?/=C?T6_43WCW[EYO=IQP=N_F
M)NYEWVY02E)M=*=:\%[S7EVKWIW1VEE6=)[7Z1EX.O1M1C*].#4&TJ=74J/V
M^)C9&>8*ER-LBD+56<JHFY$S49N34,JKZL;J50$"@7NI@;O>D!Z]N;:/3Y_2
M+[1>E[1(]RL&]CZUEX=IR\Z-N,(1N12?2HRCU-JB?4G3BES1+>]&C=U-SW_Y
M]W7U-YF;974H.Y)PCQ;Z>EM^-3*V*TO34T6[A^R,_?*D26<**JG*3Q%"@<3
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MVG=]L#'P=X7XXR7E>?.*]M(\JT\>/$W[;,RKFIZ%BY]U-3NXT).O.K29;M0
M >GI'V>G3L',?<B#G)I<RIFW%T/.<H!V^V.2*];<)>YG,95,T/\ 09_P5_\
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MGZAQ=WC8-H:P6CD=C46.US95K'1_?A%TYAU[3'"P*K",I=LR44:N''AH.4P
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M_P!+&MS[4]^],PM:LIW,C.C"+G'JBDY+FG^TKG!S+=S/PLN7_AX7H=<?#F?
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M=./$KC'TF[N#2OR]Z;<E+JBDZ<?QX>XR_H6XZGL!%!%!V1K(G*'B-1,)D5%
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MA3.VK\<3/24UY;Y+]!;'0<99(F<5!4WA"9?OIB=0W3IWB_-#J&5YW]MZ5F[
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M'@W5*S3QHJ?K(+V/FY95KI;BN5*GMZF=9_[^2J_]7VG:+;YF9_\ H,_X*_\
MQ%<@'<AO,!_V[>9O^]/OW_6G:< Q$P!@# & , 8!^@80'J B B'01^1[7RL
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M*&LW,>>=.<E=KPDJ<6_=S,\>Q6S<;4\=W)8CE<46VU&O@1\\0S=UW!1%( ,
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MVYNO4>ORLQ2R)7^JDXT15Z..0.F,TU)55#DZC>DWS/W,E22Z6_&O[0<,Z@8
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M;BN%%P+N^)U'  Z=  /3['RLD[2]AP><^2')/1X'3DN P!@# /6S*)CG /\
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MU;LQ7[S7WD:8PB/41'+?_G+]^ZU<JN!%.E3T!DOU+Z8_%G>!F?\ Z#/^"O\
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MO=?=EC(2?Y2.4OM5?'W'P2[\V0]VSL>Q7)\JHJK*OE3%,<W>$Y.^(E,!NP
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M\%?_ (BN2XB$-Y@/^W;S-_WI]^_ZT[3@&(F , 8 P!@# & , 8 P!@# & ,
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M%#F$QS\H-\&,8?28QMGV<1$?DB. 8FX P!@# & , 8 P!@# & , 8 P!@#
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M?\SUCW?3_G8!Y>>7^V_S"_WGM[_ZS[/@&)^ , 8 P!@# & , 8 P!@# & ,
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M\=2#E=Z^<N'CQTJ==RZ=+JN7#A901,=5==<ZBRRIS#U$QC"(^S@'EP!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8!EI_H>_X2_\ WZ\ Z^>7^V_S"_WG
MM[_ZS[/@&)^ , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MQ [7_!/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q
M[7_!/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7
M_!/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7_!
M/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7_!/
M'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7_!/ ,M
M/R(N9W]CW3\DKDKWOR2NOA_V';+\;O?EU=_P? ^#7C^L^#_"^#W?&]7_ (;N
M^%[O /[4F , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M$A6:*"JF4XIB84U4O=@!3"'=6(F8>PP=O3I@'KP!@# & , 8 P!@# & , 8
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M@# & , 8!"US^08C[GM?\D7 )K & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & :9O.KGKS7./M6E:_65'56C7NP)>P7:)X[5OD
MU:*Q<8?7DR_U!6&%&LE,V&C7*]M&_)(0\O8D(=TO'(&31*=MZWZTB!=SRRJ[
M4IO7M]V[%ZKI$&PFMK7Z%TEM9MQPJ''?8FP>/JAJ_*5]:Q5>$JM5EFL7&VI6
M3BF"SIFQ5F(R(9R*S<%7 J' V>X P#0GYMNT=Y0VRXVLZ3V1:JB?5_$#=W(B
MU-8S<3K1<=430%PI4;7=T1KABV>DY$V.B,XJ80_LYE?4:\^3?)F>OD#N6P'
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MDH7[Y/?YKP!XMD^DH7[Y/?YKP!XMD^DH7[Y/?YKP"'45L'P@9]6</X@PTCT
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MF("P+K )AZJ"'0  R'P!@# & , @U?Z1LON+)?7T7G-'2O"GQ_4*KE7B3F<
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MRH(J3:-FUQ6JY3YF%3@Y.6?NUXV)0:HRL6C!M9$[B+D1;'\,Q@(8ARB0X!T
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M'\/Y?+])[88NS)*L\W4HO_\ 267^/YQ?H(E68V62P,#+4:M*'")E0 &E\<&
MQ1=Q7>$!=5%L8!*(!V=.WKZ>S/=AYN\978QU# P(6>EU=O,G.2?"B498MNJY
MU=52B]O"'/#VHXORL_,Z_!2Q(I4][CDR2?NK^@F1L>P2@/>ULF<0]A"Z1)P'
MY0KLFW9DW>7J"3?Y5M__ !(?M/%^3TBO#,=/?9E_K,_ M5W+_P!)JZ5'L_\
M5K1450Z^T'CRC0<E-[6]=M1;AHV5<:\(WL3C_I7XD>.EZ/+_ .IV8_&SD?\
M-MR'PQMI?GM4VP?_ *.;H1P]GT];:0>F2F6[-SQET_W9U1KVK(TVGXYR?X'I
MCH6BR_\ K.$OC:S/_3'[\-+('3O:LNH?XLA0S=/V+CGIM;FU^:K<V_J4/C>P
M'_[.8P]!TA<M9P'_ -7F?^F/WX;3WLZPO(#_ /3TH0_9"WCGKCN#5GST;/7^
M?B?JR2&]#TSPU; I_D9?_IC'_DWR!OFJ-235MK.NYZ,ERO8V*;3-C)7GL-"^
M^2XI&DWC2)L$@Y6\/N]Q(#D*@*RA.^;I[DUC_4;WHW;VG[3:CO+0=&R/YM:=
MNW;G>\FY9LRNS4/.NQLWIS<8)MJJZ'/HC)T?&X_:GMOMW>F],70M2U;&EBSJ
MW;M>?"Y>::I;A*[9MQ3E6K?5U43HO%6?\N3<5IOM%GJ%-Q[92'UFW@F5;GFC
M?U?Q6$B$A_\ @L@!!\!9\P%GWRJ% IC)J>[ >@&&W?HP[_[X[TZ5K&G;WL1N
MY6D7;2AGVK/DVLA7E-NTX+Y%=M=*;4/W)1;X\ZR]2O:7:W;#6,/^[5WRXY2G
MUXDIJ<[70H-7*KE&YU-).O&/!^!LCS-XQB& , 8 P#45$7RY5KG#8J_RAW9R
M%T\_LNZ21O$J%B4J^SX>;NU6[I\6,%K)6<&F3;,=W.IE*74DXV:DXJQ.G:2)
MX4ZS/HG@'KA^>%BA:54X#5FL)K;-_LB'-C9*S?>&\:UKYE&T#BYOJ7UW;@-L
M,E%D6;U\^FI5FA 11(PI(V& IY%ZFFU,X6 J.&\P3;-X9:&C-8\3E;??=V\1
MD^8*T/(;JA*I4:-3%I2OLV=1F+=*4I65D;=--[,U*R!M#"V%UXI7!V[=(70@
M5)H;G]8=T36BUI7CE:=<T7E5JBW[0XX3$[>ZM)7*S? FOUVTOJUL2F1J'O9K
MB2L-?L/KD0HG-3"2J#54'@L5A(B('KTKY@E<NFV=BZ@V\ST[J^:H&ID]UR%C
MIO)"D;=I,!34+<-)L,1LRQM(BGHZYNE8FUVH+MG!'#!RDX,9N\4%!8I0*8\P
M3:MYD^(LMOOBOR;BJW4Z=(5V7>V34[:D7U38:I=G4JNEK;&^NU;'!P5;2%=^
MA+D8M%))T)BHINV@$5!4#/3=&R&VF]/;8V\]BG,ZSU5K2][(=P;-PFT=S+:C
M5>5LZ\4U=+)K)-G,BE%BB10Q#%(8X"(" =, UZV+S(++2JCHYUL;2^OM1;&Y
M+-YZW:DI.W>3-,HL!%ZIK55JECF;9MS83VJ+Q5/MC9W<F$>6NP[:R+JNW("5
MP**3E9 "I*;YALCNNN:;:\==*-]D;8VG!;KLTQ39S;->J]$H,%Q[V*TU%L:3
M=[9@H*]1MN82NRI!O'UEQ#Q[IO.-EO7C':MDU! "C-Z>:=7=(VB\U*7H%&;6
M'1NL:-LGD'4[OR.UAKZ\UUQ<ZRO<E=>:>K4FG($W?>H&KMC/% 0=1,6\,JW;
M-7BSI<4D0*LOWF#W2*L/(;^R[C)-[1UQQ>H>O]J;.OZVS*]27,U1;UK!#;)V
MVLZA)P<A*62^0-2,JY5C)%6&9K%333(_!PN5$@$+#\X]F,N1/)^0M=5HQN%V
MFN,&E^1L?L:.N;D][8U"Y5+<MP?6%*D_ =)>?=VE"C(MDXT\FA[W%:E5*JN9
MT*28%=PO.2_P<[5(C?'&Q_IU+;&HME;:TPNTV?"WYS-FU94VMZLFMMBLXZMP
MQ=>[%&GN_?!%-JK.Q1R-W:0/A5;@58"]O%+?&TN1FF(/=5LT432\7L.I56^Z
MKJLULB.M=JEZM;JNTL,6I>DX.N(15'F#J/"%,U;N9CPT%"G.<BP*-R 8I<;^
M7G*FT\39W=VWM2Z2962/VWL^G1TE(<B(FB:_3K55W=LV@.9J\6B8UPW0J+"E
M-JPRCR"U:RSR=4,#@$6PJ&(4#A">9?,7^F:)6T_Q_2V?M+=^[MZ<?DJO![GJ
M)M:U6Z:#B;=,VRUN-Q,H64C['JM['5$Z[24CHQ5^LF[0(##U@3H$ ]%A\Q/8
M;+8\/5ZYQS@)JFFY84WAA:;1*[U:5^S0VXYZM1=DL3^&U^GK>9D+%0:R$@9!
M)Z9TR?2!$Q? R1CNKH (N!\US7EHVI7*G7X#7TK0[QOB>XVTN:9;_HSW<#W8
MT1.V&EL;!8N/T?'/;96M5S]_K:\:C*F>.)-NV41D7$8DR5%0@%]O+VWER&Y
MZ4E+SR$HM'J,PCL[<]5@7])NQK0C-QM%W=LVA%:OXL*=6$H-2LLJLU8D7!5T
M:6!,79BMC*"D &>& , 8 P!@# & , U*<EO+4VGO':.U;Q0N:-GTK4=N;%X^
M[<L6N6NB-4[&9H;&XWI4DU$FV5DN #+ECUI#7T:X=L3%%%04S% 0*<V ;!]%
MTC;6OZ-[P;HW>OR!N?OS(OOA^XUS4M7*>]#HK8&$'\&*68T-W8PR2@@YZ^,M
MXON_G0P#2AS5V!Q^JG)OEA;M\)\<XW:^H=1ZFG.'U4Y;S.TMA5_:=F- /IRQ
MR6J]+/[;'ZZ40F95,*H@-0B'UM0LB"SUR=5,[1FH!N8XZ:ZHU(H:EGIVJV^F
M93=SZ-W9LF@MO%1+#[-N-.JK.S(.8\/"CXV4:DA&[9Z5HW:HKNT%'!T_'65.
M<#T[HY,:#X[%KA]W[7IVLPMB[Y*OA:),&9WZ,5ZF,S*"F0BRC.OP(2+<9"27
M!*/CP<)"X62!0G4!%\F- S>XI#C_ !.V:7(;DBV:KU[0&LLFI-$*WBF$\[9H
MB >I.YAA 2K60<L$55'K9@Y2<JI$04(H(%X9C^293[G/?K97 /!4_P"BM9_[
MOPW_ &<VP"H, 8 P!@# (,X?^TC4?8]XWP=?_M\=@$Y@# /P1 H"8P@!0 1$
M1'H  ':(B(]@  8Y<7R'/@BW;K9$8X7684^/D;W)(J"@L6O%1&%9+  ]2R5H
M>*MX!L*8@('3376<EZ?]"(]F4S<W1A7I2L:)">H9*?2_)H[494G]=]TM12E!
MPFHRG.$FJP*AM[=R;45>U><,'':JO-KYDE5<864G<?!IKJ48R7%2.H(O9$][
MJ6L$92F1Q[8VI-B34P"1@'J1>RS[0&*:G3L'P(PHE'KW5![!R''%W5J+4LS(
MLX&/7_9V(^;=<90HXROW4HJ49.JE;L^'-G=9.W<"JQK%S-OKE.\_+MIJ7-6;
M;<FI+@U.[]A;;;7&?7.TJ-+5VTJV5\],D5\SM+NP2$G/QT@P(HHW=,C22SB/
M;D, B15!)!-%1,PE[H=@A0?<KL9LSNGM6_MC<SRYW+T(*.4[LIWK<[=>B[&,
MGY/4NI]2\M*:;3\&JGV7W7W3L/7[6O:!^7M^7U)V5:A&U.$VG*W*BZVG14;D
MY1?%/FG0_!O456USH^K6F&%ZXG=JUNK7*S/7JI#]UPZB".&D4P23(4J$9%^O
M*@F ]Y0YE#&,8>H 7P]B.P&T.P.@9.C;9O9.7EYMZ-W)R<CH5R[*$>F"Z8)1
MA"";Z8JO&4FWQHNW=+NIKW=;6[>KZS;M8]FQ:\NU8M=7EVTW6375Q<IOZGPX
M**IPJ\R\OH6R& , 8 P"#5_I(R^XLE]>Q> 3F , 8 P!@# (2M_R!$?]0;?Y
M,, F\ 8 P!@# (-;^D<=V?\ Y-+=OM?YY$?NYS7A3C3\!]_W\/N_63F< 8 P
M!@# /#)Q<;-1[N*F(]E*Q;]$[9]'2+9%XR>-S_/HN6K@BB*Z1O9*8HAGCS]/
MP=5PKFG:G9M9&GWH.-RW<C&=N<7SC*$DXR3]C1'QLG)P\B&7AW)VLJW)2C.$
MG&46N3C)--->U,QXX@1<9&\<=5'CHUE''DJPUDI(S-JBV.^D5SJ%7?/3(ID,
MY>*E3*!E#]3B!0#KT ,E^WML[>VEIL='VQAX^#I<6VK=F$81J^<I=*75)\*R
ME63HJO@>G4]7U;6\IYVLY-_+S6DG<O3E.;2Y*LFW1>PR5R>$O& , 8 P#!F^
M\2-D[8V'$N=G\G;+;-#5[<E/W? Z1)K#7L))M[)KNT1][H%9D=JQC9*<DJ'5
MKM$-'R;<&*,JY(U3;N9%5$5"J :W^37 *5B]D:8:*TO<^W=/4FH\F)-E8=6Z
M\XT[6M2>U^07(Q7=CZ"MNM^1K&3J,-4X9@[%O'S$0W!X^[BC:373;@D14#8O
MQUT'M-Z?56^N1<JRBM_-^+DEH&]4^JQT UJK5"6OC*XM)GNPBKF+9V9G'1#1
MN]:QJIX8CLRX-#&;E1' / 3R_J4?6O&76#O8EW"'XUZ,V7HF.E(D(Z%L%H@M
MG:B;:@E)]63:IG/7+%%13?UUFJS*)4W8@/02E , @^,'E^): V%$["L^W";0
M5KO'EOQGKU39Z>UKJ^ELJ QM$!9FDF^AJ>R,K,V]VK ))OW*ZXM%^O>0:M [
MQ#@70Y?\6+/R8T\OI&C[?0T+39LZ?PN)!ZNK%R<S*#&<@[)$)1A)>1C&5?.S
MEX;OJG(BL+@BQBB!1 #8!=>U:CGMC<=;OHS96P5+#.;%U7>-96O9$/5XZLN%
M_AQ7IBMNK!'51)[)1<>Y8,Y8#)M_&52,=(.\/0PA@%FMM\.$KVAQ_GJ1LA;7
MVT^.58E:13KM*46L[%@9^EV>"K4+<*Q=:'8#-&4HPG%:=%OTE6;Q@\8OF*9D
ME_",LDJ!$6GB%L>2>Z>V-3N2+VB<A-6TF^:SE-H,=04-]4K]KW8TY V:;K,S
MJ,JT=!Q9(6Q5.+>0SEF]3<,U6J@.#/".7!% (6=X0W%#8\OM76W(AU5;EL2H
M:WKV[I.Z:6UAM#^T:R:P@PK,)L^);2#2 8T&]R%?$&CTK-%>$620;"6.(=$3
MJ 60L/"S>^U.2/.QRINV]:9T3R%A](Z_L$1$537EC+M*D1>E&U/OTA2)R224
MG=7W-07KR%<R().$/5_#409E701<E R/M7!FJ6"_7B187!Y"::W!QM@N,&Y-
M'DKT>^C;71*9#;%@:,[K%T4>(6*B2T%%[,?(K&1!V1X1!L/1%1,RAP*;K'!>
MSNG\'(;RY)W+>CC7&IMAZ@TNI)46F4I:DQVS:TUIMIO-H5K28_VA[-=52.08
M$D%08,$D5'0IL"*NU%  S)U!KMGJ'4VK]31TD[F8_5^NZ3KMC,/TD4'TJSI5
M:C*TUDGB#;HW1=OD(PJJA$_<%.<0+V=, P'F/+GEG=);T**Y!/V]?H?)F=Y-
M:)C+'J:E7*&H$W<)[9]CMM-O,'+/$X_;U85E-LR2L0J[+'2$(LV9+HKG<-BJ
MF K?2W .$U#,ZGL;G;%JNL_K+>G(C?CA_(UFG5Y"T6CD=6)^N6:*6B*K&Q4-
M P-?&Q*JQR+)!,2$2324$_0QS :\('C#R,H7+C9NW:)J6]-=X7'EY,W.*MUA
MUUQ<M?&\O'RS7&!BI^27W3+ICR?A9R1TLR=J>HLWA'\=/K!&,VOO.4H& V3:
MDX:6'1U]\;7.Z4([1Q-A778K/4,IIS7TO9(=UL&>G;C9:G#;B5!&R-J2>Y61
MV]:(JLW$FS04!HF_]7(F4H%UN-?'V8XZ1U_J#?9CZ[:XG=C7W8&NZM*U:(BI
M36Y=G7ZW;,M]=7M,:Y%S=(\ULN3GU!5TW;KLV2::!A6$HJB!DQ@# & , 8 P
M!@# -:O)/0G(26WE+[F)S\VQQWXEQ>FI>0OU2J!M(09=<76EK,Y#X>L[%L;2
MFP >4>=I_O@>;1?/6YHUXQ1<('.BNLDB!F-HG7\SK>@-8.;W?LGD&N^?NI]G
ML7:AZ I97,9+I-56,:@IK:D:_K2D*S2)WVQ@8"N8%3"=50.[T TD\X=F2M4Y
M@[28;ZN'F!U_64;4M93/'@_$VZZ'UY0V$>K6W*>QEI0]XM=<O$S?!NJ2QCR(
M@=@FQ,W:H&(J@OWP-^5(=M7]+J#YBYEWC)[5X!VS=S[EN]GG35S%-%F[F;>-
M%5VKN772.!G*J1SIJ+"8Q3" @. :>/,2X^<@K5R"';>J(O>]A9V+AO?]#4)O
MHBR4B$"L;^<7YK<:-([I9W22BV\QH^RIK$2FD#A(Q"R<8*4FP<%.U H$!J?C
MQR*B-RZFUA:M32S-76_/K<?-2Z\C8M2LM-4V.C[(U)LF*:5NHF3G1N!K6[M.
MSDJV>&5C4DV4-#'7,J+?U8% -WLP'6(E0]N.?!_]V5P"EJM")J5BN'&2FRB>
M!AS"!9=X!0$8YL(] [_9@$[[PI?;.=^_#SZ/ 'O"E]LYW[\//H\ >\*7VSG?
MOP\^CP![PI?;.=^_#SZ/ 'O"E]LYW[\//H\ ASPB7P@;)^^$U_(ST_?]]G??
M['S H% W?Z@7W7:'H$>GM!@$Q[PI?;.=^_#SZ/ *#EIQFC(+P-7&R6^RMSE3
M=Q["><-XR%.<.\!K+/*BHRAP[@=?! %GIP[4T#Y3V9N*W;RI:=I-IYNK1^J$
M6E;M5=*W[K^6VEQ?3\UV23Z+<GP)YCZ)?6-'4=1E'&TZ:;A*:;E=IS5J"^:?
M-?-\L%XS1Y$]5.K 4RVQK/,6 BIB*!58R3D8VFLP(/>(BHU*N$C8A*;YX[]4
MZ2@]H()]@!*/[HW]6N2R-U95W)A*?5^5MSG;Q(KPA*":ED)>/G?)/@W:C1)>
MR.XHZ:O+V_9ACSZ:>=)1GD/VN,VJ6J^#MI3BN'F/C6X3>M,FB"39HZE6C9 A
M4D&S617;MT$B!W2)HH(B1--,H>@   #*T5JU"$+=F,;=J"^6,$H17^;%)?8U
M3W%-W+MV[*4[LI2NSYRD^J3^V577W\_>=WO$E]LYS[[N_H\BMM\Z5^"7Z*+\
M"#&*BJ*OVMO]+*+OK>R0]>7<U"OV&]2ZJ@-/>-.[M:V)6SA!<JSX9*:4!F!6
MQ@*'<[3F[W4 'H.<'8MKQEK-SBM+T&L7VO2],F*E5:Y7 2:WEG8F<PG&PK)!
M259N(<Q4VK99P4Q2)*E*H4H=H8!?WWA2^V<[]^'GT> />%+[9SOWX>?1X ]X
M4OMG._?AY]'@#WA2^V<[]^'GT> />%+[9SOWX>?1X!#J0B06!FG[XS8]8>0-
MWO?9WWP$KV-#H!N_U[H]>T/0/0/:P"8]X4OMG._?AY]'@#WA2^V<[]^'GT>
M/>%+[9SOWX>?1X ]X4OMG._?AY]'@#WA2^V<[]^'GT> />%+[9SOWX>?1X!#
MUZ$24@XH_OC-E$S!N(E)+.RD ?##YTH'Z%#Y =@8!,>\*7VSG?OP\^CP![PI
M?;.=^_#SZ/ 'O"E]LYW[\//H\ >\*7VSG?OP\^CP![PI?;.=^_#SZ/ (=>&3
M^$$>E[XS7NH>4-W_ 'U= <!(\BO0;O=>AN_VAZ!Z![6 3'O"E]LYW[\//H\
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MF)J%2A[Y:Y!*P1HM:U2[!".[+!VJ=5]8 L5 RU?CUWK=ROW$E6R)U"B)2B(
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M^S[JMODEQ? I;NVK87NC'E*/2#F]RD3OL+O:&X  @=500!:G0[D1^<* 2JI
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M:-?WP_0X ^$L#]M&O[X?H< AE+#"#8&BOOFU\,D/(%.?OCT*8SV-$H#[GTF
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M,Y8*@W7M\U,M(M5BFZ),R9E5W[A%%) H&?\ ,?R3*?<Y[];*X!X*G_16M?\
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M$9"01:H)OGZ,>"X,$GKLB95W23('2O@E.8P)^(;N].\/4#VX P!@# & , 8
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MON8R^MT\ F< 8 P!@# (-7^DC+[BR7U[%X!.8 P!@# & , A*W_($1_U!O\
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M =/DX!Z\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M\4W[@X!$5W^08;[F,OK=/ )G & , 8 P"#5_I(R^XLE]>Q> 3F , 8 P!@#
M(2M_R!$?]0;_ .3# )O & , 8 P""7_I)&_<:7^O(? )W & , 8 P!@$+7/Y
M!B/N>U_R1< FL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M!-X P!@# & 02_\ 22-^XTO]>0^ 3N , 8 P!@# (6N?R#$?<]K_ )(N 36
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M %MF_LO 'P+:?;VX_P!;9O[+P!\"VGV]N/\ 6V;^R\ ? MI]O;C_ %MF_LO
M'P+:?;VX_P!;9O[+P#J&B1QE2KC-7 5B)J)$5^%DYWR)JF3.H0IO6^H%.9(H
MB'H]R& =OP+:?;VX_P!;9O[+P!\"VGV]N/\ 6V;^R\ ? MI]O;C_ %MF_LO
M'P+:?;VX_P!;9O[+P!\"VGV]N/\ 6V;^R\ ? MI]O;C_ %MF_LO .I&B1S=%
M-!":N"2*1 333);9P"D(4  I2@+P>Z4H!V '8& 5'%Q:42@=!)W)O .H*HJ2
MDB[DURB)2E[A%GBJJA$P[O7N@/3J(C[. 2> , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 8R<K]Z6#0^NJU)4JNP
M]HV-LW;>J]':VBK*_?1=32NFV+>PJ["<MS^+:O95*L5=BX<R;Q-JD9TY29B@
MD)5%2G*!T<4-\6+>M,OX7JO0E9V5IO<VQ-$;*8U9\_DJ>]MFOGC(Y+!4'DLV
M:2_P>L]<F8^010=I^LLSN3ME#*F1%4X&46 , 8 P!@&K-7GC=%.=]@XSKM=7
M475E=V+3=51]GV%7M[L;/M"[6/44=M!["Z\N[*A_V"IS21Y@K%A%OI\LG(J1
M[WPD1,1,I@-IF , 8 P!@&&/(ODOL/3.[>*.LJ[II>S4;?FW$-;WC;\I9X>)
M@:$=_2]@V:&AH.NI.7%IM5PEW%(,8_5LWBV+$3**.3K'30$"R6F.<^Q=D;BU
ME'V'7=.AM%<B=E<G=5Z*L$/8)IWLAI8.+TS;(J3D]D1#V-0KZ<1LEKKJ?>1R
M<>L*L61LV2<&7,Y,9$#9P(&Z#T/T'I[08!^DZ@4.H]X>WW7M]H]O9@'+ & 1
MLR_6BHB5E&\7(3;B-C7S]"%B :&E9=9FU5<)1<860=L& R$@=,$D07711\0Y
M>^H0O4P :=)CS*-Z(<:8W9Y^/\+2]PSW-W8_$W^SB2-LC<,90XK7UBV"B^M%
MM'050N]HL<TA6:$;UAO!LW+()5V1%)P=$ 6.!LPXW[2#=FC=;;4"R:^MQ[I7
MB2CBP:L6L2M#>NR.W3)ZE EMS&,M3,(]VU.V<M9)LW?LWB*J"Z2:J9B !>W
M& , 8!KYYD<F^0'&YZRM]4UIJZ?U&P?:NKP(VJ[RS3:^\-C[.OXU%+46BZI
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M$JR5(U-<^1$J[F-L34)(QD QMDZE)/)>2+%M91\Z0AT)9XFB @HF*0&<PAU
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M*Z0*MS&,!EY@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & 4/LVIN+YK;85&:.T(]U<Z/;*FV?N4CKMV+BQ0+^'1=N$4C$560;*/
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M=,5^1E*XAR#VOK>K:AC>3=3)%O&BL5=&] @DV\PA[E&7<1$6NI_#$744 J.
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M>$A(+A_FX"D*JH&<F , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P (=0$!] ]@_-P#B!"AT .O0!Z@'>,(!\H.O3LP#EZ< _ *
M#U]GM#TCV (]1Z!UZ!U$, !Z1^7_ '@P#]P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M^\& ?N , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M0S<"JN2+@9F8 P!@# & , 8 P!@# /P?2'R_[PX!^X P#\#TC\O^\& ?N ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8!Q-Z2?XP_\ Q#8!RP!@'63YY3_&_O8!V8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
0, 8 P!@# & , 8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>avxl-20191231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D02%2D06T20:42:44Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:avxl="http://anavex.com/20191231">
    <link:schemaRef xlink:href="avxl-20191231.xsd" xlink:type="simple" />
    <xbrli:context id="From2019-10-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_ClinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-05to2018-07-06_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-05</xbrli:startDate>
        <xbrli:endDate>2018-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-19</xbrli:startDate>
        <xbrli:endDate>2015-10-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2019-10-01to2019-12-31">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2019-10-01to2019-12-31">0001314052</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2019-10-01to2019-12-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2019-10-01to2019-12-31">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2019-10-01to2019-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-10-01to2019-12-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2019-10-01to2019-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntitySmallBusiness contextRef="From2019-10-01to2019-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-10-01to2019-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory contextRef="From2019-10-01to2019-12-31">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2019-10-01to2019-12-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2019-10-01to2019-12-31">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">74944</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">74528</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2016-10-01to2017-09-30_custom_ClinicalStudyGrantMember" unitRef="USD" decimals="0">597886</avxl:NonOperatingIncomeFromGrant>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">10997952</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">1994700</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-07-05to2018-07-06_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="USD" decimals="0">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dei:EntityFileNumber contextRef="From2019-10-01to2019-12-31">001-37606</dei:EntityFileNumber>
    <dei:EntityShellCompany contextRef="From2019-10-01to2019-12-31">false</dei:EntityShellCompany>
    <dei:EntityInteractiveDataCurrent contextRef="From2019-10-01to2019-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-10-01to2019-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="From2019-10-01to2019-12-31" unitRef="Shares" decimals="INF">9226266</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="From2018-10-01to2019-09-30" unitRef="Shares" decimals="INF">8812933</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <avxl:ValueOfSharesObligatedToPurchase contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:ValueOfSharesObligatedToPurchase contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:AgreementTerm contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <avxl:AgreementTerm contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationDescription contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase.  The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park&amp;#8217;s committed obligation under any single purchase shall not exceed $2,000,000.  The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2019 Purchase Agreement.</us-gaap:UnrecordedUnconditionalPurchaseObligationDescription>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2018-10-01to2018-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">3584</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">35675</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:PercentageOfGrossProceedsFromSales contextRef="From2019-10-01to2019-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="Pure" decimals="INF">0.03</avxl:PercentageOfGrossProceedsFromSales>
    <avxl:PercentageOfGrossProceedsFromSales contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" unitRef="Pure" decimals="INF">0.1999</avxl:PercentageOfGrossProceedsFromSales>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-8750</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1264424</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">2066987</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">481101</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">783323</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-10-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">1011399</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-10-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1055588</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-10-01to2019-12-31" unitRef="Pure" decimals="INF">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-10-01to2018-12-31" unitRef="Pure" decimals="INF">0.0296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-01to2019-12-31">P5Y2M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-10-01to2018-12-31">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-10-01to2019-12-31" unitRef="Pure" decimals="INF">1.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-10-01to2018-12-31" unitRef="Pure" decimals="INF">1.0615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-10-01to2019-12-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-10-01to2018-12-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member">The exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2019Member">The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2019Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2018-10-01to2018-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">950000</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">4394160</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2018-10-01to2018-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">1994700</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">10997952</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-10-01to2018-12-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">953584</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">4429835</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10076680</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:StockIssuedDuringPeriodValueNewIssues4 contextRef="From2019-10-01to2019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">34367543</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:RemainingAllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">4602000</avxl:RemainingAllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">943215</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">413682</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2019-10-01to2019-12-31_currency_AUD" unitRef="USD" decimals="0">1345000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2018-10-01to2018-12-31_currency_AUD" unitRef="USD" decimals="0">587000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-02-06" unitRef="Shares" decimals="INF">58664946</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:LeaseAndRentalExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">50054</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">37754</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">309383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">265000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">2265399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6506917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">8726266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">8462933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">5883586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2019-10-01to2019-12-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">2353088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">2195111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">4115032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">2047275</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2019-12-31_custom_PurchaseWarrants2Member" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2019-12-31_custom_PurchaseWarrants1Member" unitRef="Shares" decimals="INF">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_PurchaseWarrants2Member" unitRef="USDPShares" decimals="INF">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_PurchaseWarrants1Member" unitRef="USDPShares" decimals="INF">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2019-12-31_custom_PurchaseWarrants2Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2019-12-31_custom_PurchaseWarrants1Member">2021-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-319629</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">678379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-12-31_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod contextRef="From2019-10-01to2019-12-31_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">150000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">1.46</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">1.13</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">2.87</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice contextRef="From2019-10-01to2019-12-31_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.17</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">57080356</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">52650251</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">57080356</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">52650251</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">31424067</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">25329373</us-gaap:Assets>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">234972</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">500998</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">3730672</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">2642745</us-gaap:IncomeTaxesReceivable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">5463917</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">5039674</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2336419</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">1516342</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">3127498</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">3523332</us-gaap:AccountsPayableCurrent>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">57082</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">52652</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">31424067</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">25329373</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">25960150</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">20491510</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">17633466</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45935</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">46888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">57082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">129377542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">133438276</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">165891753</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-108931967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-115851698</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-139988685</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-139988685</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">-133396760</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">165891753</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">153633807</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:OperatingExpenses contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">7700703</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">7473517</us-gaap:OperatingExpenses>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">6348668</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">5712210</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1352035</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">1761307</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">9214</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">8717</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-6582711</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-6911014</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1117992</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">562503</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">53113</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-4507</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">46720</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">78800</us-gaap:InterestIncomeExpenseNet>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">943215</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">413682</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-6591925</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-6919731</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-6919731</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-6591925</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-10-01to2019-12-31" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-10-01to2018-12-31" unitRef="USDPShares" decimals="INF">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-10-01to2019-12-31" unitRef="Shares" decimals="INF">54773685</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-10-01to2018-12-31" unitRef="Shares" decimals="INF">46327482</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1264424</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">2066987</us-gaap:ShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-5725159</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-4160169</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">820077</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-92262</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-395834</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">1083531</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-266026</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-105189</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1087927</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">403883</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">27458423</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">22185630</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">10997952</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">1944700</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2019-10-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">50000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">5272793</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-2215469</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">27458423</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">22930638</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">20715169</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">22185630</us-gaap:Cash>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">1994700</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">950</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1993750</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-3</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1264424</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">2066987</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2066987</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1264424</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:StockIssuedDuringPeriodSharesAcquisitions2 contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">950000</avxl:StockIssuedDuringPeriodSharesAcquisitions2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3584</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">10997952</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4394</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10993558</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">36</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-36</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4394160</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">35675</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;2&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#9;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recently&#13;Adopted Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840,&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leases.&#13;The main difference between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees&#13;for those leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability&#13;to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the&#13;lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class&#13;of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize&#13;lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is largely&#13;unchanged from that applied under previous U.S. GAAP. The adoption of this standard on October 1, 2019 did not have any impact&#13;on the Company's results of operations, financial condition, cash flows, and financial statement disclosures. The Company elected&#13;to the package of practical expedients permitted under the transition guidance that allowed, among other things, the historical&#13;lease classifications to be carried forward without reassessment. Further, the Company elected to not recognize lease assets and&#13;lease liabilities for leases with a term of 12 months or less.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based&#13;Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning&#13;it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the&#13;Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the&#13;date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results&#13;of operations, financial condition, cash flows, and financial statement disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results&#13;of operations, financial position or cash flow.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;3&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#9;&lt;u&gt;Other Income &lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Grant&#13;Income&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received&#13;in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for&#13;a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;grant income is deferred when received and amortized to other income as the related research and development expenditures are&#13;incurred. During the three months ended December 31, 2019, the Company recognized $74,944 (2018: $74,528) of this grant on its&#13;statement of operations within grant income.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development incentive income&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development incentive income represents the receipt by the Company&amp;#8217;s Australian subsidiary, of the Australian research&#13;and development incentive credit, (the &amp;#8220;ATO R&amp;#38;D Credit&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended December 31, 2019, the Company recorded research and development incentive income of $943,215 (AUD 1,345,000)&#13;(2018: $413,682 (AUD 587,000)) in respect of the ATO R&amp;#38;D Credit for eligible research and development expenses incurred during&#13;the period.&lt;/font&gt;&lt;/p&gt;</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recently&#13;Adopted Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840,&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leases.&#13;The main difference between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees&#13;for those leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability&#13;to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the&#13;lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class&#13;of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize&#13;lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is largely&#13;unchanged from that applied under previous U.S. GAAP. The adoption of this standard on October 1, 2019 did not have any impact&#13;on the Company's results of operations, financial condition, cash flows, and financial statement disclosures. The Company elected&#13;to the package of practical expedients permitted under the transition guidance that allowed, among other things, the historical&#13;lease classifications to be carried forward without reassessment. Further, the Company elected to not recognize lease assets and&#13;lease liabilities for leases with a term of 12 months or less.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based&#13;Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning&#13;it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the&#13;Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the&#13;date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results&#13;of operations, financial condition, cash flows, and financial statement disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results&#13;of operations, financial position or cash flow.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of the Company&amp;#8217;s outstanding share purchase warrants is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 68%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.87&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.13&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(319,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.46&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.88&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2019, the Company had share purchase warrants outstanding as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 29%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 29%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 32%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30,&#13;    2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May&#13;    6, 2024&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of Company&amp;#8217;s outstanding stock purchase options is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="right" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Grant Date Fair Value ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    intrinsic value ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; width: 10%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.83&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,353,088&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,265,399&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.79&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.27&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(309,383&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.25&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,462,933&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.58&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,115,032&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;265,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.36&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.98&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,667&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,726,266&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.54&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,195,111&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,&#13;    December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,883,586&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.85&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,047,275&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These amounts have been&#13;included in general and &amp;#9;administrative expenses and research and development expenses on the Company&amp;#8217;s statement of&#13;&amp;#9;operations as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="right" style="border-collapse: collapse; width: 90%; font: 10.5pt Arial, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General&#13;    and administrative&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,101&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,011,399&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;    and development&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;783,323&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,055,588&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    share based compensation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,264,424&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,066,987&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following&#13;weighted average assumptions:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="right" style="border-collapse: collapse; width: 90%; font: 10.5pt Arial, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options&#13;    (years)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.21&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.45&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;101.60&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;106.15&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">45933472</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">46887056</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">52650521</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">57080356</us-gaap:SharesOutstanding>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;5&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &amp;#9;&lt;u&gt;Commitments &lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 42.75pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Leases&#13;                                         &lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended December 31, 2019, the Company incurred office lease expense of $50,054 (2018: $37,754).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 42.75pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;The&#13;Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently&#13;uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that&#13;the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.&#13;The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its&#13;consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 42.75pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Share&#13;                                         Purchase Warrants&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of the Company&amp;#8217;s outstanding share purchase warrants is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 68%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.87&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.13&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(319,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.46&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.88&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&lt;br style="clear: both" /&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2019, the Company had share purchase warrants outstanding as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 29%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 29%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 32%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30,&#13;    2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May&#13;    6, 2024&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&lt;p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 42.75pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock&amp;#8211;based&#13;                                         Compensation Plan&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&#13;Stock Option Plan&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 66pt; text-align: justify; text-indent: -1in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;September 18, 2015, the Company&amp;#8217;s board of directors (the &amp;#8220;Board&amp;#8221;) approved a 2015 Omnibus Incentive Plan (the&#13;&amp;#8220;2015 Plan&amp;#8221;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees&#13;and consultants of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event&#13;of a change of the Company&amp;#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were&#13;granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing&#13;stock option plans remain outstanding in accordance with their terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The&#13;exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.&#13;If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value&#13;of the Company&amp;#8217;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise&#13;period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject&#13;to earlier termination in accordance with the terms of the 2015 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&#13;Stock Option Plan&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &amp;#8220;2019 Plan&amp;#8221;), which provides for the grant&#13;of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under&#13;the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition&#13;to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&amp;#8217;s 2007 Stock Option&#13;Plan (the &amp;#8220;2007 Plan&amp;#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and&#13;any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards&#13;(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The&#13;exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value&#13;on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair&#13;market value of the Company&amp;#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan&#13;for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by&#13;the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of Company&amp;#8217;s outstanding stock purchase options is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="right" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Grant Date Fair Value ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    intrinsic value ($)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; width: 10%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.83&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,353,088&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,265,399&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.79&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.27&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(309,383&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.25&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,462,933&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.58&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,115,032&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;265,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.36&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.98&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,667&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,726,266&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.54&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,195,111&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,&#13;    December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,883,586&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.85&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,047,275&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&lt;br style="clear: both" /&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market&#13;price of the Company&amp;#8217;s stock for the options that were in-the-money at December 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended December 31, 2019, the Company recognized stock-based compensation expense of $1,264,424 (2018: $2,066,987)&#13;in connection with the issuance and vesting &amp;#9;of stock options and warrants in exchange for services. These amounts have been&#13;included in general and &amp;#9;administrative expenses and research and development expenses on the Company&amp;#8217;s statement of&#13;&amp;#9;operations as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="right" style="font: 10.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 90%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General&#13;    and administrative&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,101&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,011,399&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;    and development&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;783,323&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,055,588&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    share based compensation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,264,424&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,066,987&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&lt;br style="clear: both" /&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;An&#13;amount of approximately $4,602,000 in stock-based compensation is expected to be recorded over the remaining term &amp;#9;of such&#13;options through fiscal 2022.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following&#13;weighted average assumptions:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="right" style="font: 10.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 90%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 4%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options&#13;    (years)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.21&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.45&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;101.60&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;106.15&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;1 &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#9;&lt;u&gt;Business Description and Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Anavex&#13;Life Sciences Corp. (the &amp;#8220;Company&amp;#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated&#13;therapeutics by applying precision medicine to central nervous system (&amp;#8220;CNS&amp;#8221;) diseases with high unmet need. Anavex&#13;analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic&#13;benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&amp;#8217;s lead compound ANAVEX&amp;#174;2-73&#13;is being developed to treat Alzheimer&amp;#8217;s disease, Parkinson&amp;#8217;s disease and potentially other central nervous system&#13;diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in&#13;the X-linked gene, methyl-CpG-binding protein 2 (&amp;#8220;MECP2&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basis&#13;of Presentation&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the&#13;Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) and accounting principles generally accepted in the United States of America&#13;(&amp;#8220;U.S. GAAP&amp;#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the&#13;annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.&#13;In the opinion of management, the disclosures are adequate to make the information presented not misleading.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring&#13;adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated&#13;balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures&#13;required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction&#13;with the audited consolidated financial statements and notes thereto included in the Company&amp;#8217;s annual report on Form 10-K&#13;for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies&#13;in the preparation of interim reports.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating&#13;results for the three months ended December 31, 2019 are not necessarily indicative of the results that may be expected for the&#13;year ending September 30, 2020.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Liquidity&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;All&#13;of the Company&amp;#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its&#13;research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved&#13;for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.&#13;The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,&#13;if ever, our business might become profitable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will&#13;be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated&#13;financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials&#13;is uncertain.&amp;#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to&#13;change.&amp;#160;The actual amount of the Company&amp;#8217;s expenditures will vary depending upon a number of factors including but&#13;not limited to the design, timing and duration of future clinical trials, the progress of the Company&amp;#8217;s research and development&#13;programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels&#13;based on the timing of future clinical trials.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance&#13;that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable&#13;terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to&#13;delay or scale down some or all of our research and development activities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Use&#13;of Estimates&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect&#13;the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and&#13;expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research&#13;and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss&#13;contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors&#13;that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the&#13;carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.&#13;The actual results experienced by the Company may differ materially and adversely from the Company&amp;#8217;s estimates. To the extent&#13;there are material differences between the estimate s and the actual results, future results of operations will be affected.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Adjustment&#13;of Prior Period Financial Statements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;previously disclosed in Note 1 to the Company&amp;#8217;s consolidated financial statements included in the Company&amp;#8217;s annual&#13;report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial&#13;statements which were immaterial&lt;font style="color: gray"&gt;. &lt;/font&gt;These adjustments were identified in connection with the preparation&#13;of the consolidated financial statements for the year ended September 30, 2019 and related to the timing of recognition of research&#13;and development incentive income. Previously the Company accounted for research and development incentive income when received&#13;in cash. During the year ended September 30, 2019, based on a continuing assessment regarding the Company&amp;#8217;s eligibility&#13;for the incentive programs under which it was receiving such income, the Company determined that the income should have been accrued&#13;and recorded in the period in which the qualifying research and development expenditures were incurred.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;interim condensed consolidated financial statements for the three months ended December 31, 2018 have been similarly adjusted&#13;to reflect the adjusted research and development incentive income for the quarter accordingly in the amount of $413,682 and should&#13;be read in conjunction with Note 1 to the Company&amp;#8217;s consolidated financial statements for the year ended September 30, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Principles&#13;of Consolidation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex&#13;Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the&#13;laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company&#13;transactions and balances have been eliminated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Fair&#13;Value Measurements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last&#13;unobservable, that may be used to measure fair value which are the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;1 - &amp;#9;quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active &amp;#9;&amp;#9;markets, quoted prices&#13;for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable&#13;or whose significant value drivers are observable; and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;3 - &amp;#9;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant&#13;to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the&#13;short-term maturity of those instruments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2019 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Basic&#13;and Diluted Loss per Share&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic&#13;loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common&#13;shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except&#13;that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into&#13;shares of common stock that were outstanding during the period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of December 31, 2019, loss per share excludes 9,226,266 (September 30, 2019 &amp;#8211; 8,812,933) potentially dilutive common shares&#13;related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2019-10-01to2019-12-31">&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;4&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#9;&lt;u&gt;Equity Offering Agreements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Controlled&#13;Equity Offering Sales Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;July 6, 2018, the Company entered into a Controlled Equity Offering&amp;#160;Sales Agreement (the &amp;#8220;Sales Agreement&amp;#8221;) with&#13;Cantor Fitzgerald&amp;#160;&amp;#38; Co., as agent (&amp;#8220;Cantor Fitzgerald&amp;#8221;), pursuant to which the Company may offer and sell&#13;shares of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the&#13;&amp;#8220;Offering&amp;#8221;).&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon&#13;delivery of a placement notice based on the Company&amp;#8217;s instructions and subject to the terms and conditions of the Sales&#13;Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an &amp;#8220;at the market offering&amp;#8221; offering, in&#13;negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,&#13;or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.&#13;The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend&#13;or terminate the offering of Shares upon notice to the other party, subject to certain conditions.&amp;#160; Cantor Fitzgerald will&#13;act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable&#13;state and federal law, rules&amp;#160;and regulations and the rules&amp;#160;of Nasdaq.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds&#13;from the sale of the Shares pursuant to the Sales Agreement.&amp;#160; The Company also agreed to provide Cantor Fitzgerald with customary&#13;indemnification and contribution rights. As of December 31, 2019, no shares had been sold pursuant to the Offering.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&#13;Purchase Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &amp;#8220;2015 Purchase Agreement&amp;#8221;) with Lincoln&#13;Park Capital Fund, LLC (&amp;#8220;Lincoln Park&amp;#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln&#13;Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended December 31, 2019, the Company did not issue any shares to Lincoln Park under the 2015 Purchase Agreement.&#13;During the three months ended December 31, 2018, the company issued to Lincoln Park an aggregate of 953,584 shares of common stock&#13;under the 2015 Purchase Agreement, including 950,000 shares of common stock for an aggregate purchase price of $1,994,700 and&#13;3,584 commitment shares. At December 31, 2019 and September 30, 2019, all remaining purchase amounts available for issuance under&#13;the 2015 Purchase Agreement had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further&#13;shares will be sold under the 2015 Purchase Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&#13;Purchase Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &amp;#8220;2019 Purchase Agreement&amp;#8221;) with Lincoln&#13;Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000&#13;in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares&#13;of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day&#13;of the next month following the 36-month anniversary of June 12, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of&#13;common stock on any business day (a &amp;#8220;Regular Purchase&amp;#8221;). The amount of a Regular Purchase may be increased under certain&#13;circumstances up to 250,000 shares, provided that Lincoln Park&amp;#8217;s committed obligation for Regular Purchases on any business&#13;day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business&#13;day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase&#13;price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares&#13;at the time of sales as described in the 2019 Purchase Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2019 Purchase Agreement limits the Company&amp;#8217;s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common&#13;Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i)&#13;shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock&#13;to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on&#13;the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock&#13;on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company&amp;#8217;s&#13;sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company&amp;#8217;s&#13;outstanding shares of Common Stock at any given time.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock&#13;as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company&amp;#8217;s&#13;discretion the $50,000,000 aggregate commitment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended December 31, 2019, the Company issued to Lincoln Park an aggregate of 4,429,835 shares of common stock&#13;under the 2019 Purchase Agreement, including 4,394,160 shares of common stock for an aggregate purchase price of $10,997,952 and&#13;35,675 commitment shares. At December 31, 2019, an amount of $34,367,543 remained available under the 2019 Purchase Agreement.&lt;/font&gt;&lt;/p&gt;</avxl:EquityOfferingAgreementsTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>avxl-20191231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D02%2D06T20:42:44Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9KhZw7xRiXgen8uCa3dcOauMacPtw5NxaYkhv2d7felKbyYtLHonGy/LUjIWkXgP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:avxl="http://anavex.com/20191231" elementFormDefault="qualified" targetNamespace="http://anavex.com/20191231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" id="InterimCondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreements" id="EquityOfferingAgreements">
	  <link:definition>00000010 - Disclosure - Equity Offering Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/Commitments" id="Commitments">
	  <link:definition>00000011 - Disclosure - Commitments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
	  <link:definition>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsTables" id="CommitmentsTables">
	  <link:definition>00000013 - Disclosure - Commitments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" id="BusinessDescriptionAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000015 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" id="EquityOfferingAgreementsDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails" id="CommitmentsDetails">
	  <link:definition>00000017 - Disclosure - Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails1" id="CommitmentsDetails1">
	  <link:definition>00000018 - Disclosure - Commitments (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails2" id="CommitmentsDetails2">
	  <link:definition>00000019 - Disclosure - Commitments (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails3" id="CommitmentsDetails3">
	  <link:definition>00000020 - Disclosure - Commitments (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails4" id="CommitmentsDetails4">
	  <link:definition>00000021 - Disclosure - Commitments (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Commitments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AgreementTerm" name="AgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_RemainingAllocatedShareBasedCompensationExpense" name="RemainingAllocatedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueAcquisitions2" name="StockIssuedDuringPeriodValueAcquisitions2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesAcquisitions2" name="StockIssuedDuringPeriodSharesAcquisitions2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalStudyGrantMember" name="ClinicalStudyGrantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreementMember" name="PurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>avxl-20191231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D02%2D06T20:42:44Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20191231.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20191231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20191231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20191231.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20191231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20191231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20191231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20191231.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20191231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20191231.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20191231.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20191231.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20191231.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20191231.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20191231.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20191231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000013 - Disclosure - Commitments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000017 - Disclosure - Commitments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000018 - Disclosure - Commitments (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000019 - Disclosure - Commitments (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000020 - Disclosure - Commitments (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000021 - Disclosure - Commitments (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>avxl-20191231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D02%2D06T20:42:44Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20191231.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20191231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20191231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20191231.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20191231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20191231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20191231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20191231.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20191231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20191231.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20191231.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20191231.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20191231.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20191231.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20191231.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20191231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_50" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000013 - Disclosure - Commitments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAgreementTerm_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_90" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000017 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000018 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000019 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:label="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000020 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000021 - Disclosure - Commitments (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_60" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>avxl-20191231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D02%2D06T20:42:44Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ClinicalStudyGrantMember" xlink:label="avxl_ClinicalStudyGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalStudyGrantMember_lbl" xml:lang="en-US">Clinical Study Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseAgreementMember" xlink:label="avxl_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreementMember_lbl" xml:lang="en-US">2015 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_DocumentAndEntityInformationAbstract" xlink:label="avxl_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DocumentAndEntityInformationAbstract" xlink:to="avxl_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding:57,080,356 common shares (September 30, 2019 - 52,650,251)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Deferred financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance Beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance Ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="us-gaap_OtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Component of Operating Income [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ProductOrServiceAxis_2_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_2_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_AgreementTerm" xlink:label="avxl_AgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AgreementTerm_lbl" xml:lang="en-US">Agreement term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xml:lang="en-US">Description of purchases price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross sale proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:label="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate intrinsic value [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of grant option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_AgreementTerm_doc" xml:lang="en-US">Terms of the agreement under agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ClinicalStudyGrantMember_doc" xml:lang="en-US">Information by clinical study grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingAgreementsTextBlock_doc" xml:lang="en-US">Represents information related to equity offering agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NonOperatingIncomeFromGrant_doc" xml:lang="en-US">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_OtherIncomeDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of other income disclosure.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreementMember_doc" xml:lang="en-US">Terms of the purchase agreement under purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xml:lang="en-US">It represents as a remaining stock based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_doc" xml:lang="en-US">It refers to amount of research and development incentive income during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xml:lang="en-US">The number of exercised in period made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xml:lang="en-US">Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_doc" xml:lang="en-US">Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average expired price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2019Member_doc" xml:lang="en-US">Represents the information pertaining to stock option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodValueAcquisitions2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2_doc" xml:lang="en-US">Stock issued during period value acquisitions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodSharesAcquisitions2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2_doc" xml:lang="en-US">Stock issued during period shares acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares issued shares underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares Issued value Underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_doc" xml:lang="en-US">Commitment shares issued shares underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_doc" xml:lang="en-US">Commitment shares issued value underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>avxl-20191231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D02%2D06T20:42:44Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20191231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20191231.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20191231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20191231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20191231.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20191231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20191231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20191231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20191231.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20191231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20191231.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20191231.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20191231.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20191231.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20191231.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20191231.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20191231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_DocumentAndEntityInformationAbstract" xlink:label="loc_avxlDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000013 - Disclosure - Commitments (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000017 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000018 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000019 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:label="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000020 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000021 - Disclosure - Commitments (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20191231.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6760920560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 4)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.88%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 2 months 16 days<span></span>
</td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">101.60%<span></span>
</td>
<td class="nump">106.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6772326000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, at beginning</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">678,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(319,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Granted</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, at ending</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, at beginning</a></td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Granted</a></td>
<td class="nump">3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, at ending</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercised in period made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average expired price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6706963456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 68%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2018</font></td>
    <td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.87</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(8,750</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.13</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(319,629</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2019</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2019</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.88</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2019, the Company had share purchase warrants outstanding as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 29%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 3%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 29%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 3%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 32%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 30,
    2021</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May
    6, 2024</font></td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"></p>

<table cellpadding="0" cellspacing="0" align="right" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: middle"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value ($)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate
    intrinsic value ($)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; width: 10%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2018</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,353,088</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,265,399</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.27</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(309,383</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.25</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2019</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,462,933</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.58</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,115,032</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">265,000</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.36</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.98</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,667</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.64</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2019</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,726,266</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.54</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,195,111</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    December 31, 2019</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,883,586</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.85</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,047,275</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These amounts have been
included in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s statement of
&#9;operations as follows:</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" align="right" style="border-collapse: collapse; width: 90%; font: 10.5pt Arial, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">481,101</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,011,399</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Research
    and development</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">783,323</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,055,588</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Total
    share based compensation</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,264,424</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,066,987</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" align="right" style="border-collapse: collapse; width: 90%; font: 10.5pt Arial, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.88</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.96</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.21</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.45</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">101.60</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">106.15</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Dividend rate</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6761625328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note
1 &#160;&#160;&#160;&#160;&#160;&#9;<u>Business Description and Basis of Presentation</u></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Business</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX&#174;2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K
for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies
in the preparation of interim reports.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">Operating
results for the three months ended December 31, 2019 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2020.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Liquidity</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</font></p>



<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated
financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to
change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but
not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels
based on the timing of future clinical trials.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Use
of Estimates</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent
there are material differences between the estimate s and the actual results, future results of operations will be affected.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">Adjustment
of Prior Period Financial Statements</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">As
previously disclosed in Note 1 to the Company&#8217;s consolidated financial statements included in the Company&#8217;s annual
report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial
statements which were immaterial<font style="color: gray">. </font>These adjustments were identified in connection with the preparation
of the consolidated financial statements for the year ended September 30, 2019 and related to the timing of recognition of research
and development incentive income. Previously the Company accounted for research and development incentive income when received
in cash. During the year ended September 30, 2019, based on a continuing assessment regarding the Company&#8217;s eligibility
for the incentive programs under which it was receiving such income, the Company determined that the income should have been accrued
and recorded in the period in which the qualifying research and development expenditures were incurred.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">These
interim condensed consolidated financial statements for the three months ended December 31, 2018 have been similarly adjusted
to reflect the adjusted research and development incentive income for the quarter accordingly in the amount of $413,682 and should
be read in conjunction with Note 1 to the Company&#8217;s consolidated financial statements for the year ended September 30, 2019.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Principles
of Consolidation</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Fair
Value Measurements</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Level
1 - &#9;quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Level
3 - &#9;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2019 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Basic
and Diluted Loss per Share</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2019, loss per share excludes 9,226,266 (September 30, 2019 &#8211; 8,812,933) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763865200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">57,080,356<span></span>
</td>
<td class="nump">52,650,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">57,080,356<span></span>
</td>
<td class="nump">52,650,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763505888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Jul. 06, 2018</div></th>
<th class="th"><div>Oct. 21, 2015</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,997,952<span></span>
</td>
<td class="nump">$ 1,994,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC [Member] | 2019 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription', window );">Description of purchases price</a></td>
<td class="text">The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase.  The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park&#8217;s committed obligation under any single purchase shall not exceed $2,000,000.  The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2019 Purchase Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="nump">324,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,429,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,394,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,997,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,367,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC [Member] | 2015 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">953,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,994,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | 2019 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,076,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember', window );">Cantor Fitzgerald &amp; Co [Member] | Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms of the agreement under agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001731122-20-000103-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-20-000103-xbrl.zip
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M'>Y&$&JS*%Y'*&W4/S>AQMLG'%>9$+G60N.&!S.ULL/YSOB']IO:?[M$A:,
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M>;?]E>CU4ZBT>2[.QX$Z?/&*O9_- Q!%XA@!!OOH>WPV=_T%"$0R *^H?H:
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M$:41-.[ -.-%7L (J@TU=? Z9-<QACE<Q_18&(]#QW;,8*$( </SOP;5 +%
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M@:4"6#?PP#APUDJ41\>.[E^Q4??'UVR,+NH /7.N.0_Y*Y;\]2R##@$+DGG
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MITLO-96%)#[IK0BN3Z2OENC^RW_^QT\OOXT#UWF%_X:/_S]02P,$%     @
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M60-]KS%](&)$YS;3?U\SRX#9:?C_'0SFDYBGU,,I[+W9"9,2(09$Z-S<RNB
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MOL"Z=,P7V$&/F1 W9 5M%GB?S%\N)6J4=BI#Z1L\5#F673LE5IG=8=L"QN_
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M%@7V4>RD*2W2KB""NW-=KSVJ4,0+"_P45D'!)QVU49/I0F\L-U<]>IZTHH6
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M(A,];>H-:U#5\?G5R]8I=9/.O$RE[.;L-M6R;Z.J"F3*"P;J/066!F->$*.
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M4E.^^P1([J<1F/W16WTL"?C=:=$.)#3ZH4/2[@"E0AOY]DR#^)-FX/3'7"H
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M/2'6._18"=%):H-F=Z=MI#6WHANDU:\NZ2?Z=?$5_0^KBG[S_P%02P,$%
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M>B"S0V.AO<JI(8G17^S#2"P#T.&4(DHYV;^3F=7-Z12/H_H:DN!<V >.6 :
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M=30D5*WL.#ZH[3CN9N2_7\?79+<QO72F-^/;P6Q""E@2))V%G+WPT[R]X%8
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MZIE^U5#+D\NWAZVV ?M"H'7A)I"7(> V[WJ64\MGG[]$A)\4X64RG=^LL?=
M>!TL,&+F 0_(?1JT+YI9&=C]Y7E0H-E$H1%GJ?;LBU76!+."-"TR@R66CP;C
M6*H%^R*26YO,"A*S&N?=Y489Z+HF[ LNUH@T7V:VK= ]W2MTSX+@7L@ENF?I
M$JT&M%1[X.&]@&NT-IBU9SJ8Q1P7-V/P?ON>]"W*)BETA_!CX*%L J,WMA<1
M:Z7A]77S/8.'&>M9*@X%D1T*:391BN7N-(M3HNSGTU8) [35(R9D3HO7<S=.
ML&-N;168;76@B7@SA/)AHT$_K9,@0DDR0HF'@Q7#)?)I*CUJKY2Z>>&W$O3Y
M9^?$V23R([\4[3FE!ATB,X<UZ<1SI](HX%M->.%&P1^,C$T(;,9^F<32>XR;
M9'T2+]SI:1[R,:M].-CHQ(RHXZ=0> =0?T_ :>ZTZM;VJUN&8 %/DTGSL41I
MGHF!^D!P')&/7D9Y_?3SE^WI)VO$V;3B;#4#:<M^XS%'[_04X?;E,@&!;Q7*
M9(K3TCBHH=^:?HD)1D_KP).*1OW9V6CH$S[X-,)R"V^]O%69,RZVYPQ6P\FK
M *ZW&\(ES(NZPCH=A*4.Y-9R6JNI$O2RS)=PV9DGQSJXHF=[E^F<;#GHI>#"
MI5B_4O;.MK4^J^X4]9U2 ]"A_!)9\75<G>)H/D^N3<HO40]8_\47HB1YL$3[
M-QYWCL+WMA6^7 /V/D1.!5U;67: !2*K*2H9Y\T#0+$9X L@.:5*F\*F>L!C
MJ16.-3=%FD4#/M3$&[,;L@'URKDH*J.PK[I!<[XK&H1\G>"X5VLG'(;=<_9S
MOWT9IZ6WN <3"E7SI3*P19S=0N5,(N>"I=SY+JL).5N\N37]SGM _CI$TSG;
M*]6G3L_3%#TS?"0F@[T:?076@ :AFHJX?Z&,$55$L?SF8OKV?/E8K!%K%I#>
MNCGH"VM[P;P?ZU:=_F^XH&>I4W;(EY1.4=6'O&1#T'?A](YS)>G9!OUXN0KC
M9U1$$W&FJY#1PHZC\DBC/Y"?11ZQ'(A*2J*]2^AK=WK5R1 BMBG>AJ\\M^:
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MT!]4B<DW_P]02P$"% ,4    "  0BT90]+?6*&A/  #"D@, $0
M    @ $     879X;"TR,#$Y,3(S,2YX;6Q02P$"% ,4    "  0BT90"'DS
MQAH*  "C6@  $0              @ &73P  879X;"TR,#$Y,3(S,2YX<V10
M2P$"% ,4    "  0BT90H!M!UN (  "J6@  %0              @ '@60
M879X;"TR,#$Y,3(S,5]C86PN>&UL4$L! A0#%     @ $(M&4.FK6K6"$0
MWQL! !4              ( !\V(  &%V>&PM,C Q.3$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( !"+1E# 5=/>/BX   BS @ 5              "  :AT  !A
M=GAL+3(P,3DQ,C,Q7VQA8BYX;6Q02P$"% ,4    "  0BT90O$(:K*(;  #0
MWP$ %0              @ $9HP  879X;"TR,#$Y,3(S,5]P<F4N>&UL4$L%
3!@     &  8 B@$  .Z^      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6630724336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recently
Adopted Accounting Pronouncements</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840,</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Leases.
The main difference between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees
for those leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability
to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is largely
unchanged from that applied under previous U.S. GAAP. The adoption of this standard on October 1, 2019 did not have any impact
on the Company's results of operations, financial condition, cash flows, and financial statement disclosures. The Company elected
to the package of practical expedients permitted under the transition guidance that allowed, among other things, the historical
lease classifications to be carried forward without reassessment. Further, the Company elected to not recognize lease assets and
lease liabilities for leases with a term of 12 months or less.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6771443216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning at Sep. 30, 2018</a></td>
<td class="nump">$ 45,935<span></span>
</td>
<td class="nump">$ 129,377,542<span></span>
</td>
<td class="num">$ (108,931,967)<span></span>
</td>
<td class="nump">$ 20,491,510<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2018</a></td>
<td class="nump">45,933,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="nump">1,993,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,994,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">3,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,066,987<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,066,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,919,731)<span></span>
</td>
<td class="num">(6,919,731)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Dec. 31, 2018</a></td>
<td class="nump">$ 46,888<span></span>
</td>
<td class="nump">133,438,276<span></span>
</td>
<td class="num">(115,851,698)<span></span>
</td>
<td class="nump">17,633,466<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Dec. 31, 2018</a></td>
<td class="nump">46,887,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares</a></td>
<td class="nump">$ 4,394<span></span>
</td>
<td class="nump">10,993,558<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,997,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">4,394,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">35,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,264,424<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,264,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,591,925)<span></span>
</td>
<td class="num">(6,591,925)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Dec. 31, 2019</a></td>
<td class="nump">$ 57,082<span></span>
</td>
<td class="nump">$ 165,891,753<span></span>
</td>
<td class="num">$ (139,988,685)<span></span>
</td>
<td class="nump">$ 25,960,150<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Dec. 31, 2019</a></td>
<td class="nump">57,080,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued shares underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued shares underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued value underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares Issued value Underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763466832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,458,423<span></span>
</td>
<td class="nump">$ 22,185,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">3,730,672<span></span>
</td>
<td class="nump">2,642,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">234,972<span></span>
</td>
<td class="nump">500,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">31,424,067<span></span>
</td>
<td class="nump">25,329,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,127,498<span></span>
</td>
<td class="nump">3,523,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,336,419<span></span>
</td>
<td class="nump">1,516,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Liabilities</a></td>
<td class="nump">5,463,917<span></span>
</td>
<td class="nump">5,039,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding:57,080,356 common shares (September 30, 2019 - 52,650,251)</a></td>
<td class="nump">57,082<span></span>
</td>
<td class="nump">52,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">165,891,753<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(139,988,685)<span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">25,960,150<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 31,424,067<span></span>
</td>
<td class="nump">$ 25,329,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763575504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 1,264,424<span></span>
</td>
<td class="nump">$ 2,066,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">481,101<span></span>
</td>
<td class="nump">1,011,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 783,323<span></span>
</td>
<td class="nump">$ 1,055,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6706482464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">9,226,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,812,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">$ 943,215<span></span>
</td>
<td class="nump">$ 413,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to amount of research and development incentive income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608418336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offering Agreements</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Note
4&#160;&#160;&#160;&#160;&#160;&#160;&#9;<u>Equity Offering Agreements</u></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Controlled
Equity Offering Sales Agreement</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
July 6, 2018, the Company entered into a Controlled Equity Offering&#160;Sales Agreement (the &#8220;Sales Agreement&#8221;) with
Cantor Fitzgerald&#160;&#38; Co., as agent (&#8220;Cantor Fitzgerald&#8221;), pursuant to which the Company may offer and sell
shares of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the
&#8220;Offering&#8221;).&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.
The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend
or terminate the offering of Shares upon notice to the other party, subject to certain conditions.&#160; Cantor Fitzgerald will
act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds
from the sale of the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. As of December 31, 2019, no shares had been sold pursuant to the Offering.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2015
Purchase Agreement</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &#8220;2015 Purchase Agreement&#8221;) with Lincoln
Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2019, the Company did not issue any shares to Lincoln Park under the 2015 Purchase Agreement.
During the three months ended December 31, 2018, the company issued to Lincoln Park an aggregate of 953,584 shares of common stock
under the 2015 Purchase Agreement, including 950,000 shares of common stock for an aggregate purchase price of $1,994,700 and
3,584 commitment shares. At December 31, 2019 and September 30, 2019, all remaining purchase amounts available for issuance under
the 2015 Purchase Agreement had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further
shares will be sold under the 2015 Purchase Agreement.</font></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln
Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000
in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares
of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day
of the next month following the 36-month anniversary of June 12, 2019.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
2019 Purchase Agreement limits the Company&#8217;s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common
Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i)
shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock
to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on
the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock
on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company&#8217;s
sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company&#8217;s
outstanding shares of Common Stock at any given time.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock
as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2019, the Company issued to Lincoln Park an aggregate of 4,429,835 shares of common stock
under the 2019 Purchase Agreement, including 4,394,160 shares of common stock for an aggregate purchase price of $10,997,952 and
35,675 commitment shares. At December 31, 2019, an amount of $34,367,543 remained available under the 2019 Purchase Agreement.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to equity offering agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6756539120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6632340144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Note
2&#160;&#160;&#160;&#160;&#160;&#160;&#9;<u>Recent Accounting Pronouncements</u></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recently
Adopted Accounting Pronouncements</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840,</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Leases.
The main difference between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees
for those leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability
to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is largely
unchanged from that applied under previous U.S. GAAP. The adoption of this standard on October 1, 2019 did not have any impact
on the Company's results of operations, financial condition, cash flows, and financial statement disclosures. The Company elected
to the package of practical expedients permitted under the transition guidance that allowed, among other things, the historical
lease classifications to be carried forward without reassessment. Further, the Company elected to not recognize lease assets and
lease liabilities for leases with a term of 12 months or less.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763713376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,352,035<span></span>
</td>
<td class="nump">$ 1,761,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,348,668<span></span>
</td>
<td class="nump">5,712,210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(7,700,703)<span></span>
</td>
<td class="num">(7,473,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">74,944<span></span>
</td>
<td class="nump">74,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">943,215<span></span>
</td>
<td class="nump">413,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">46,720<span></span>
</td>
<td class="nump">78,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="nump">53,113<span></span>
</td>
<td class="num">(4,507)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,117,992<span></span>
</td>
<td class="nump">562,503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(6,582,711)<span></span>
</td>
<td class="num">(6,911,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(9,214)<span></span>
</td>
<td class="num">(8,717)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (6,591,925)<span></span>
</td>
<td class="num">$ (6,919,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">54,773,685<span></span>
</td>
<td class="nump">46,327,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to amount of research and development incentive income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    "  0BT90Y*3\T^\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9)12\,P$,>_BN2]O325B:'KBV-/"H(#Q;>0W+9@DX;DI-VW-ZU;
MA^@'\#%W__SN=W"-#E+W$9]C'S"2Q70SNLXGJ<.:'8F"!$CZB$ZE,B=\;N[[
MZ!3E9SQ 4/I#'1 $YRMP2,HH4C !B[ 06=L8+75$17T\XXU>\.$S=C/,:, .
M'7I*4)45L'::&$YCU\ 5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.=1S+N]0
MP=O3X\N\;F%](N4UYE_)2CH%7+/+Y-?Z8;/;LE9PP0LN"K[:57=2U/+V_GUR
M_>%W%7:]L7O[CXTO@FT#O^ZB_0)02P,$%     @ $(M&4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    "  0BT904Y^C**,"  !R"@  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U6T8[:,!#\E2@?<(F=$. 4D("J:J560E>U?39@(+HD3FT#
MU[^O[>32U+ON"[&=F1VOUT.V? CYJJZ<Z^BMJ5NUBJ]:=\])HHY7WC#U)#K>
MFC=G(1NFS51>$M5)SDZ.U-0)3=,B:5C5QNO2K>WENA0W75<MW\M(W9J&R=];
M7HO'*B;Q^\)+=;EJNY"LRXY=^#>NOW=[:6;)&.54-;Q5E6@CR<^K>$.>=S2U
M!(?X4?&'FHPCF\I!B%<[^7Q:Q:G=$:_Y4=L0S#SN?,?KVD8R^_@U!(U'34N<
MCM^C?W3)FV0.3/&=J']6)WU=Q8LX.O$SN]7Z13P^\2&A61P-V7_A=UX;N-V)
MT3B*6KG?Z'A36C1#%+.5AKWUSZIUST?_)L\'&DZ@ X&.!#K_+R$;"-E(($XA
MZ7?F4OW -%N74CPBV5>K8_92D.?,'.;1+KJS<^],MLJLWM=IF=QMF &Q[1%T
M@B C(C&Q1P&*"6PIH--_!780D>$"&9I!YNC9A)[C]!REYXZ>3^@S[P @HL %
M9JC #-#GG@!$+'"! A4H 'WI"4 $27&%.:HPAWSB22 0BDLL4(D%Y&>>! ()
M5'J)2BPAWR\U @G4FJ2XG5(8P2\WA@D4G 1,2V $O^8(A@:*3E#G;@B%$?RR
M8YA W0EN7Y+!"'[E,4Q(!7<Y@2:FN:^"8&8!%=SJ!#J9%KX*Q(2N,<']3J"=
M*;AC""9TQW#/$^AH"NX8XOI0+KCM"31UYGV =@-FYC!M_Q>]*(I\F8>\B?N?
M0'=GX#XCF,!-H_@_ (7NSOS[C&'\<TLF7_"&RXMK=E1T%+?6=5J3U;&AVE#7
M ?R%]]W85R8O5:NB@]"FCW!?^[,0FINMI$_F6*^F 1PG-3]K.YR;L>R[H'ZB
M13=T>,G89J[_ %!+ P04    "  0BT90)<34YNP"  #T"@  &    'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;'V67V^;,!3%OPKB?<7_P542:66:-FF3JD[=
MGFGB)*B &3A)]^UG XV(?>E+P>2<Z]^UK5.O+KI[[8]*F>BMKII^'1^-:>^3
MI-\>55WT=[I5C?UEK[NZ,';8'9*^[52Q&TQUE1"$1%(791-O5L.WQVZSTB=3
ME8UZ[*+^5-=%]^]!5?JRCG'\_N&I/!R-^Y!L5FUQ4+^4>6X?.SM*KE5V9:V:
MOM1-U*G].OZ,[W,LG&%0_"[5I9^]1ZZ5%ZU?W>#[;ATC1Z0JM36N1&$?9Y6K
MJG*5+,??J6A\G=,9Y^_OU;\.S=MF7HI>Y;KZ4^[,<1UG<;13^^)4F2=]^::F
MAG@<3=W_4&=56;DCL7-L==4/?Z/MJ3>ZGJI8E+IX&Y]E,SPO4_UW&VP@DX%<
M#9A]:*"3@7J&9"0;6OU2F&*SZO0EZL;=:@MW*/ ]M8NY=1^'M1M^L]WV]NMY
M0_DJ.;LZD^1AE)"9A-PJ\E!!Q562V/FO$ 2$((.?SOTI[*>@GPY^-O=G7A.C
M1 R29FPB93QCA'J] $*",RXH@HD82,1"(ND1C1(^FXBF%(G47]Q01P1S\# /
M!WEXP,.0Q\/#>2B3 4XHXPA)F<$T J01(0WV:$2X.I@19M?'XPF%A%,B[5K"
M1"E(E 8GD!'8GX'^+.S(.U@/&="1W4;IG=0<T'%"*5W@D2"/#'F8QR.!_::"
M8>^<YJ$.<RSHTOI@!.<,"HF"H$'AV6*"2NSO.21$5(J4+3 M9!\.F83/!&@"
MG \UMR1P &(25O 3;-+<-)VB+,AB0$8$7]HM.%!QF*C,SZ])<W,P!,_L;G$_
M4R$IIX+2#"VM$QRK.,Q5[N<8#@/S$Z8VH3*1<1\,U%)WE,1"WF,X8'&8L-S/
M- Q$+)<"8;^''%(BDDDAY0(5'+0X3%I.?"H1_,=;B%I N9"UR>SZX>Z#/XON
M4#9]]**-O<D,]XV]UD;9JNC.=GFT5]#KH%)[XUY3^]Z-][!Q8'0[W3&3ZT5W
M\Q]02P,$%     @ $(M&4. ,A[,9 @  IP8  !@   !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6R-E=N.FS 417\%\0&Q@7!I1)":C$:MU$K15&V?G>0DH#&8
MVDZ8_GUM0Q QGD[R$%_8^WAM@^R\8_Q5E #2>ZMI(]9^*66[0D@<2JB)6+ 6
M&O7DQ'A-I!KR,Q(M!W(TIIJB$.,$U:1J_"(W<SM>Y.PB:=7 CGOB4M>$_]T
M9=W:#_S;Q$MU+J6>0$7>DC/\ /FSW7$U0F.58U5#(RK6>!Q.:_]SL-IF6F\$
MORKHQ*3OZ21[QE[UX.MQ[6,-!!0.4E<@JKG"%BC5A13&GZ&F/RZIC=/^K?JS
MR:ZR[(F +:._JZ,LUW[F>T<XD0N5+ZS[ D.>V/>&\-_@"E3)-8E:X\"H,/_>
MX2(DJX<J"J4F;WU;-:;MAOHWF]L0#H9P- 3+_QJBP1!9!M23F:A/1)(BYZSS
M>/^R6J*_B6 5J<T\Z$FS=^:92BO4[+6(HQQ==9U!LNDEX402WBNV<T64C!*D
MUA\A0B=$:/S1%&+I]D=.?V3\RZD_MD+TDM1(&B/!"XP#*\A'JCN6I9-E.6=)
M+)9>$D]6"7#_LW >$-X1Q4ZB>$Z46D3Q0[OSD>J.)7&R)'.6S&))W@UM;\\C
MRCNFU,F4SID^64SI;*4XQ1F.[%>[=0C#),9A_,XN94ZB;$:46-DWV:-$#J&;
M"$V.#'V$?R?\7#7"VS.I3A]S1IP8DZ"*XH6J5ZI;8QQ0.$G=356?]V=G/Y"L
M':X%--Y-Q3]02P,$%     @ $(M&4-_&,?XN P  _0L  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q]5F%OFS 0_2N([RT^&VRHDDA-IFF3-JGJM.TS
M39P$%7 &3M/]^]F&IM0^]B78YKV[=\9^N<5%=<_]44H=O39UVR_CH]:GNR3I
MMT?9E/VM.LG6O-FKKBFUF7:'I#]ULMPY4E,GE!">-&75QJN%6WOH5@MUUG75
MRH<NZL]-4W9_U[)6EV4,\=O"8W4X:KN0K!:G\B!_2/WS]-"967*-LJL:V?:5
M:J-.[I?Q/=QMH+ $A_A5R4L_&4>VE">EGNWDZVX9$ZM(UG*K;8C2/%[D1M:U
MC61T_!F#QM><EC@=OT7_[(HWQ3R5O=RH^G>UT\=EG,?13N[+<ZT?U>6+' O*
MXFBL_IM\D;6!6R4FQU;5O?N-MN=>JV:,8J0TY>OPK%KWO QO1#[2< (="?1*
M,+G_1V C@;T34E?\H,R5^JG4Y6K1J4O4#5_K5-I# 7?,;.;6+KJ]<^],M;U9
M?5EQ6"0O-LX(60\0.H&\(Q(3_)J!8AG6-*#3CPDV(8)3/ -#:V".SZ9\AO-3
ME)\Z?CKEI]X>#!#N(.VP!RRCA&5>*0A.<&!$X'HR5$\6ZO'RK =(-LG#69IS
MGGMZ0EPF@%(@N!Z.ZN&A'N[IX4&>&R$($81Y@C!@*E@&,SLD4$4B_.(S_!SE
MYV%%WLZM\T"H2(O4.Q<;#)71'-=2H%J*4$OA:2F"+$7**/B'+X2EP'@^<Y>
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ML;TQ5CNAZ-8E[NC:\^N@TGO;WTIWWPX]ZC"PYC3VW]GU3\#J'U!+ P04
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MI__=O_L\R-M.0HUUF=?=[V3]5C=ET6<)K139S_-V?^BVIS[_1Q@?(/L >0D
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MSK\VQ@-*V5SA"K7XP&9'0NV#>8.V'==L=+SIIA?$YF=<_ -02P,$%     @
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M'VPQ)-0N'#_YLYG&;#(<]O,/8LLW+GX#4$L#!!0    ( !"+1E#2.WFRM $
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M4/MX/(2S'<=L-#QVTP]B\S<N?@%02P,$%     @ $(M&4'. MA&T 0  T@,
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MA&<[C=ED>-///X@MW[CX"U!+ P04    "  0BT90149$-+<!  #2 P  &0
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MV4YC-AG>]/,/8LLW+OX 4$L#!!0    ( !"+1E"X2'C&Z $  &8%   9
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;'54VXZ<, S]%<0';+C-I2- VMFJ
M:J56&FW5]CD#YJ)-"$W"L/W[)H&A+/6^D-@Y/L=.L--1R!?5 &COE;-.97ZC
M=7\B1!4-<*H>1 ^=.:F$Y%0;4]9$]1)HZ8(X(U$0[ FG;>?GJ?-=9)Z*0;.V
M@XOTU, YE7_.P,28^:%_=SRW=:.M@^1I3VOX#OI'?Y'&(@M+V7+H5"LZ3T*5
M^8_AZ7RT> ?XV<*H5GO/5G(5XL4:7\K,#VQ"P*#0EH&:Y09/P)@E,FG\GCG]
M1=(&KO=W]D^N=E/+E2IX$NQ76^HF\X^^5T)%!Z:?Q?@9YGIVOC<7_Q5NP S<
M9F(T"L&4^WK%H+3@,XM)A=/7:6T[MXXS_ST,#XCF@&@30"8AE_E'JFF>2C%Z
M<KK[GMHG#D^1N9O".MU5N#.3O#+>6Q[&24INEFC&G"=,M,8L"&+8%XD(DSA'
M_X5'>'B,9AB[\/A-A@%.D* $B2-(WA#L-B5BF#TNLD-%=@C!82."88ZXR!X5
MV2,$'S8B""9YY[H.J,@!(0@W(ACFG4<]HB)'A"#>B&"89"-"5O\Y!UF[#E=>
M(8;.39>5=QDBCY'KDW_P:0)]H[)N.^5=A3;=YGJB$D*#225X,$_7F*&W& PJ
M;;<'LY=3ZT^&%OT\U<@R6O._4$L#!!0    ( !"+1E#QX@2(% (  ' %   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U4T8Z;,!#\%<0'G(,Q7!(!
MTB51U4JM%%W5Z[-#-@&=C:GMA.O?US:$$*#W@NWUS'AVL3=IA'Q7!8#V/CBK
M5.H76M=KA%1> *?J2=10F9V3D)QJLY1GI&H)].A(G"&\6,2(T[+RL\3%]C)+
MQ$6SLH*]]-2%<RK_;H"))O4#_Q9X+<^%M@&4)34]PT_0O^J]-"O4JQQ+#I4J
M1>5).*7^2[#>11;O &\E-&HP]VPF!R'>[>+;,?47UA PR+55H&:XPA88LT+&
MQI].T^^/M,3A_*;^Q>5N<CE0!5O!?I='7:3^TO>.<*(7IE]%\Q6Z?"+?ZY+_
M#E=@!FZ=F#-RP93[>OE%:<$[%6.%TX]V+"LW-IW^C39/P!T!]X0@^I00=H3P
M3B"?$DA'('="[*K5IN)JLZ.:9HD4C2?;OUM3>XF"-3'5SVW0%=OMF?(H$[UF
M 8D2=+5"'6;38O 0\XC8S2!(W&.0<=#;P',V-G@B@!^/V$X1\0BRFT+"_Y@(
M9VL1.GXXS")8S@N060'B!,A#&9Y'Q6PQD<-4#K/".,9Q/$IFBELN [P*PWE#
MT:RA:&(H7HW\M)!XZ(>$.!C=@>T41H(P7N*1&S2X=QSDV;UIY>7B4FG[:P;1
MOFV\8'MO1_%-L-ZVK_\NT_:B'U2>RTIY!Z'-JW!W]R2$!N-R\61L%J;]]0L&
M)VVGSV8NVR;0+K2HN_Z&^B:;_0-02P,$%     @ $(M&4$')R3%" @  HP8
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MC'%!X2SU-%%SWO?-?B%9.SP):'R7\O]02P,$%     @ $(M&4+..G8,B P
MR T  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULE5=A;]L@$/TKEG]
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M<LS:3MM.!&W,+2+HKC+K_U!+ P04    "  0BT90'[AOMOX!   (!@  &0
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M@F22('%.JL=0@ZD-AB<,9X0XS?@X1F.6H10F1$%"U"?$8X<0]0IA72EV8%L
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M4BJA^<0+?3PG/:\/BU(<5/>:ZO>F'UK[A9)G.Y!'PW\%Z[]02P,$%     @
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M?=/^Y5VD-& M1G?VUFK;B^<%AXMQTZV=J[$CC0LCNZG9DKGC%W\!4$L#!!0
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M?0_$*?Y/@K):*  WX&$> )1*P&:AY+-^#T2)W  ?D$:JS8\:\46V\>?J#]_
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M4SJ8.HT4LMJ,$P^R+0>#2 B)0!*0$R=@/F#)7O&0@6L/TAB%J$Y;S I,$('
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M%YDYI4.!OS6=7-35PA+0EOC0 RL8_3BFZA"?K?[*QJOV!->DIFA>U<Z)FQ.
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M-QV-#_)ZV@^G]'K@!,!E&4P^S^_I@^-SYIV/A^SXC+W)V?A0S\>CZ<O4X0A
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MZ=0ZHD-O.!E[HW-T?,G['9Z)5TFZ4'1SW-&H?T[QUF-X?SC>L]RYG'JG$VK
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MMI!.9Z=29W#H*6?X[VI_^']^H+.V)JK*'.W],N4\S[,L_^%_ %!+ P04
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MIF[.'P5N;FAVC./5]_X74$L#!!0    ( !"+1E \Q[AV0@$  (<.   :
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M2P$"% ,4    "  0BT90'R// \     3 @  "P              @ $
M7W)E;',O+G)E;'-02P$"% ,4    "  0BT90)^B'#H(   "Q    $
M        @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !"+1E#D
MI/S3[P   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( !"+1E"97)PC$ 8  )PG   3              "  ;<"
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ $(M&4%.?HRBC @
M<@H  !@              ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( !"+1E EQ-3F[ (  /0*   8              "  =$+
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  0BT90X R'
MLQD"  "G!@  &               @ 'S#@  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ $(M&4-_&,?XN P  _0L  !@
M ( !0A$  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !"+
M1E#Z+HTW,0,  ! ,   8              "  :84  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    "  0BT9031Z@9P@$  #V$0  &
M        @ $-&   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ $(M&4%&FOB"Q 0  T@,  !@              ( !2QP  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !"+1E"W[$TALP$  -(#   8
M              "  3(>  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    "  0BT90[&PA;K0!  #2 P  &               @ $;(   >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ $(M&4-([>;*T 0
MT@,  !D              ( !!2(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    "  0BT90<X"V$;0!  #2 P  &0              @ 'P
M(P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !"+1E!%
M1D0TMP$  -(#   9              "  =LE  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ $(M&4+A(>,;H 0  9@4  !D
M     ( !R2<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !"+1E ?N&^V_@$   @&   9              "
M <PT  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ $(M&
M4'.URQ$: P  (0P  !D              ( ! 3<  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    "  0BT90\'-TYAT"  #+!0  &0
M        @ %2.@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( !"+1E"#OFB;"P(  /T%   9              "  :8\  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ $(M&4"%WPJ=S @  $P@
M !D              ( !Z#X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    "  0BT907%*#G><H  ",HP  %               @ &200
M>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  0BT90K$XIA#P"  "
M"@  #0              @ &K:@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (
M !"+1E W8-5_G (  'X/   /              "  1)M  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  0BT90/,>X=D(!  "'#@  &@
M@ ';;P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  0
MBT903A4V#6\!  ",#P  $P              @ %5<0  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     'P ? $L(  #U<@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6771730192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expense</a></td>
<td class="nump">$ 50,054<span></span>
</td>
<td class="nump">$ 37,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,264,424<span></span>
</td>
<td class="nump">$ 2,066,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_RemainingAllocatedShareBasedCompensationExpense', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 4,602,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">The exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_RemainingAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a remaining stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_RemainingAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>54</ContextCount>
  <ElementCount>207</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity Offering Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreements</Role>
      <ShortName>Equity Offering Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/Commitments</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Business Description and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative</Role>
      <ShortName>Equity Offering Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferingAgreements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails1</Role>
      <ShortName>Commitments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails2</Role>
      <ShortName>Commitments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails3</Role>
      <ShortName>Commitments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails4</Role>
      <ShortName>Commitments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="avxl-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20191231.xml</File>
    <File>avxl-20191231.xsd</File>
    <File>avxl-20191231_cal.xml</File>
    <File>avxl-20191231_def.xml</File>
    <File>avxl-20191231_lab.xml</File>
    <File>avxl-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763928384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 2) - 2015 Omnibus Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">8,462,933<span></span>
</td>
<td class="nump">6,506,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">2,265,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,667)<span></span>
</td>
<td class="num">(309,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">8,726,266<span></span>
</td>
<td class="nump">8,462,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at ending</a></td>
<td class="nump">5,883,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">2.36<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">2.64<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">3.54<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at ending</a></td>
<td class="nump">3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate intrinsic value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at beginning</a></td>
<td class="nump">$ 4,115,032<span></span>
</td>
<td class="nump">$ 2,353,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at ending</a></td>
<td class="nump">2,195,111<span></span>
</td>
<td class="nump">$ 4,115,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at ending</a></td>
<td class="nump">$ 2,047,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763427744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">$ 74,944<span></span>
</td>
<td class="nump">$ 74,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">943,215<span></span>
</td>
<td class="nump">413,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 1,345,000<span></span>
</td>
<td class="nump">$ 587,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember', window );">Clinical Study Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6761650256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Note
5&#160;&#160;&#160;&#160;&#160; &#9;<u>Commitments </u></font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><font style="font: 10pt Times New Roman, Times, Serif">a)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif"><i>Leases
                                         </i></font></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2019, the Company incurred office lease expense of $50,054 (2018: $37,754).</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><font style="font: 10pt Times New Roman, Times, Serif">b)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif"><i>Litigation</i></font></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><font style="font: 10pt Times New Roman, Times, Serif">c)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif"><i>Share
                                         Purchase Warrants</i></font></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 68%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2018</font></td>
    <td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.87</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(8,750</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.13</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(319,629</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2019</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2019</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.88</font></td></tr>
</table><br style="clear: both" />
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2019, the Company had share purchase warrants outstanding as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="right" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 29%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 3%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 29%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 3%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 32%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 30,
    2021</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May
    6, 2024</font></td></tr>
<tr style="background-color: #CCEEFF">
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><font style="font: 10pt Times New Roman, Times, Serif">d)</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Stock&#8211;based
                                         Compensation Plan</i></font></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 66pt; text-align: justify; text-indent: -1in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors (the &#8220;Board&#8221;) approved a 2015 Omnibus Incentive Plan (the
&#8220;2015 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees
and consultants of the Company.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were
granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.</font></p>



<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"></p>

<table cellpadding="0" cellspacing="0" align="right" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: middle"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value ($)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate
    intrinsic value ($)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; width: 10%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2018</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,353,088</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,265,399</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.27</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(309,383</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.25</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2019</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,462,933</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.58</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,115,032</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">265,000</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.36</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.98</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,667</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.64</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2019</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,726,266</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.54</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,195,111</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: middle; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    December 31, 2019</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,883,586</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.85</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,047,275</font></td></tr>
</table><br style="clear: both" />



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-indent: 1in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money at December 31, 2019.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2019, the Company recognized stock-based compensation expense of $1,264,424 (2018: $2,066,987)
in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have been
included in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s statement of
&#9;operations as follows:</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" align="right" style="font: 10.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">481,101</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,011,399</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Research
    and development</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">783,323</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,055,588</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Total
    share based compensation</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,264,424</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,066,987</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><br style="clear: both" />



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99.25pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $4,602,000 in stock-based compensation is expected to be recorded over the remaining term &#9;of such
options through fiscal 2022.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 49.65pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" align="right" style="font: 10.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.88</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.96</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.21</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.45</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">101.60</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">106.15</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Dividend rate</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6771125792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,591,925)<span></span>
</td>
<td class="num">$ (6,919,731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,264,424<span></span>
</td>
<td class="nump">2,066,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(1,087,927)<span></span>
</td>
<td class="num">(403,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">266,026<span></span>
</td>
<td class="nump">105,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(395,834)<span></span>
</td>
<td class="nump">1,083,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">820,077<span></span>
</td>
<td class="num">(92,262)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,725,159)<span></span>
</td>
<td class="num">(4,160,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">10,997,952<span></span>
</td>
<td class="nump">1,994,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing charges</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,997,952<span></span>
</td>
<td class="nump">1,944,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents during the period</a></td>
<td class="nump">5,272,793<span></span>
</td>
<td class="num">(2,215,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">22,185,630<span></span>
</td>
<td class="nump">22,930,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 27,458,423<span></span>
</td>
<td class="nump">$ 20,715,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6763750320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,664,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6761661552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Component of Operating Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Note
3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9;<u>Other Income </u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Grant
Income</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received
in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for
a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The
grant income is deferred when received and amortized to other income as the related research and development expenditures are
incurred. During the three months ended December 31, 2019, the Company recognized $74,944 (2018: $74,528) of this grant on its
statement of operations within grant income.</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income represents the receipt by the Company&#8217;s Australian subsidiary, of the Australian research
and development incentive credit, (the &#8220;ATO R&#38;D Credit&#8221;).</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2019, the Company recorded research and development incentive income of $943,215 (AUD 1,345,000)
(2018: $413,682 (AUD 587,000)) in respect of the ATO R&#38;D Credit for eligible research and development expenses incurred during
the period.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other income disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
